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Abstract 
 
Epidermal growth factor receptor (EGFR)-dependent signaling is involved in numerous 
physiological processes, and its deregulation leads to cellular dysfunctions and pathologies, 
first and forecast, cancer. Endocytosis has a crucial impact on the downstream EGFR 
signaling response and it is regulated by ligand concentration. Indeed, depending on the EGF 
dose, the EGFR can be internalized through clathrin-mediated endocytosis (CME) or non-
clathrin endocytosis (NCE). The switch between these two internalization mechanisms occurs 
over a narrow range of EGF concentrations (1-10 ng/ml). Importantly, EGFR ubiquitination 
shows a threshold response over the same range of EGF doses and is responsible for the 
commitment of EGFR to NCE, and thus, for EGFR signal extinction through receptor 
degradation. 
In this project, we were interested in elucidating the cellular mechanisms that regulate and 
coordinate the choice between these two endocytic routes, in addition, we aim to clarify how 
the integration of the two pathways influences EGFR downstream signaling. In order to deal 
with the complexity of the system, we adopted an integrated research approach combining 
mathematical modeling with wet-lab experiments. To this purpose, in collaboration with the 
Systems Biology group at our Institute, we developed a mathematical model of early EGFR 
activation that quantitatively accounts for the ubiquitination threshold observed at 2 minutes 
of EGF stimulation. The ‘early model’ was able to generate important predictions; in 
particular, it predicts a weakness in the system that is unveiled in the presence of high EGF 
concentrations and EGFR overexpression, two conditions frequently observed in cancer. 
We tested these predictions using different cell-based model systems subjected to varying 
perturbations. A challenge in the biological validation of the model, was obtaining 
quantitative reproducible data. To this aim, we optimized a quantitative ELISA-based assay to 
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measure EGFR ubiquitination/phosphorylation upon different perturbations. This assay 
revealed to be powerful and allowed us to validate the predictions generated by the model. 
Thanks to our integrative approach, we identified Cbl as the limiting and weak element of the 
system. 
We expect that our model of EGFR activation will provide novel insights into the role of 
EGFR endocytosis, controlling the balance between EGFR signaling and downmodulation, 
frequently altered in cancer. 
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1 - Receptor Tyrosine Kinases 
 
Receptor Tyrosine Kinases (RTKs) are a class of proteins important for the control of cell 
growth and proliferation, differentiation, metabolism and migration. These processes stand at 
the base of organisms’ development and homeostasis, but are also involved in cancer 
development when deregulated [for complete reviews, see (Lemmon and Schlessinger 2010; 
Maruyama 2014)]. 
RTKs are a large family of transmembrane receptors with intrinsic tyrosine kinase activity 
(Lemmon and Schlessinger 2010). This family comprises a large number of surface receptors, 
such as the ErbB receptor family, the insulin receptor (IR) family, the platelet-derived growth 
factor (PDGF) receptor (PDGFR) family, the fibroblast growth factor receptor (FGFR) family 
and many others (Fig. 1; Lemmon and Schlessinger 2010). These receptors are usually 
activated upon the binding of an extracellular ligand, which induces the auto-phosphorylation 
of the intracellular part of the receptor, thus allowing for downstream signaling events. RTKs 
show a high affinity for many specific polypeptides, including growth factors, hormones and 
cytokines. 
Each RTK recognizes its specific ligands via diverse extracellular ligand-binding domains, 
but all RTKs present a highly conserved intracellular domain, which harbors the kinase 
activity. Among the vast family of cellular tyrosine kinases, 58 out of the 90 tyrosine kinase 
genes encode for an RTK. Different subfamilies of RTKs are categorized according to their 
amino acid sequence identities and extracellular structural similarities; in humans, 20 distinct 
subfamilies of RTKs have been identified (Fig. 1; Lemmon and Schlessinger 2010). 
The overall structure of an RTK consists of four domains: an N-terminal ligand-binding 
domain outside the cell, a single membrane-spanning domain, a tyrosine kinase domain inside 
the cell and a regulatory C-terminal region (Lemmon and Schlessinger 2010). The protruding 
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extracellular N-terminal domain, termed ectodomain, is specific for each RTK and confers 
specificity towards the ligand: it contains a ligand-binding site that can interact with 
extracellular molecules. The N-terminal region can exhibit a variety of conserved elements 
that confer ligand specificity. For example, cysteine-rich repeats are typical of the ErbB 
family of RTKs whose prototype is the epidermal growth factor (EGF) receptor (EGFR). 
Immunoglobulin-like domains are found in the PDGFR family receptors of class III. 
Moreover, other domains such as leucine-rich repeats, EGF-like domains and fibronectin type 
III repeats, are found in different combinations in the extracellular regions of other RTKs. 
Each receptor shows a single hydrophobic transmembrane (TM) domain that consists of 
25-40 amino acids. The TM domain is then followed by intracellular C-terminal region of the 
protein that displays the highest level of conservation among RTKs and comprises the 
catalytic domain responsible for both the kinase activity of the receptor and for the 
phosphorylation of downstream substrates. The C-terminal portion comprises also a 
regulatory region containing autophosphorylation residues, which serve as docking sites for 
Figure 1: Schematic representation of receptors belonging to the receptor tyrosine kinase family, with 
their domain organization. All RTKs consist of an extracellular portion, a transmembrane (TM) domain 
and an intracellular cytoplasmic portion that harbors the tyrosine kinase (TK) domain (red rectangle). The 
extracellular domain is responsible for ligand specificity and receptor dimerization, and thus determines the 
cellular response to extracellular signals that are translated inside the cell through the TM domain. The 
lengths of the receptors as shown are only approximately to scale (adapted from Hubbard and Till 2000). 
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signaling molecules, endocytic adaptors and the ubiquitination machinery (Lemmon and 
Schlessinger 2010).  
1.1 - RTK activation and signal transduction 
RTKs are activated upon binding of growth factors by a mechanism of receptor dimerization 
(Ullrich and Schlessinger 1990; Lemmon and Schlessinger 2010). Typically, inactive RTKs 
are found at the PM as monomers and only the binding of the ligand can induce receptor 
dimerization. More recently, it was also found that a subset of RTKs form oligomers even in 
the absence of the ligand. This is the case of the IR and the insulin-like growth factor 1 
receptor (IGF-1R), which are both expressed on the PM as disulphide-bond dimers; binding 
of insulin or IGF-1, respectively, triggers structural rearrangements within the dimer that 
activate the tyrosine kinase domain (Tatulian 2015). Moreover, there is evidence indicating 
that EGF can bind to and activate pre-existing EGFR dimers (Moriki, Maruyama et al. 2001; 
Tao and Maruyama 2008) or even tetramers (Clayton, Walker et al. 2005), while the 
activation of other RTKs, such as Tie2 and Eph receptor, relies on the formation of even 
larger oligomers (Himanen and Nikolov 2003; Barton, Tzvetkova-Robev et al. 2006). 
Regardless of whether the inactive state of an RTK is monomeric or oligomeric, binding of 
the ligand is required to stabilize the dimeric/oligomeric form (Schlessinger 2000). This event 
is necessary for intracellular structural rearrangements of the kinase domain that activate the 
kinase activity of the receptor, permitting the trans-phosphorylation of one or more tyrosine 
residues in the C-terminal region of the neighboring RTK, leading to a pattern of 
phoshotyrosines (pY) specific for each receptor. 
Most RTKs present an activation loop in the cytoplasmic region that is phosphorylated 
upon ligand binding. This event is necessary for the activation of the tyrosine kinase (TK) 
domain and the phosphorylation of tyrosine residues, and this is the case - for example - of 
the IR and the FGFR (Hubbard and Miller 2007). One exception to this mechanism is 
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represented by the ErbB family of receptors, which includes the EGFR and ErbB2 receptor. 
The activation of these RTKS does not require the phosphorylation of an activation loop, but 
rather necessitates asymmetric rearrangements of the intracytoplasmic domain, lending this 
class of receptor the name “not-so-prototypical” RTK (Lemmon, Schlessinger et al. 2014). 
The first response to autophosphorylation of an RTK is the recruitment and subsequent 
activation of signal-transducing molecules. These molecules contain Src homology 2 (SH2) 
and phosphotyrosine binding (PTB) domain-containing proteins (Zwick, Bange et al. 2001) 
that can bind the pYs of the RTK (Schlessinger and Lemmon 2003) and elicit the activation 
of signaling cascades. Signaling molecules can be directly recruited to the pYs of the 
activated receptor, or can also be indirectly recruited to the receptor through the action of 
docking proteins that recognize the RTK-pY, and which are then phosphorylated by the RTK 
with which they associate with (Schlessinger 2000). With the presence of multiple tyrosine 
residues in the intracytoplasmic domain of many RTKs, and the involvement of many 
docking proteins, activated RTKs can clearly recruit and affect a large number of signaling 
effectors. Thus, stimulated RTKs can be considered as a central node from which complex 
signaling events originate, and which transmit information from the exterior compartments of 
the cell to the interior. Initially thought to be linear chains of events (Noselli and Perrimon 
2000), RTK-dependent signaling pathways are now recognized as an authentic network of 
reactions that act through positive and negative feedback mechanisms (Lemmon and 
Schlessinger 2010; Volinsky and Kholodenko 2013), with the common aim to regulate cell 
proliferation and survival. 
Signaling pathways based on RTKs are multiple and interconnected, and an essential 
effector cascade required for most RTK function is the mitogen-activated protein kinase 
(MAPK) cascade that comprises also the extracellular signal-regulated kinase (ERK) kinases. 
This pathway relies on the activation of the small G protein Ras, and is crucial for RTK-
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induced proliferation due to the activation of nuclear transcription factors (McKay and 
Morrison 2007). 
As will be discussed later, docking proteins not only facilitate, or even permit, the 
interaction of the RTK with the signaling components of the cell, but also link the 
phosphorylated RTK to other protein modifying enzymes, such as the E3 ligases responsible 
for RTK ubiquitination. This is the case of the E3 ligase Casitas B-lineage Lymphoma (c-Cbl 
or Cbl) that is recruited directly to the phosphorylated EGFR via its tyrosine kinase binding 
(TKB) domain; only upon interaction with the docking protein Growth factor Receptor-
Bound protein 2 (Grb2) is Cbl stably recruited to the EGFR and the receptor fully 
ubiquitinated (see Chapter 3). 
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2 - The EGFR 
 
The EGFR is a member of the RTK subfamily of the ErbB receptors (Holbro and Hynes 
2004), which has critical roles in physiological and pathological processes in epithelial cells 
(Citri and Yarden 2006). EGFR is the leading member of this subfamily, which includes four 
closely related proteins: alongside EGFR (also called ErbB1) the family also includes ErbB2 
(or HER2/neu), ErbB3 and ErbB4, which are normally expressed in epithelial cells (Citri and 
Yarden 2006). 
The EGFR can form functional homodimers upon the binding of multiple ligands, as well 
as three functional heterodimers with the other ErbB family members. Indeed, the EGFR is 
known to preferentially heterodimerize with ErbB2 (Li, Macdonald-Obermann et al. 2012), 
and this combination plays a critical role in cancer (Hynes and Lane 2005). Moreover, 
heterodimerization regulates the activation of specific intracellular signaling pathways and 
contributes to signaling diversification [for a review on ErbB family members see (Sorkin and 
von Zastrow 2009)].  
The gene that encodes the EGFR is located on the short arm of chromosome 7 in the 
Figure 2 (next page): Mechanism of activation of the EGFR upon ligand binding. Schematic 
representation of the different stages of EGFR activation. The plasma membrane (PM) is represented by the 
purple arc. Above the PM two different representations of the ectodomain are shown. The upper shows a 
ribbon structure determined by X-ray crystallography of the soluble extracellular domain, the lower shows a 
schematic representation of those structures. The different subdomains within the ectodomain are indicated 
with different colors: domain I is purple, domain II green, domain III red, and domain IV dark blue. The 
ligand (EGF) is yellow. The dimerization arm, a part of domain II, is in orange. The receptor is proposed to 
exist at the PM as a monomer prior to ligand binding (left). EGF binding to domains I and III in the tethered 
closed conformation induces a conformational change that exposes the ‘dimerization arm’ (orange) of 
domain II, determining the open configuration (center). This dimerization arm interacts with the counterpart 
on the other receptor moiety to form a dimer (right) in which two intracellular kinase domains assume the 
asymmetric active structure.  
Below the PM diagrams of the intracellular domain are shown: the N-lobe of the kinase domain is colored 
grey and the C-lobe light-blue. The activation loop is blue, and the C-terminal tail is represented by a dashed 
line. Left and middle: the inactive conformation of the kinase is depicted. Right: ectodomain dimerization 
juxtaposes the kinase domains, with the C-lobe of one kinase attached to the N-lobe of the other. The 
activated kinase phosphorylates tyrosine residues (blue circles) in the C-terminal tail of its dimerization 
partner. In this scheme, only one receptor is activated; however, in reality, the flexibility of the hinge region 
allows the two receptors to switch positions and thus, each may activate the other. (Adapted from Bublil and 
Yarden 2007) 
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human genome; it is 186 kb long and comprises 28 exons. The mature EGFR is composed of 
1186 residues, and it is synthesized starting from a precursor protein of 1210 residues, which, 
after cleavage of the N-terminal sequence, is inserted into the cell membrane (Ullrich, 
Coussens et al. 1984).  
EGFR can be divided into three main topological regions: an extracellular globular region, 
a TM domain that spans over the PM and an intracellular portion that harbors the kinetic 
activity. The EGFR ectodomain is composed of 621 amino acids and contains four distinct 
subdomains (I-IV) (Fig. 2). Domains I and III are leucine-rich regions responsible for ligand 
binding, with both domains simultaneously contacting the same ligand, whereas domains II 
and IV are cysteine-rich regions that do not contact the ligand (Burgess, Cho et al. 2003; 
Lemmon 2009). The 23 amino acid TM domain consists of a patch of hydrophobic residues 
that extends from the outer part of the PM to the inside, while the C-terminal portion of the 
protein consists of 542 residues extending into the cytoplasm. This last cytoplasmic portion 
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contains the catalytic tyrosine kinase domain, as well as the tyrosine residues that can be 
phosphorylated upon external stimulus. 
At the molecular level, EGFR activation and the subsequent signaling cascade can be 
divided into three essential steps: (1) ligand binding and receptor dimerization, (2) trans-
phosphorylation of the intracytoplasmic tyrosine residues and (3) communication with 
downstream effectors. 
2.1 - Ligand-induced EGFR dimerization and activation 
The EGFR exists on the cell surface as a monomer, where it waits for activation by a specific 
ligand that can bind to its ectodomain and trigger the dimerization with another monomer 
(Fig. 2). A series of EGFR crystal structures are available in literature, which have helped to 
decipher the mechanism of EGFR activation (Garrett, McKern et al. 2002; Ogiso, Ishitani et 
al. 2002). It is now well accepted that binding of EGF (or other agonists) to EGFR shifts the 
monomer-dimer equilibrium to favor the dimeric state (Schlessinger 2000; Lemmon and 
Schlessinger 2010). 
Based on crystal structures of the soluble extracellular domain (Ogiso, Ishitani et al. 
2002) the four domains can fluctuate between a tethered and closed conformation, and an 
open conformation (Fig. 2 upper part). In the closed conformation, domains II and IV are 
close together and a tethering arm in domain IV is exposed (Burgess, Cho et al. 2003), while 
the dimerization arm that resides in domain II is occluded. In the absence of the ligand, the 
closed conformation is prevalent and is stabilized by disulfide bonds between the 
dimerization and the tethering arms (Fig. 2 left), preventing dimerization of the receptor with 
another monomer. EGF binding to the pocket between domains I and III, at a site remote from 
the dimer interface, induces a conformational change through a ~130° rotation of domains I 
and II, until the open or extended conformation is reached (Fig. 2 center). This 
conformational change exposes the dimerization arm in domain II that can subsequently 
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interact with a counterpart dimerization arm in another ligand-bound and open monomer, 
thereby driving the dimerization of the receptor (Fig. 2 right) (Lemmon 2009). This creates an 
active-state dimer that is able to trans-autophosphorylate the intracytoplasmic region and 
initiate a signaling events. 
There is also evidence indicating that pre-formed EGFR dimers are able to bind EGF. In 
a study by Chung et al. (Chung, Akita et al. 2010) that used quantum dot-based optical 
tracking of single molecules, it was observed that before ligand addition, EGFRs can 
spontaneously form finite-lifetime dimers, kinetically stabilized by the dimerization arms. 
The dimers were primed both for ligand binding and for signaling, such that after EGF 
addition the dimers displayed a rapid activation. Although the kinetic stability of EGF 
unloaded dimers was in principle sufficient for EGF-independent activation, ligand binding 
was still required for signaling (Chung, Akita et al. 2010). 
Once the receptor has been activated by the ligand, an asymmetric conformational 
change takes place in the cytoplasmic domain of the receptor, allowing trans-phosphorylation 
reactions that result in phosphorylation of specific tyrosine residues. The intracytoplasmic 
kinase domain can be divided into an N-lobe and a C-lobe, and structural studies have 
revealed that autophosphorylation takes place in an asymmetric kinase domain dimer (Fig. 2 
lower part), in which the C-lobe of one kinase domain activates the second kinase domain by 
binding to the N-lobe of the latter (Zhang, Gureasko et al. 2006). 
Interestingly, we can highlight two features that differentiate EGFR (and ErbB family 
receptors) from the rest of the RTK family: (1) the activating ligand does not interact with the 
dimerization surface, differently to what has been observed for the other RTKs; (2) activation 
of the tyrosine kinase domain relies on an asymmetric conformational change in the TK 
domain, rather than on phosphorylation of an activation-loop. These characteristics make 
EGFR, and the other ErbB family members, non-prototypical RTKs. 
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2.2 - The EGFR ligands and their role in physiology 
The EGFR can bind to 7 ligands that exert different effects on the receptor and that are 
available under different circumstances (Harris, Chung et al. 2003). EGF is the best-
characterized EGFR ligand, but alongside it, the transforming growth factor-α (TGFα), 
amphiregulin (AREG), epiregulin (EREG), betacellulin (BTC), heparin-binding EGF-like 
growth factor (HB-EGF), and epigen (EPI) can all act as EGFR ligands (Fig. 3).  
EGFR ligands are synthesized as membrane-anchored precursors that are later processed 
by metalloproteases to generate soluble ligands. Metalloproteases of the ADAM (a disintegrin 
and metalloproteinase) family are thought to be responsible for the shedding of certain EGFR 
ligands (Sahin, Weskamp et al. 2004). Under certain circumstances, the membrane-anchored 
isoforms, as well as the soluble growth factors, may also act as biologically active ligands. It 
is for this reason that these ligands have been observed to act in a justacrine, autocrine, 
paracrine and/or endocrine fashion (Singh and Harris 2005). 
Justacrine signaling is a type of cell/cell signaling that is based upon the interaction of a 
non-cleaved ligand precursor and the EGFR. This kind of cell/cell communication produces 
spatially non-uniform patterns in the expression of genes that guide the development of 
tissues and organs. The first ligand to be discovered to activate EGFR in a justacrine fashion 
was the TGFα (Anklesaria, Teixido et al. 1990), followed by HB-EGF (Raab, Kover et al. 
1996) and AREG (Inui, Higashiyama et al. 1997). 
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The other modes of receptor activation (autocrine, paracrine, endocrine) are also important 
in development and are necessary for different cellular functions. These modes of activation 
all involve a ligand that has been released from the cell that generated it, and which acts in the 
fluid phase. Similarly to justacrine signaling, autocrine signaling also exhibits space-restricted 
dynamics, with the ligand activating receptors on the cell that produced it. In contrast, longer 
distances can be covered by paracrine signaling, where the ligand is released into the tissue 
and can interact with the extracellular matrix and cell surface receptors as it spreads through 
the tissue. Paracrine stimulation can exert effects on the same cell type or on a different cell 
type. Finally, when the ligand is released systemically, it is known as endocrine signaling. 
This type of signaling is a frequent mechanism in hormone-dependent stimulations (Singh 
and Harris 2005). An example of such a hormone-like mechanism is given by the role of EGF 
Figure 3: The EGFR ligands. Structural features and schematic representation of the membrane-
anchored precursor forms of the seven EGFR ligands. All the EGFR ligands are synthesized as 
precursor transmembrane proteins that comprise an N-terminal extension, the specific ligand module, a 
hydrophobic transmembrane domain and a carboxy-terminal fragment, also known as the cytoplasmic 
tail. Through a proteolytic cleavage, a ‘‘soluble’’ growth factor is released into the extracellular milieu. 
Overall protein sequence identity between EGFR ligands is low (about 25%) and these proteins also 
differ concerning the distribution of glycosylation sites, the presence of a heparin-binding domain, and 
other biochemical characteristics (Harris et al., 2003). EGF is the only ligand harboring a total of nine 
EGF motifs, although only the one adjacent to the cell membrane is functional as an EGFR-binding 
domain after two proteolytic cleavages. Abbreviations: Epidermal Growth Factor (EGF), Transforming 
Growth Factor α (TGFα), Heparin-Binding EGF-like Growth Factor (HBEGF), AmphiREGulin 
(AREG), betacellulin (BTC), EpiREGulin (EREG) and EPpiGeN (EPGN). (Adapted from Schneider 
and Wolf 2009) 
INTRODUCTION 
 14 
in newborn mammals. In the developing animal, pro-EGF mRNA, EGF mature ligand, as 
well as TGFα and EGFR, are present in many tissues. EGF is also produced and secreted by 
the maternal mammary gland, and mammary-derived EGF appears to be important in gut 
development in the neonatal rodent (Brown, Lam et al. 1990; Mroczkowski and Reich 1993). 
EGF and TGFα are the best-studied EGFR ligands that specifically bind to and activate 
the EGFR. A parallel field of study has also highlighted an important role of HB-EGF in 
EGFR activation. It was observed that EGFR transactivation, mediated by G-protein coupled 
receptors, requires metalloprotease-dependent cleavage of pro-HB-EGF, suggesting an 
autocrine or paracrine mode of EGFR activation by this ligand (Prenzel, Zwick et al. 2000). 
However, HB-EGF can also activate ErbB4, another member of the ErbB family, making 
HB-EGF a non-specific EGFR ligand.  
Earlier, we mentioned the importance of EGF in the development of newborn mammals, 
but EGF, together with TGFα and HB-EGF, have an important role in the development of the 
nervous system (Xian and Zhou 1999). An interesting question arises from the fact that 
although EGF has been detected in the majority of body fluids of several mammalians, neither 
EGF antibody administration to newborn animals, nor passive immunization of pregnant 
rodents against EGF, caused major detrimental effects (Brown, Lam et al. 1990). Moreover, 
to date, no pathological EGF deficiency disorder has been characterized (Singh and Harris 
2005). These observations can be explained by the possible redundancy between the EGFR 
ligands in a defined body context. Further evidence suggests that TGFα and HB-EGF could 
be alternative functional growth factors in fetal development. 
2.2.1 - Different ligands correlate with distinct biological outcomes 
Various studies have observed how EGFR activation by different receptor ligands is 
translated into distinct biological activities (as schematized later, in Fig. 4) (Yarden and 
Sliwkowski 2001; Harris, Chung et al. 2003). However, the mechanism that underlies these 
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diverse modes of action is unknown. In biochemical terms, the ligand dynamics involved in 
activating the receptor appears to be the same for all ligands, encompassing ligand binding, 
EGFR dimerization and intracytoplasmic trans-phosphorylation. Thus, how can these ligands, 
which interact in similar way with the receptor, induce distinct biological effects? As 
mentioned above, EGFR is known to form homo- and heterodimers upon ligand binding, and 
this has been postulated to affect the binding affinity of the ligand to the EGFR. Therefore, 
differential dimerization of receptor moieties could be a possible system to induce ligand-
dependent signaling specificity, and thus different outputs. Another possible mechanism for 
discriminating between signaling induced by the different EGFR ligands could involve the 
strength of the ligand–receptor interaction, which could determine differential trafficking of 
the EGFR after ligand-dependent internalization. Indeed, as will be discussed in Section 5, 
following ligand binding, EGFR undergoes internalization through different endocytic 
pathways, in which the EGFR is sorted into early, recycling and/or late endosomes. For all 
EGFR ligands, it has been reported that following activation, the receptor is internalized and 
trafficked to early endosomes (Roepstorff, Grandal et al. 2009). However, the fate of 
receptors after reaching the early endosomes appears to vary depending on the stimulating 
ligand. It has been shown that the different ligands vary in their potential to stimulate EGFR 
degradation or recycling. For example, EPI and TGFα were observed to stimulate endocytosis 
of EGFR followed by complete recycling to the cell surface, whereas EGF, BTC and HB-
EGF stimulate EGFR degradation (Roepstorff, Grandal et al. 2009). 
Consequently, some studies have proposed that specific EGFR signaling pathways are 
triggered within different types of endosomes. In contrast to the requirement of kinase activity 
for the recruitment into internalization structures (Dikic 2003), regulated endosomal sorting 
appears to be independent of receptor kinase activity and the strength of the binding between 
EGFR and its ligands has been proposed to be the mechanism responsible for signaling 
diversification (Singh and Harris 2005). 
INTRODUCTION 
 16 
In the present work, we followed EGFR activation, endocytosis and signaling in the 
context of EGF-dependent stimulation. In the next paragraph, the EGF ligand will be 
described in more detail, and in the following sections, the sequential molecular steps that 
lead to EGF-dependent EGFR activation and endocytosis will be detailed. 
2.2.2 - EGF concentration as a variable element in the organism 
EGF is a 6 kDa protein and in humans it is composed of 53 amino acid residues. EGF is a 
growth factor whose concentration is regulated locally and not systemically like hormones. 
Indeed, under physiological conditions, EGFR-expressing cells seem to be exposed to a wide 
range of EGF (and EGF-like ligands) concentrations. There has been a huge debate in the 
field regarding the establishment of accepted physiological concentrations of EGF, since 
historically the erroneous perception has been that only low doses of EGF (below 1 ng/ml) are 
physiological. 
The notion that EGF might act locally, rather than systemically as an endocrine factor, 
is substantiated by findings that various organs seem to independently regulate their levels of 
EGF. This notion is further supported by the vast differences in EGF concentrations in 
various bodily fluids (Table I): from low concentrations (1-5 ng/ml) in plasma, serum, and 
saliva (with the exception of mice that have high EGF in saliva), to medium concentrations 
(5–50 ng/ml) in tears, follicular fluid, sperm, and seminal plasma, to high concentrations (50–
500 ng/ml) in bile, urine, milk, and prostate fluid. Bodily EGF might further be derived from 
exocrine (salivary gland, especially in mice), local/endocrine, and alimentary (milk, where 
EGF concentrations are very high) sources (reviewed in Carpenter and Cohen 1990). In 
addition, EGF is produced as a transmembrane precursor, which is not obligatorily processed, 
but might still act (especially in the kidney) as a juxtacrine stimulator (also reviewed in 
Carpenter and Cohen 1990). 
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In physiological conditions, epithelia prevent these EGF-containing fluids from 
reaching EGFRs that are expressed basolaterally, but when the tight junctions of the epithelia 
become leaky, e.g. as a result of a lesion or in premalignant neoplasia, elevated doses of EGF 
will reach and activate EGFR present on the cell membranes (Mullin 2004).  
Furthermore, elevated levels of EGFR ligands have been found in different cancer types 
(Thogersen, Sorensen et al. 2001; Revillion, Lhotellier et al. 2008; reviewed in Normanno, 
Bianco et al. 2005). Although an exact ligand concentration has not been measured in tumors, 
due to the autocrine and paracrine nature of the system, local EGFR ligand concentrations in 
the tumor microenvironment may reach very high levels, such as in breast and bone marrow 
cancers (Normanno, Campiglio et al. 2008; Revillion, Lhotellier et al. 2008; Roepstorff, 
Grandal et al. 2009). 
  
 Tissue/bodily fluids Concentration 
LOW 
Plasma 
Serum 
Saliva 
~1 ng/ml 
~5 ng/ml 
1-3 ng/ml 
MEDIUM 
Tears 
Follicular fluid 
Sperm 
Seminal plasma 
10-30 ng/ml 
3-30 ng/ml 
20-40 ng/ml 
~50 ng/ml 
HIGH 
Bile 
Urine 
Milk 
Prostate fluid 
~150 ng/ml  
~100 ng/ml 
~400 ng/ml 
150 ng/ml 
 
 
 
 
 
 
 
 
 
 
Table I: Concentration of EGF in 
human tissues and bodily fluids. The 
concentration of EGF is locally 
regulated and varies in different tissues 
and bodily fluids. 
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2.3 - Other ErbB family members 
Class I RTKs are frequently co-expressed in various combinations and, depending on the 
activating ligand, they can form various homodimers or heterodimers, generating a complex 
signal transduction network, as schematized in Fig. 4 (Alroy and Yarden 1997; Riese and 
Stern 1998). ErbB receptors are activated by a large group of EGF-related polypeptides, 
which all contain a conserved EGF-like motif. ErbB receptor ligands include the 7 EGFR 
ligands that we have described previously (see Introduction Section 2.4), plus 4 members of 
the neuregulin family (NRG1-4), for a total of 11 ErbB ligands (Garrett, McKern et al. 2002). 
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Figure 4: The ErbB signaling network. A - ErbB receptor ligands and the ten dimeric receptor 
combinations constitute the input layer. Numbers under each ligand indicate the respective high-affinity 
ErbB receptors. Receptors are indicated as follows: 1=EGFR, 2=ErbB2, 3=ErbB3, 4=ErbB4. For 
simplicity, specificities of receptor binding are shown only for the epidermal growth factor (EGF). 
ErbB2 binds no ligand with high affinity, and ErbB3 homodimers are catalytically inactive (crossed 
kinase domains). B - Signaling to the adaptor/enzyme layer is shown only for two receptor dimers: the 
weakly mitogenic ERGF homodimer, and the relatively potent ErbB2–ErbB3 heterodimer. Only some 
of the pathways and transcription factors are represented in this layer. Numbers 1 to 5 refer to the main 
text. C How the signal from the above layers are translated to specific types of output; many signaling 
cascades are involved in these complex signal transduction pathways. (Adapted from Yarden 2001) 
INTRODUCTION	  
 19 
These growth factors bind with different specificities and affinities to EGFR, ErbB3 and 
ErbB4, while no ligand for ErbB2 has been identified yet (Fig. 4). Of note, EGF, TGFα, EPI 
and AREG are specific for the EGFR (Hynes and Lane 2005; Schneider and Yarden 2014), 
while BTC, HB-EGF and EREG have been shown to have a dual specificity towards EGFR 
and ErbB4. Finally, the neuregulins can bind to ErbB3 and/or ErbB4 according to their own 
specificity. 
Despite the fact that ErbB2 is an orphan receptor (Lonardo, Di Marco et al. 1990), it is 
well known that it acts as a co-receptor for the other EGFR family members. In particular, the 
EGFR ligands and the neuregulins that bind to ErbB3 or ErbB4 are able to induce 
heterodimer formation with ErbB2. These heteromolecular interactions are of 
pathophysiological relevance, because such receptor combinations show strong mitogenic 
signaling and tumorigenicity. Indeed, signaling pathways involving Ras, Src, 
phosphatidylinositol 3-kinase (PI3K), MAPK/ERK and c-Jun NH2-terminal kinase (JNK) 
have been shown to be activated by ErbB2-expressing cell lines (Yamamoto, Saito et al. 
2011). 
2.4 - EGF-dependent signal transduction 
Trans-autophosphorylation of intracytoplasmic tyrosine residues determines the presence of 
pY signals that are interpreted by the cell through molecules harboring SH2 or PTB domains 
(see Introduction Section 1.1; Schlessinger 2000). There are 10 tyrosine residues in the EGFR 
that can be phosphorylated upon ligand binding and which could serve as docking sites for 
SH2 and PTB domain-containing proteins (Shoelson 1997). Only seven of these tyrosine 
residues have been demonstrated to be linked to signaling effector activity. A signal-specific 
array of molecules is recruited to the PM, where the activated receptor still resides, and can 
initiate distinct signaling pathways. Ongoing research in the field is still attempting to link 
specific phosphosites to the different effectors. It has been reported that many pYs can 
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interact with multiple effectors, and conversely, some effectors bind to multiple pYs, as in the 
case of Grb2 and Shc (Schulze, Deng et al. 2005). 
The major EGF/EGFR signaling pathways include the MAPK/ERK, the PI3K/AKT, the 
phospholipase C (PLC)/protein kinase C (PKC), the Janus kinase (JAK) and the signal 
transducer and activator of transcription (STAT) proteins (Kloth, Catling et al. 2002; Andl, 
Mizushima et al. 2004), the JNK and p38 MAPKs (Mialon, Sankinen et al. 2005), and the 
Ca2+/calmodulin-dependent protein kinase (CaMK; Sengupta, Bosis et al. 2009). 
The transcriptional response to EGF can be divided into three temporal phases. The initial 
wave, up to 45 minutes from stimulation, consists of a limited set of genes, called immediate 
early genes (IEGs), which include transcription factors and cell cycle regulators, such as FOS 
and JUN (Kujubu, Norman et al. 1991). The second wave is activated 45-120 minutes after 
stimulation, and drives the activation of delayed early genes (DEGs) and includes many 
newly induced phosphatases, as well as DNA and RNA-binding proteins. This second wave 
regulates components that positively or negatively influence the EGFR signal (Amit, Wides et 
al. 2007). DEGs act by strongly shutting down IEGs either by inhibiting upstream signal 
transduction pathways or by promoting transcriptional attenuation. The late, secondary 
response genes (SRGs) are activated after 120 minutes from stimulation and confer stable 
phenotypes, which are crucial for fate determination. 
2.4.1 - The MAPK/ERK pathway 
The MAPK/ERK cascade (Fig. 4, yellow label 1) is a critically important signaling pathway 
that transmits the signal of extracellular stimuli to the nucleus, to regulate cellular processes 
such as proliferation, differentiation and motility. The signaling pathway that acts through the 
ERK cascade is mediated by sequential phosphorylation and activation of protein kinases. 
The central phosphorylation stream of the cascade includes Raf kinases, MEK1/2, ERK1/2 
and ribosomal S6 kinases (RSKs): once the EGFR has been activated, the complex formed by 
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the adaptor proteins Grb2 and son-of-sevenless (SOS) can bind the EGFR through the pY 
signals (Lowenstein, Daly et al. 1992; Batzer, Rotin et al. 1994). This interaction leads to a 
conformational modification of Sos, which is then able to activate Ras. In turn, Ras activates 
Raf-1 that, through intermediate steps, phosphorylates the MAPKs, ERK1 and ERK2 
(Hallberg, Rayter et al. 1994; Liebmann 2001). As a result of this phosphorylation cascade, 
ERK kinases act on a dual level. First, they can phosphorylate cytoplasmic proteins, such as 
protein kinases and phosphatases, cytoskeletal elements, regulators of apoptosis, and a variety 
of other signaling-related molecules. Second, they migrate into the nucleus to phosphorylate 
target transcription factors, thus promoting transcription of mitogenic genes (Hill and 
Treisman 1995; Gaestel 2006).  
2.4.2 - The PI3K/AKT pathway 
The PI3K/AKT pathway (Fig. 4, yellow label 2) is involved in cell growth, apoptosis 
resistance and invasion. PI3K is a dimeric enzyme composed of a regulatory p85 subunit and 
a catalytic p110 subunit. p85 is responsible for the anchorage to ErbB receptor-specific 
docking sites, whereas p110 generates the second messenger, the phosphatidylinositol 
trisphosphate (PIP3). This messenger molecule in turn promotes phosphorylation and 
activation of the serine/threonine kinase AKT (Fig. 4) (Vivanco and Sawyers 2002). 
Although docking sites for p85 are absent on EGFR, they are instead abundant on ErbB3 
(Carpenter, Auger et al. 1993; Yarden and Sliwkowski 2001). Indeed, the dimerization of the 
EGFR with ErbB3 represents the principal mechanism that drives EGFR-dependent PI3K 
pathway activation. Alternatively, the p85 subunit can interact with EGFR through the 
docking protein Grb2-associated-binding protein 1 (Gab-1; Mattoon, Lamothe et al. 2004). 
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2.4.3 - The PLCγ pathway 
The EGFR also activates PLCγ (Fig. 4, yellow label 3), an enzyme that drives the hydrolysis 
of phosphatidylinositol bisphosphate (PIP2) to inositol triphosphate (IP3). This hydrolysis 
event is critical for the intracellular release of Ca2+ from the endoplasmic reticulum (ER) and 
subsequent activation of calcium-regulated pathways, and the release of diacylglycerol 
(DAG), a cofactor in PKC activation (Chattopadhyay, Vecchi et al. 1999; Patterson, van 
Rossum et al. 2005).  PLCγ interacts directly with the phosphorylated EGFR via its SH2 
domain and its activation results in MAPK and JNK activation (Schonwasser, Marais et al. 
1998; McClellan, Kievit et al. 1999). 
The EGF-induced increase in the cellular concentration of Ca2+ exhibits two 
components: a release of Ca2+ from intracellular stores, such as the ER, and a net influx of 
Ca2+ from the extracellular milieu through the channel transient receptor potential channel 1 
(TRPC1). Ca2+ entry through TRPC1 conversely activates EGFR, suggesting that TRPC1 is a 
component of a Ca2+-dependent amplification of EGF-dependent cell proliferation (Tajeddine 
and Gailly 2012). 
2.4.4 – The JAK/STAT pathway 
Another signaling pathway relies on the activity of the JAK/STAT pathway (Fig.4, yellow 
label 4). Upon ligand-induced receptor phosphorylation, JAK forms homodimers that are 
capable of trans-autophosphorylation. Phosphorylated JAK activates the cytosolic 
transcription factor STAT, which translocates to the nucleus and initiates transcription of 
specific target genes (Haura, Zheng et al. 2005). Importantly, constitutive activation of STAT 
proteins and especially STAT3 has been observed in numerous primary tumor cells and 
tumor-derived cell lines. Indeed, increased activity of membrane-associated tyrosine kinases, 
such as the EGFR, promotes persistent STAT3 activation, which contributes to oncogenesis 
and tumor progression (Bromberg 2002). 
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2.4.5 – The Src kinase pathway 
The proto-oncogene, non-receptor tyrosine kinase Src (Fig. 4, yellow label 5) plays a critical 
role in the regulation of cell proliferation, migration, adhesion, angiogenesis, and immune 
function. Src, which is located in the cytosol, activates a series of substrates, including focal 
adhesion kinase (FAK), PI3K, and STAT proteins (Summy and Gallick 2006;Yeatman 2004). 
Although Src can function independently, it also cooperates with other tyrosine kinases, such 
as RTKs. Src interaction with the EGFR is complex: on the one hand, Src serves as a signal 
transducer and enhancer of EGFR activation (Jorissen, Walker et al. 2003; Leu and Maa 
2003), and on the other, Src appears to be involved in resistance to anti-EGFR therapies 
through its EGFR-independent activation, either by Src-dependent EGFR transactivation 
through distinct pathways involving integrins and G-protein coupled receptors (GPCRs) 
(Kopetz 2007). 
2.5 - EGFR dephosphorylation 
For what regards EGFR phosphorylation kinetics, many data are available in literature (Guo, 
Kozlosky et al. 2003; Boeri Erba, Matthiesen et al. 2007).  In contrast, the kinetics of EGFR 
dephosphorylation are little understood, although much is known about the specific 
phosphatases that can regulate EGFR (Tonks 2006). The first protein tyrosine phosphatase 
(PTP) to be purified and characterized was PTP1B in 1988 (Tonks, Diltz et al. 1988; Tonks, 
Diltz et al. 1988). Since then, over 100 PTPs have been identified in the human genome. 
PTP1B was shown to localize to the ER and to dephosphorylate several RTKs, including 
EGFR (Frangioni, Beahm et al. 1992; Lammers, Bossenmaier et al. 1993). This finding led to 
the initial hypothesis that EGFR can only be regulated by PTPs after internalization. This 
hypothesis was corroborated by a successive study that demonstrated that EGFR could only 
interact with PTP1B after EGFR endocytosis (Yudushkin, Schleifenbaum et al. 2007). These 
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observations have contributed to the widespread assumption that EGFR dephosphorylation 
occurs only in the cell interior, after EGFR internalization. However, the identification of 
multiple cell surface-localized PTPs that are able to dephosphorylate EGFR, suggested that 
EGFR regulation by PTPs might not be restricted to the cell interior (Monast, Furcht et al. 
2012). This notion is supported by a study in MCF7 and COS7 cells, in which EGFR 
phosphorylation was reduced to basal levels after approximately 2 min of treatment with an 
EGFR tyrosine kinase inhibitor (TKI), regardless of the EGFR cellular localization 
(Offterdinger, Georget et al. 2004). The same study demonstrated that EGFR could become 
phosphorylated at the cell surface in the absence of stimulatory ligand if cells were treated 
with pervanadate, a potent and irreversible inhibitor of PTPs (Huyer, Liu et al. 1997).  
These data suggest that EGFR pYs are under the control of PTPs, regardless of EGFR 
cellular localization, in contrast to the classic view of EGFR dephosphorylation. These data 
also support the possibility that PTPs are important regulators of EGFR-mediated signaling 
and internalization. 
2.6 - From input to output 
One big task in the study of EGFR signaling pathways, and more broadly RTK signaling 
pathways, is to decode the exact mechanisms, and their timings, by which an extracellular 
signal is translated to a specific cellular outcome. This goal is particularly challenging when 
dealing with receptor signaling pathways, because they are highly complex and 
interconnected (Citri and Yarden 2006). For instance, a decade ago, a review on the ErbB 
signaling network assigned 122 proteins to the network with 211 interactions among these 
proteins (Oda, Matsuoka et al. 2005). It is plausible that this network has been enriched with 
new players and interactions since the publication of the review. 
In addition to the intricate network of signaling proteins associated with the EGFR 
signaling pathway, another level of regulation exists that influences EGFR signaling, i.e., 
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endocytosis of the receptor (see Chapter 5). Following activation, the EGFR undergoes cycles 
of endocytosis and recycling, while still phosphorylated and active (Sigismund, Confalonieri 
et al. 2012), thus complicating the regulation of the signaling pathway. 
Although biochemistry and molecular biology offer tools to study local and direct 
interactions within networks, and cell biology allows the interpretation of spatial input–output 
connections, this experimental approach is unable to draw connections that link long-range or 
systemic elements, as well as to infer the dynamic aspects of complex networks (Enuka, 
Feldman et al. 2015). A possible solution aimed at overcoming the limitations of experimental 
approaches, is the application of computational modeling to biological data to reveal the 
hidden functional and topological properties of the protein under analysis, as will be 
discussed in Chapter 7. 
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3 - EGFR Ubiquitination 
 
The post-translational modification of a wide array of proteins consisting of the covalent 
attachment of one or more ubiquitin (Ub) moieties has emerged as one of the major 
mechanisms involved in protein regulation. Signaling receptors are tightly regulated by 
ubiquitination, and Ub is responsible for receptor trafficking, sorting and downregulation 
(reviewed in Haglund and Dikic 2012). In the next pages, the structure of Ub and the 
signaling network generated by this small protein, which is responsible for complex and 
various cellular responses, will be briefly discussed. 
Ub was first identified in 1975 as a protein with an unknown function, being expressed 
ubiquitously in all eukaryotic cells (Schlesinger, Goldstein et al. 1975). In the early 1980s, the 
basic functions of Ub and some components of the ubiquitination pathway were elucidated by 
Aaron Ciechanover and colleagues (Ciehanover, Hod et al. 1978). The importance of this 
research was formally recognized when Ciechanover was awarded the Nobel Prize in 
Chemistry in 2004. 
Ub is a small regulatory protein of only 8.5 kDa that is composed of 76 amino acid 
residues and is encoded in mammals by four different genes, reflecting the importance of its 
role in cellular dynamics. It is highly conserved among eukaryotic organisms, sharing an 
extremely high sequence identity: human and yeast share a 96% identity in their Ub amino 
acid sequences, differing only in 3 residues out of 76. No ubiquitination machinery is known 
to exist in prokaryotes, with the exception of the Prokaryotic Ub-like Protein found in 
Mycobacterium tuberculosis (Pearce, Mintseris et al. 2008). 
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3.1 - The ubiquitination machinery 
Ubiquitination is a post-translational modification in which the carboxylic acid of the di-
glycine motif in the activated Ub moiety is covalently attached to the ε-amino group of a 
lysine residue in the target protein. 
The sequential activity of three types of proteins is necessary for substrate ubiquitination 
(Fig. 5; Woelk, Sigismund et al. 2007): 
• Ub-activating enzyme - E1: this enzyme catalyzes the ATP-dependent activation of 
the carboxyl terminus of Ub and its conjugation to the active site cysteine residue in 
the E1. 
• Ub-conjugating enzyme – E2: this enzyme accepts the Ub molecule from E1 in a 
trans-thioesterification reaction with an active cysteine in E2. 
• Ub-protein ligase – E3: this class of protein is involved in substrate recognition and 
determines the specificity of the reaction. 
Indeed, there are few E1 enzymes, despite the 
fact that there are dozens of E2s and hundreds 
of E3s, creating a network that easily 
modulates the response after receiving a 
specific stimulus. The E3 ligase class of 
proteins includes hundreds of members, and 
Figure 5: Schematic representation of the 
ubiquitination process. Hierarchical set of three 
types of proteins is required for substrate 
ubiquitination: the ubiquitin-activating enzyme (E1), 
the ubiquitin-conjugating enzyme (E2) and 
ubiquitin-ligase (E3). The two major classes of E3 
ligases are shown: the RING-type E3-ligases 
function as adaptors, bringing the ubiquitin (Ub) 
moiety close to the substrate, whereas the HECT-
type E3-ligases act as enzymes catalyzing directly 
substrate ubiquitination. (Adapted from Woelk, 
Sigismund et al. 2007). 
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can be subdivided in two main branches: the HECT ligases and the RING domain-
containing ligases. E3 ligases that possess the RING domain work as adaptors, 
bringing the E2 close to the substrate and allowing the direct transfer of Ub from the 
E2 enzyme to the substrate, whereas those possessing the HECT domain act as real 
enzymes creating an E3-Ub intermediate state before transferring the Ub molecule to 
the target protein. In both cases, an isopeptide bond between a lysine residue in the 
target protein and the C-terminal glycine of Ub is formed.  
3.1.1 - Different types of Ub signal  
The amino acid sequence of Ub comprises seven lysine residues (Fig. 6A) that can be 
potentially used as acceptors for the attachment of other Ub moieties, allowing the formation 
of different types of Ub chains. However, it is currently not known if all of the linkages have 
a specific function (Woelk, Sigismund et al. 2007). 
Ubiquitination has long been studied for its role in proteasomal degradation. The 
polyubiquitination (i.e., attachment of multiple Ub moieties or of a Ub chain - see next page) 
of target proteins to be destroyed by the proteasome is a well-known pathway, necessary for a 
number of physiological aspects of the cell, such as homeostasis and cell cycle progression, as 
well as cellular differentiation and apoptosis (Fig. 6B). More recently, new roles for Ub were 
highlighted, not involving proteasomal degradation. For example, an important process in 
which Ub plays a central role is the endocytosis and trafficking of PM receptors. In this case, 
ubiquitination has been shown to be involved in receptor internalization mechanisms or in 
targeting receptors for lysosomal degradation. 
Substrate proteins can also be modified by the attachment of a single moiety of Ub, in a 
process denoted as monoubiquitination. This reversible modification is not a proteolytic 
signal, but is involved in various cellular mechanisms, such as endocytosis, endosomal sorting, 
histone regulation, DNA repair, virus budding and nuclear export (Fig. 6B). Moreover, 
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substrate proteins can also be ubiquitinated on several lysine residues, giving rise to multiple 
monoubiquitination, which is involved mainly in receptor internalization and endocytosis 
(Fig. 6B). In addition, the seven lysine residues of Ub themselves can be potentially used as 
acceptors of other Ub molecules, determining the formation of different types of Ub chains. 
As above mentioned, the process by which a protein is modified by the addition of one or 
more Ub chains is known as polyubiquitination, and the potential number of modifications 
that can be achieved is impressive. It has been shown that all the seven lysine residues in Ub 
can be used for chain formation in vitro, but the physiological relevance of the different types 
of Ub chains is far from being fully understood. 
There is evidence indicating that structurally different polyUb chains contribute to the 
generation of functionally distinct signals. Indeed, the importance of the specific lysine-
dependent linkage was first highlighted in yeast, where a mutation that abolished the Lys63 
linkage (Ub-Lys63Arg) resulted in a DNA repair-defective phenotype (Spence, Sadis et al. 
1995). Lys63 linkage has since been shown to be a non-proteolytic signal involved in DNA 
repair, transcriptional regulation, endocytosis and activation of protein kinases (Bach and 
Figure 6: Schematic representation of 
the different ubiquitin modifications. 
A - Schematic representation of Lys 
residues (K) present in the ubiquitin amino 
acid sequence B - The different types of 
ubiquitin (Ub) modification with 
associated biological functions are shown. 
Target proteins can be modified by a 
single or by multiple monoubiquitins 
(MonoUb and MultiUb, respectively), or 
by different types of polubiquitin (PolyUb) 
chains, both linear and branched (K48-
linked, linear K11,29,63-linked, and 
branched polyUb chains). The question 
mark indicates that the functions of 
branched PolyUb chains are mostly 
unknown (adapted from Woelk, 
Sigismund et al. 2007). 
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Ostendorff 2003; Huang and D'Andrea 2006) see also Introduction Section 3.2 for details on 
its role in endocytosis). Instead, Ub-mediated degradation via the 26S proteasome, the most 
well-known Ub function, requires the presence of four or more Lys48-linked Ub molecules. 
Structural studies showed that there is a conformational difference between Lys63- and 
Lys48-linked chains, highlighting the possibility that chain recognition could be based on the 
topology adopted by different chain types. This hypothesis could explain how specific cell 
components interpret the diversity of Ub signals, and translate them into specific biological 
responses. This concept also raises the idea that ubiquitination is a code, exploited by cells to 
diversify cellular responses starting from a narrow range of different molecules. 
Indeed, the Ub signal is emerging to be as versatile as the phosphorylation-based signal 
in transducing intracellular outputs. Similarly to phosphorylation (see Introduction Section 
2.1), a reversible post-translational modification that can be recognized by specific protein 
domains (e.g. the SH2 domain), ubiquitination is an inducible signal (e.g. in response to 
growth factors or DNA damage) that can be recognized by proteins harboring Ub-binding 
domains (UBDs). These Ub-UBD interactions generate a network of Ub-based connections.  
Ubiquitination is also reversible due to the presence of deubiquitinating enzymes 
(DUBs), which modulate the cellular response to the Ub signal. Compared to phosphorylation, 
the ubiquitination signal is even more complex because the 76-residue molecule appended to 
the target proteins is obviously bigger than a phosphate group. In addition, as we discussed 
above, Ub can form chains that increase the number of, and differentiate between, the 
possible readouts. 
3.2 - Ligand-induced ubiquitination of the EGFR  
One of the most studied examples of a receptor undergoing Ub-mediated downregulation 
following ligand stimulation is the EGFR. EGFR is a well-characterized model for receptor 
internalization and for ligand-induced trafficking (for a recent review see Tomas, Futter et al. 
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2014). Once the EGFR is activated by its cognate ligand EGF, it undergoes structural and 
biochemical modifications including intracytoplasmic tail phosphorylation (see Introduction 
Section 2.1). At this stage, EGFR can subsequently be ubiquitinated by a specific machinery 
that is recruited to the receptor tail by signals transmitted from the activated receptor itself. 
EGFR ubiquitination starts at the plasma membrane (PM), however, it can also continue all 
along the endocytic route (Stang, Blystad et al. 2004; Umebayashi, Stenmark et al. 2008).  
EGFR ubiquitination is exerted by the E3 RING ligase Cbl (Levkowitz, Waterman et al. 
1998; Waterman, Levkowitz et al. 1999). The Cbl family is composed of three genes: c-Cbl, 
Cbl-b and Cbl-c (Schmidt and Dikic 2005; Lipkowitz and Weissman 2011). c-Cbl (henceforth 
Cbl) is best characterized for its role in EGFR ubiquitination and is responsible also for the 
ligand-induced ubiquitination of other RTKs, for example the mesenchymal epithelial 
transition factor (MET) receptor (Peschard, Fournier et al. 2001; Mettlen, Pucadyil et al. 
2009). For these receptors, it has been shown that Cbl recognizes and binds directly to a 
phosphotyrosine (Emde, Kostler et al. 2012) in the activated receptor, through its N-terminal 
TKB domain and drives the attachment of Ub moieties to the intracytoplasmic tail of the same 
receptor. In addition, the adaptor protein Grb2, which is recruited to other pY residues on the 
cytoplasmic tail of the RTK, was found to be an additional, indirect docking site for Cbl to the 
receptor, both in the case of the EGFR and MET. Cooperation of the direct and indirect 
binding sites has been proposed (Capuani, Conte et al. 2015), in the case of the MET receptor, 
to be necessary for the correct positioning of Cbl on the receptor or for full receptor 
ubiquitination (Peschard, Fournier et al. 2001). 
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The interaction between Cbl and the EGFR has also been hypothesized to be a bi-dented 
contact. Cbl is recruited to the activated EGFR by two distinct mechanisms (Fig. 7): it can 
interact directly with a specific site in the receptor tail - the pY1045 (Waterman, Levkowitz et 
al. 1999), or it can indirectly interact with the receptor through the Grb2 adaptor that binds to 
pY1068 or pY1086 (Waterman, Katz et al. 2002; Jiang, Huang et al. 2003). We have shown 
that a two-pronged cooperative interaction between Cbl and the EGFR, involving both pY 
sites, is needed for optimal recruitment of Cbl to the receptor and for an efficient 
ubiquitination (Sigismund, Algisi et al. 2013). 
We have previously described how EGF concentration varies among different body 
tissues and fluids, being present from 1 ng/ml up to hundreds of ng/ml even in physiological 
or pathological conditions (see Introduction Section 2.2.2). Interestingly, it was observed by 
our lab that in HeLa cells, treated with increasing doses of EGF, the ubiquitination of the 
EGFR increases sharply over a narrow range of EGF concentrations: EGFR-Ub is minimal at 
1 ng/ml and nearly maximal at 10 ng/ml (Fig. 8A). Conversely, the EGFR-pY content, used 
as a surrogate for receptor activation, follows a typical hyperbolic dose-response curve, which 
can be translated into a linear behavior when a log scale is used for EGF concentration (Fig. 
8B). This behavior was referred to as the threshold effect for EGFR ubiquitination due to the 
Figure 7: EGFR ubiquitination. Schematic 
representation of cooperative binding between the 
Cbl/Grb2 complex and the EGFR. Cbl can bind 
directly to the receptor through pY1045, and 
indirectly through the interaction with Grb2, 
which binds pY1068/86 on the receptor. Only the 
binding of both Cbl and Grb2 to the receptor 
allows for full ubiquitination of the EGFR. 
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fact that ubiquitination is minimal at low doses of EGF, maximal at high doses of EGF, but 
presenting a rapid increase in a very narrow interval of EGF concentrations. 
The mechanism of threshold generation depends in part on the cooperativity of Cbl 
recruitment to the two pY sites, but the exact machinery that determines the ubiquitination 
threshold as a function of EGF concentration remains to be elucidated and represents the 
subject of the present thesis work. 
Initial studies on EGFR ubiquitination showed that when stimulated with high doses of 
EGF, the receptor presented a multi-monoubiquitination pattern (Haglund, Sigismund et al. 
2003). Moreover, a single Ub moiety was sufficient to drive internalization of the receptor, 
although multiple Ub signals were more efficient at driving the process. This is possibly due 
to a higher affinity of the ubiquitinated proteins for ubiquitin receptors, that contain a Ub-
interacting motif (UIM) domain, able to specifically recognizes and bind to ubiquitin. Instead, 
thanks to mass spectrometry analysis approaches, it is now widely accepted that EGFR can be 
both mono- and poly-ubiquitinated through Lys63 chains (Huang, Kirkpatrick et al. 2006), 
but not through Lys48, amplifying the diversity of EGFR-Ub signals. It has been speculated 
Figure 8: EGFR and ubiquitination. A - HeLa cells were stimulated with increasing concentrations of 
EGF for 2 min, as indicated. Total cell lysates were subjected to immunoprecipitation (IP) using an anti-
EGFR antibody and immunoprecipitates were then analyzed by immunoblotting (IB) using the indicated 
antibodies: anti-ubiquitin (Ub), anti-total phosphotyrosine (pY), anti-EGFR intracellular domain (EGFR). B 
- Quantitation of the pY and Ub immunoblots shown in A by densitometry. A threshold effect for EGFR 
ubiquitination is evident, whereas EGFR phosphorylation presents a gradual increment over EGF 
concentrations. (From Sigismund, Algisi et al. 2013; Capuani, Conte et al. 2015). 
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that Lys63 linked chains can increase the avidity of binding of the receptor to UIM-containing 
proteins or act as a completely distinct signal with respect to mono-Ub.  
Ubiquitination of the EGFR was initially shown not to be essential for its internalization. 
Indeed, different studies in which ubiquitination of the EGFR was abolished, either by 
mutagenizing the Cbl binding site (Huang, Kirkpatrick et al. 2006) or the acceptor lysine 
residues in the receptor (Haglund, Sigismund et al. 2003), demonstrated that internalization 
was impaired. However, this simplistic view of EGFR internalization has now been replaced 
by a much more complicated scenario in which the receptor can be internalized by multiple 
and redundant pathways with different Ub requirements (Goh, Huang et al. 2010). 
Although not essential for EGFR internalization, EGFR ubiquitination plays a 
fundamental role both in receptor endocytosis and intracellular fate. Indeed, we have 
previously shown that when EGFR is stimulated with low doses of EGF, it almost exclusively 
undergoes internalization through a clathrin-dependent pathway and, importantly, it is not 
ubiquitinated. Conversely, as EGF doses reach higher concentrations, a substantial fraction of 
the receptor becomes ubiquitinated and is internalized through a clathrin-independent 
pathway (Sigismund, Woelk et al. 2005). Later, it was discovered that the two internalization 
pathways are associated with distinct receptor fates: the clathrin-dependent pathway is mainly 
associated with EGFR recycling to the PM and sustained signaling (Sigismund, Argenzio et al. 
2008), whereas clathrin-independent endocytosis targets the receptor to lysosomal 
degradation resulting in signal attenuation (Sigismund, Argenzio et al. 2008; Sigismund, 
Algisi et al. 2013). Thus, the balance between these two pathways controls the fate (recycling 
vs. degradation) of the EGFR, and consequently the level of signaling and the final biological 
outcome. Together, these findings highlight the importance of the cell’s response to 
increasing levels of ligand and how this response is converted into a biological outcome, as 
discussed in more detail in the following sections. 
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4 - Endocytosis: a brief overview 
 
The PM is a dynamic structure that separates the intracellular environment from the 
extracellular space, regulating the transport of small and big molecules. Whereas small 
molecules, such as amino acids, sugars and ions, can cross the membrane, reaching the 
intracellular compartment through integral membrane proteins like pumps or channels, 
macromolecules are internalized by vesicles derived from invagination of the PM itself, in a 
process known as endocytosis. 
EGFR trafficking is a well-characterized series of events determined by EGF stimulation: 
following ligand-induced activation, the EGFR is internalized by the cell through different 
pathways. Plenty of evidence supports the notion that endocytosis is the major mechanism by 
which the cell attenuates RTK signals, by removing active receptors from the PM. However, 
recent data has demonstrated that endocytosis is also involved in sustaining signaling, thus 
dramatically changing our perspective on this process (Sorkin and von Zastrow 2009; Scita 
and Di Fiore 2010). In the next paragraph (4.1), a general overview on endocytosis will be 
presented, while in the following section (5), the mechanisms underlying the different EGFR 
internalization pathways and their downstream effects, will be described. 
4.1 - The endocytic pathways: different entry portals and sorting 
routes 
Endocytosis is tightly linked to almost all aspects of cellular signaling, leading to the notion 
that endocytosis is actually the master organizer of cellular signaling, providing the cell with 
understandable messages, resolved in space and time. In essence, endocytosis provides the 
communications and supply routes (the logistics) of the cell (Le Roy and Wrana 2005; Platta 
and Stenmark 2011; Sigismund, Confalonieri et al. 2012). 
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Based on the present knowledge, it is thought that endocytosis has evolved for the purpose 
of bringing nutrients inside the cell. Indeed, early prokaryotic life forms used relatively 
simple transport mechanisms, such as pumps or channels, to transport essential molecules 
through the PM. As prokaryotes evolved to eukaryotes, more complex “entry portals” began 
to appear, perhaps due to the selective pressure provided by the transition from a situation in 
which nutrients were present in a concentrated form, to a new and more diluted environment. 
This transition might have selected for those life forms capable of actively searching for and 
concentrating nutrients (Sigismund, Confalonieri et al. 2012). 
Regardless of how endocytosis evolved, in mammalian cells it can occur by distinct 
mechanisms, whose complexity already starts at the PM, where multiple entry portals have 
been described (Fig. 9 and Table II). A traditional way to differentiate between the different 
endocytic pathways is on the basis of cargo size. Particles larger than 500 nm are taken up by 
phagocytosis, a specific form of endocytosis occurring in specialized cells, such as immune 
system cells, which can actively remove solid particles, e.g. pathogens (bacteria) and cell 
debris (apoptotic cells). Phagocytosis is dependent on the receptor-ligand interaction, a 
process through which the specialized cell recognizes a ligand on the particle, which initiates 
the endocytosis of the whole particle. The internalized particle is then broken down by 
enzymes and absorbed into the cell. The uptake of fluids and solutes generally occurs by 
macropinocytosis in which smaller particles are brought into the cell within vesicles up to 500 
nm in diameter, that subsequently fuse with lysosomes to hydrolyze the cargo particles. Both 
phagocytosis and macropinocytosis involve large rearrangements of the PM guided by 
extensive actin cytoskeleton remodeling, and coordinated by the stepwise involvement of the 
RHO-GTPase. 
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 Smaller invaginations (< 200 nm), are instead characteristic of micropinocytosis, which 
includes clathrin-mediated endocytosis (CME) and non-clathrin endocytosis (NCE). Both 
CME and NCE are required for the endocytosis of transmembrane receptors, a wide category 
of proteins that carry out many different roles and which have important implications for cell 
physiology. In the late 70s, Brown and Goldstein established the concept of receptor-
mediated endocytosis in the optimization of the uptake of nutrients. They discovered a clever 
strategy used by cells for increasing the efficiency of the internalization of macromolecules, 
by concentrating them in focused regions of the PM, and thus reducing the energy 
consumption (Anderson, Brown et al. 1977). 
Receptor-mediated endocytosis also harbors other interesting implications connected with 
the signaling network downstream of the internalized receptor. As illustrated in the following 
sections, RTKs are internalized by ligand-mediated endocytosis, a process that is predicted to 
Figure 9: Pathways of entry into the cell. The first distinction between the different entry routes is based 
upon the size of the entering cargo and thus the type of membrane rearrangements. Large particles can be 
taken up by phagocytosis, whereas fluid uptake can occur by macropinocytosis. These two processes are 
dependent on extensive actin-mediated remodeling of the PM. Compared with the other endocytic 
pathways, phagocytosis and macropinocytosis lead to bigger endocytic vesicles. Molecules and receptors 
residing on the PM can be internalized through mechanisms that are dependent on coat proteins (e.g. 
clathrin- and caveolin-dependent pathways) or independent of coat proteins (e.g. clathrin- and caveolin-
dependent pathways, and the CLIC-GEEK pathway). Most internalized cargoes are delivered to the early 
endosome via vesicular or tubular intermediates that are derived from the plasma membrane. (Adapted 
from Mayor and Pagano 2007). 
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remove active signaling receptors from the PM, and to target them for lysosomal degradation. 
However, this process was also found to recycle the receptor back to the membrane, 
determining an extraordinary plasticity of the PM in response to various external stimuli, and 
allowing the cell to polarize the signal (Tomas, Futter et al. 2014). Moreover, it has been 
found that endocytosis of active RTKs could sustain signaling, exposing the receptors to 
substrates that were inaccessible at the PM (Sigismund, Confalonieri et al. 2012). 
The vast impact of endocytosis on cellular homeostasis highlights the importance of 
understanding this process and its many complex pathways. In the following sections, CME 
and NCE, along with their impact on RTK signaling will be discussed in more detail. 
4.2 - Clathrin-mediated endocytosis 
Among the different cell entry routes, the best-characterized endocytic pathway is CME 
(McMahon and Boucrot 2011), whereby PM-resident cargoes are removed from the cell 
surface via clathrin-coated pits, a multi-component endocytic machinery (Schmid and 
McMahon 2007; Kirchhausen, Owen et al. 2014). The CME pathway involves the action of 
adaptor molecules (e.g., adaptor protein 2; AP2) that bridge the internalizing cargo to clathrin. 
Polymerization of the latter drives the progressive invagination of the pit, which is later 
released into the cytoplasm as an endocytic vesicle through the action of the GTPase dynamin 
(Marks, Stowell et al. 2001; Mettlen, Pucadyil et al. 2009). Indeed, the formation of 
invaginated pits and the subsequent budding of the vesicles is an energetically demanding 
process and the contribution in energy, above the structural contribution, is provided by the 
cooperation of clathrin with many different proteins (McMahon and Boucrot 2011). Although 
the most abundant proteins found in coated pits are clathrin and AP2, many other proteins, 
such as EPS15 (which derives its name from ‘EGFR pathway substrate clone number 15’), 
EPS15-interacting proteins (epsins) and adaptor protein 180 (AP180), associate with clathrin-
coated pits and assist in coat formation and vesicle release. Some of these proteins, are found 
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in coated pits, but are not enriched in clathrin-coated vesicles (CCV), suggesting that they 
play assisting roles during clathrin-coat assembly (Mousavi, Malerod et al. 2004). The wide 
variety of proteins involved in CME has raised the possibility that they might be required for 
the formation of distinct types of clathrin pits, specialized in cargo-selection and in specific 
intracellular fate (Sigismund, Confalonieri et al. 2012). 
Clathrin-coated pits and CCV were first 
observed by electron microscopy in the early 
1960s (Roth and Porter 1964).  They are 
characterized by a ‘bristle-like’ appearance of the 
coat in cross sections of forming vesicles. This is 
due to the presence of a lattice of hexagons and 
pentagons on the surface of the PM, making them 
easily discernible (Fig. 10). This distinctive 
pattern is given by the structure of the assembly 
unit of clathrin, a three-legged structure called the 
triskelion (Fig. 11A) that consists of three clathrin heavy chains (CHC) and three clathrin 
light chains (CLC) (Kirchhausen, Owen et al. 2014). When triskelia interact they form a 
polyhedral lattice that surrounds the vesicle: the three CHCs provide the structural backbone 
of the clathrin lattice, and the three CLCs are thought to regulate the formation of and 
Figure 10: The clathrin lattice. Rapid 
freeze-etch micrograph views of clathrin 
lattices on the inner surface of a HeLa cell. It 
shows large, flat hexagonal sheets and the 
progression to a deeply invaginated state 
before membrane scission. (Picture from 
Traub 2009). 
 
Figure 11: The architecture of 
clathrin. A - A schematic 
representation of a clathrin 
triskelion, which highlights the 
various domains of the clathrin 
heavy chain (CHC) with different 
colors (as indicated in the color 
legend). B - A clathrin barrel with a 
single triskelion highlighted in blue. 
(Adapted from Edeling, Smith et al. 
2006). 
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disassembly of the clathrin lattice. When triskelia assemble, they interact with enough 
flexibility to form 6-sided rings - or hexagons - that yield a flatter lattice, or 5-sided rings - or 
pentagons - that are necessary for curved lattice formation. When many triskelions connect, 
they can form a basket-like structure that resembles the panels on a soccer ball (Fig. 11B); by 
constructing different combinations of 5-sided and 6-sided rings, vesicles of different sizes 
can assemble. These clathrin structures generate the force necessary to curve the membrane 
and pull it into a bud (Mousavi, Malerod et al. 2004). 
As anticipated, clathrin alone is not sufficient to drive the invagination and budding of 
endocytic pits; AP2 is the principal protein associated with traffic at the PM in CME. AP2 is a 
heterotetrameric protein that binds clathrin and can interact with membrane proteins and 
lipids. It is a large protein complex that belongs to the Adaptor Protein family involved in 
vesicle formation in different subcellular compartments; however, it is the only member of 
the family involved in the formation of clathrin-coated pits at the PM. AP2 is composed of 
four subunits tightly bound to each other: α, β2, µ2 and σ2 (Edeling, Smith et al. 2006). The 
flexibility of the α2 and β2 subunits permits the simultaneous interaction of the complex with 
phosphoinositides in the PM and with clathrin, whereas µ2 can bind the cargo, thus 
orchestrating clathrin-coated pit assembly.  
The assembly of the clathrin pits originates on the cytoplasmic side of the PM, where 
Figure 12: Clathrin dependent endocytosis. Clathrin-dependent endocytosis starts when clathrin and 
adaptor (AP2) complexes associate with the cargo, thus initiating the formation of a coated pit. As the 
pit matures, additional adaptor and scaffold proteins join the pit, providing a structural platform that 
regulates interactions between the adaptors and the other endocytic proteins. The pinching-off of the pit 
is an event driven by the GTPase dynamin, which releases the clathrin-coated vesicle (CCV) into the 
cytoplasm. (Adapted from Schmid and McMahon 2007) 
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triskelia start to assemble. The assembly is a progressive and dynamic event that starts from a 
small clathrin-coated bud, which grows into a pit that imposes on the membrane a deep 
curvature (Fig. 12). After the formation of deeply invaginated pits, the formation of endocytic 
vesicles requires fission of the budded membrane from the parent membrane. The large 
GTPase dynamin is required for this process. Dynamin has been most studied in the context 
of CCV budding from the PM, but, in addition to acting as a part of the scission machinery 
for the clathrin-dependent pathway, dynamin function is also implicated in vesicle formation 
in some clathrin-independent pathways (McMahon and Boucrot 2011). 
4.3 - Non-Clathrin Endocytosis  
One central obstacle in defining clathrin-independent endocytic pathways has been the lack of 
specific endocytic markers and pathway-specific cargoes. Analysis of the CME pathway 
significantly benefited from signature cargoes, such as the transferrin receptor (TfR) 
(McMahon and Boucrot 2011), which are enriched in the forming endocytic vesicle. 
Moreover, the transient assembly of clathrin and adaptor proteins marks the forming vesicle 
specifically in space and time (Kirchhausen, Owen et al. 2014). In contrast, clathrin-
independent endocytosis has largely been defined by morphological criteria and by the 
persistent uptake of cargoes that can utilize multiple pathways following perturbation of the 
clathrin machinery. Thus, compared to CME, the current picture of NCE is at a much lower 
level of resolution. Additionally, NCE pathways have been studied in the context of CME 
perturbation. Abrogation of CME should affect the endocytosis of cargoes that specifically 
enter through that pathway, leaving relatively unaffected the endocytosis of many other types 
of cargo. Of note, exploiting methods that inhibit CME as a tool to discover new constitutive 
uptake pathways is far from a perfect approach, because such treatment might functionally 
up-regulate a pathway whose role is usually minor or even non-existent under physiological 
conditions. 
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The term NCE is used to refer to a heterogeneous group of pathways that share the 
common property of being insensitive to clathrin depletion, but that frequently depend on 
cholesterol-rich PM microdomains called rafts. The dependency of these pathways on rafts 
renders these pathways sensitive to pharmacological depletion of cholesterol (Cheng, Singh et 
al. 2006). Indeed, there is strong evidence that lipid rafts play a fundamental role in NCE 
pathways. Lipid rafts are membrane microdomains, particularly rich in cholesterol, 
glycosphingolipids, glycosylphosphatidylinositol-anchored proteins (GPI-APs), and signaling 
molecules (Pike 2009). They consist of a dynamic assembly of these structural elements that 
form liquid-ordered domains that float in the less-ordered surrounding membrane. Their size, 
lifetime, biogenesis and lipid/protein composition have yet to be defined. Nevertheless, it is 
thought that lipid rafts probably cluster into large platforms that can segregate membrane 
components, and they have been implicated in the regulation of various physiological 
processes, including protein trafficking and signal transduction. 
The current classification for NCE pathways is based on three major criteria (Table II): 
1. dependency on dynamin for vesicle release: clathrin-independent pathways are 
divided according to whether they use a dynamin-mediated scission mechanism 
(dynamin-dependent) or not (dynamin-independent) (Mayor and Pagano 2007); 
2. presence of coat-like proteins, such as caveolins or flotillins in the case of caveolae-
mediated or flotillin-mediated internalization, respectively; 
3. dependency on small GTPases involved in the endocytic process, which control the 
entry of specific cargoes. In fact, the terminology Cdc42-, RhoA- or Arf6-regulated 
endocytic pathway indicates that modifying the function of these GTPases affects the 
internalization or trafficking of one set of NCE markers (Ellis and Mellor 2000; 
D'Souza-Schorey and Chavrier 2006). 
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Pathway Morphology and size Coat 
Dynamin 
dependence 
Small GTPase 
involved 
Internalized 
cargoes 
Associated/ 
regulatory 
proteins 
Phagocytosis  Cargo shaped > 500 nm None No 
RAC1/RHOA/ 
CDC42 
(depending on 
type) 
Pathogens, 
apoptotic cells, 
FcRs  
Actin, ARP2/3; 
Formins; PI3K; 
WASP; WAVE2; 
amphiphysin; 
coronin; others 
Macro-
pinocytosis 
Ruffled 
0.2-10 µm None 
In some 
cases 
RAC1, 
CDCD42, 
ARF6, RAB5  
RTKs; fluids, 
some bacteria 
Actin, ARP2/3, 
cortactin; PI3K; 
SRC; PAK1; Ras, 
CTBP1/BARS; 
others 
Clathrin-
mediated 
Vesicular 
150-200 nm Clathrin Yes RAB5 
RTKs; GPCR; 
TFR; some toxins; 
bacteria; viruses 
AP-2, EPSINS, 
EPS15, 
intersectin, 
amphiphysin 
(plus many 
others, >50 
Caveolae-
mediated 
Flask-shaped 
 50-120 nm 
Caveolin 
1 and 2 Yes Not clear 
GPI-linked 
proteins; CTxB; 
SV40 
PTRF/cavin; 
SRC, SDPR  
Flotillin-
dependent Vesicular 
 Flotillin 
1 and 2 No None 
CTxB, CD59, 
proteoglycans 
(Glebov, Bright et 
al. 2006; Frick, 
Bright et al. 2007; 
Payne, Jones et al. 
2007) 
None as yet 
CLIC/GEEC Tubular None No CDC42, ARF1 
Fluids, bulk 
membrane, GPI-
linked proteins 
Actin; GRAF1; 
ARHGAP10 
IL-2Rb Vesicular  50-100 nm None Yes  RHO-A, RAC1 IL-2Rb 
PAK1 and 2, 
cortactin, N-
WASP 
Arf6-
dependent Tubular None No (so far) ARF6 
MHC I; MHC II; 
CD59; CD55, 
GLUT1 
None as yet 
 
Table II: Pathways of internalization. Endocytic pathways are mainly classified based on the type of PM 
rearrangements that take place in the internalization event, which depend on the size of the cargo to be 
internalized. Large cargoes (> 500 nm) are internalized through phagocytosis, whereas fluids and solutes are 
generally internalized through macropinocytosis, which involves extensive actin rearrangements. 
Micropinocytic events are responsible for the internalization of smaller cargoes, such as PM resident 
proteins. These pathways  are differentiated based on the presence of coat proteins, the requirement of 
dynamin or other small GTPases. For details on clathrin-mediated, caveolae-mediated, flotillin-dependent, 
and CLIC-GEEK pathways refer to the main text. The IL-2Rb pathway is specific for the uptake of IL-2Rb 
receptor and is dependent on the small GTPase RHO-A, whereas no coat proteins have been identified. The 
GTPase ARF6 seems to be involved in the clathrin- and dynamin-independent internalization of several 
proteins, such as the major histocompatibility complex I (MHC I), β1-integrin, E-cadherin and GPI-
anchored proteins, although a direct role of ARF6 in a non-clathrin endocytosis (NCE) pathway has not yet 
been established. The similitude in cargo specificity with other internalization pathways suggests that IL-
2Rb and ARF6-dependent pathways could represent variations of the same process. 
 
INTRODUCTION 
 44 
By far, the best-characterized NCE pathway is the caveolae-mediated endocytosis 
pathway (Rothberg, Heuser et al. 1992; Pelkmans and Zerial 2005), which is dynamin-
dependent and sensitive to cholesterol depletion (Table II). Caveolae are 50-80 nm flask-
shaped PM invaginations that are marked by the presence of a coating element that belongs to 
the caveolin protein family (Fig. 9). 
 The presence of a coat protein is also a peculiar characteristic of the flotillin-dependent 
pathway, an NCE internalization mechanism in mammalian cells distinct from caveolae-
mediated endocytosis (but still morphologically similar to it), and not inhibited by 
overexpression of GTPase-null dynamin mutants. It was also shown that flotillin1 is 
necessary for cholera toxin (CTxB) uptake (Glebov, Bright et al. 2006). Both caveolin and 
flotillin are inserted into the inner leaflet of the PM and it has been proposed that they induce 
membrane curvature. 
The CLIC/GEEC pathway (CLathrin-Independent Carrier/GPI-anchored protein- 
Enriched Early endosomal Compartment) was discovered while studying the internalization 
of CTxB (Torgersen, Skretting et al. 2001) and GPI-anchored proteins (Kirkham, Fujita et al. 
2005) (for a review see Lundmark, Doherty et al. 2008). This pathway is characterized by 
long and wide tubular invagination, in contrast to the spherical structures that are typical for 
the clathrin and caveolar pathways (Fig. 9). In the CLIC/GEEC pathway, a large volume of 
fluid-phase is co-internalized in a single endocytic event. Of note, the type of cargo 
internalized by this pathway is the same as that depicted in the case of caveolar internalization, 
underlining the redundancy between internalization pathways for some molecules. In addition, 
disruption of the CLIC/GEEC pathway appears to induce compensatory CME of GPI-linked 
proteins (Sabharanjak, Sharma et al. 2002), but whether this allows internalized proteins to be 
trafficked to their appropriate destinations remains unclear. The intracellular destination for 
the CLIC/GEEC pathway internalization route appears to differ between cell types, and 
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includes the lysosomal and the pericentriolar recycling compartments (Fivaz, Vilbois et al. 
2002; Sabharanjak, Sharma et al. 2002). 
One emerging NCE pathway relies on the activity of the coat-like protein endophilin, 
initially ascribed as a component of the CME. Recent evidence indicates that endophilin 
marks and controls a fast-acting tubulovesicular endocytic pathway, referred to as fast 
endophilin-mediated endocytosis (FEME; Boucrot, Ferreira et al. 2015). This pathway is 
independent of clathrin and AP2, and is activated upon ligand binding to cargo receptors, 
resulting in rapid (within seconds) ligand-induced internalization (Boucrot, Ferreira et al. 
2015). The FEME pathway was shown to be dynamin-dependent and the main cargoes 
internalized by this pathway, so far, include some G-protein-coupled receptors, some RTKs 
(including the EGFR), the Interleukin-2 (IL-2) receptor, CTxB and Shiga toxins (Renard, 
Simunovic et al. 2015). The FEME pathway is prominent at the leading edge of the cell and, 
importantly, is also dependent on actin polymerization (Boucrot, Ferreira et al. 2015; Renard, 
Simunovic et al. 2015). 
This link between an endocytic route and a cytoskeleton component highlights how 
endocytosis and actin dynamics are intimately connected. On the one hand, endocytosis and 
recycling can exert spatial and temporal control over a number of critical regulators of actin 
dynamics (Sigismund, Confalonieri et al. 2012), thus influencing the biological outcome of a 
variety of actin-based processes. On the other hand, the actin cytoskeleton is a strong 
requirement along the various steps of the endocytic process, both to provide structural 
support for the intermediates of membrane trafficking, but also to generate forces aimed to 
deform membranes into invaginations or permit the scission of vesicles and their motility. 
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4.4 - The endosomal sorting station 
The budding of the vesicle into the cytoplasm is the first step in a series of events that are 
defined as endosomal sorting (Fig. 13). The endocytic compartments of mammalian cells are 
mainly endosomes and lysosomes and, for the purpose of endocytosis, they travel from the 
periphery to the center of the cell. In contrast, endosomes can also be directed backward to the 
external limits, in the case of recycling or when they are carrying exocytic cargoes. 
Endosomes are compartments containing cargoes internalized at the PM, and which 
represent a station where cargoes can be sorted to the lysosome or recycled back to the cell 
surface. Endosomes can be divided into three categories - early, late and recycling - 
characterized by the time it takes the internalized cargo to reach them or by their function. 
Figure 13: The endosomal sorting station. Endocytic vesicles derived from both clathrin-dependent 
and clathrin-independent internalization fuse at the level of early endosomes. Endosomal trafficking is 
controlled by several Rab proteins (small GTP- binding proteins of the Ras superfamily), which 
specifically reside in a particular type of endosome and which function by recruiting specific effector 
proteins. Following their internalization into early endosomes, receptors can recycle back to the plasma 
membrane or proceed to the late endosomes (LEs), also known as multivesicular bodies (MVBs). In the 
MVBs, cargo destined for degradation is incorporated into intraluminal vesicles (ILVs). The following 
fusion of this compartment with the lysosomes - which host proteolytic enzymes - results in cargo 
degradation. (Adapted from Sorkin and von Zastrow 2009) 
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Early endosomes (EEs) are temporally and spatially the first station on the endocytic 
pathway, and they are often located at the periphery of the cell, receiving most types of 
vesicles from the surface. The EEs represent the major sorting station responsible for: 
• ensuring that receptors that need to be recycled to the PM, reach the recycling endosomes; 
• sorting material towards the trans-Golgi network (TGN); 
• shuttling receptors and internalized materials, which require downregulation/degradation, 
to the late endosomes (LEs). 
The EE environment is mildly acidic causing the dissociation of certain ligands from their 
receptor (not in the case of the EGFR). Moreover, the structure of EEs directly relates to their 
function. EEs present a tubulovesicular morphology with vesicles up to 1 µm in diameter. 
Cargoes destined for the recycling pathway or the TGN are localized in the tubule portion of 
the EE, through which they can be recycled back to the PM. In contrast, cargoes destined for 
degradation are localized in the vesicular portion of the EE, through which they proceed to the 
LE compartment (Fig. 13). 
The LE compartment receives material from EEs, from the TGN on the biosynthetic 
pathway, and from phagosomes on the phagocytic pathway, and are characterized by low 
levels of endocytosed recycling proteins and high levels of endocytosed proteins destined for 
degradation. LEs are mainly spherical, although not entirely lacking tubules. Inside the late 
endosomes, molecules are also sorted into smaller vesicles that bud from the perimeter 
membrane into the endosomal lumen, forming intraluminal vesicles, where cargoes destined 
for degradation are entrapped. This leads to the multivesicular appearance of LEs, and so they 
are also known as multivesicular bodies (MVBs). Mature LE/MVBs fuse with lysosomes, 
pouring vesicles present in the endosomal lumen directly into the lysosomal lumen. 
Lysosomes are the final compartment of the endocytic pathway, and they are considered 
the main hydrolytic and degradative compartment of the cell. Their principal role is to break 
down discarded cellular products and to return new building material to the cytoplasm. 
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Lysosomes have a high content of lysosomal hydrolases provided from the Golgi apparatus 
via LEs, and their internal environment is acidic - pH is around 4.8. By electron microscopy, 
lysosomes are characterized as an electron-dense material and they appear as large vacuoles 
(1-2 µm in diameter), where proteins are efficiently degraded. 
The decision to target cargoes to recycling or degradation is critical for cell homeostasis 
and viability, and thus determinants for cargo fate needed to be identified. Ubiquitination was 
found to be the key signal directing cargoes to the degradative pathway (Raiborg and 
Stenmark 2009; Wollert, Yang et al. 2009), via the action of several proteins harboring UBDs 
that recognize ubiquitinated cargoes and lead them along the degradative route. Ubiquitinated 
cargoes first bind to the UIM-containing protein HRS and then to the endosomal sorting 
complexes required for transport (ESCRTs) in the endosomal station, which sort them to the 
luminal LE vesicles that are then delivered to lysosomes. The ESCRT multiprotein complexes 
play a key role in MVB sorting of ubiquitinated receptors, and they have two important 
features: first they recognize ubiquitinated cargoes, preventing their recycling and retrograde 
trafficking; then they drive the sorting of the cargo in endosomal membrane invaginations, 
forming the intraluminal vesicles that will later fuse with lysosome. 
4.5 - Role of Ub in endocytosis 
Considering the plasticity of Ub signals, it is not surprising that in recent years ubiquitination 
has emerged as a fundamental player in the endocytosis and downmodulation of receptors 
(Dikic 2003; Haglund, Sigismund et al. 2003), thus, having also implications on signaling. 
Many signaling receptors were found to be modified by the attachment of one or more Ub 
moieties, including RTKs, GPCRs and others (Hicke and Riezman 1996). 
Ub-mediated endocytosis was first identified in studies using the yeast Saccharomyces 
cerevisiae that demonstrated that internalization of several PM cargoes required Ub (Kolling 
and Hollenberg 1994; Hicke and Riezman 1996; Galan and Haguenauer-Tsapis 1997). Indeed, 
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monoubiquitination of several yeast membrane receptors is necessary and sufficient for 
endocytosis, causing their internalization and degradation in the vacuole (Hicke and Riezman 
1996). 
In mammalian cells, the role of Ub in endocytosis is somewhat more complicated. In the 
case of ion channels, ubiquitination is essential for their internalization (Sorkin and von 
Zastrow 2009). Instead, for what concern many endocytic cargoes - including RTKs and 
GPCRs - ubiquitination appears to be sufficient for endocytic uptake (Haglund, Sigismund et 
al. 2003; Sigismund, Woelk et al. 2005). Importantly, although many of these cargoes exhibit 
ligand-dependent Ub modification, they can also undergo Ub-independent endocytosis. Thus, 
in mammalian cells, ubiquitination is often sufficient - but not required - for internalization, 
and the involvement of Ub depends on the type of receptor and the internalization route it 
takes. However, as observed in yeast, ubiquitination is required for receptor degradation in a 
ligand-induced Ub-mediated sorting mechanism, where Ub-receptors specifically recognize 
the ubiquitinated cargo through their UBDs. This inexorably destines receptors to lysosomal 
degradation and drives them away from a recycling pathway. 
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5 - Endocytosis of EGFR 
 
When no external stimuli are supplied, the EGFR at steady-state is mainly localized at the PM. 
Binding of EGF to an inactive EGFR results in the dimerization of two EGFR monomers and 
subsequent receptor activation (see Section 2.1), leading to the phosphorylation of Tyr 
residues that can function as docking sites for signaling molecules, as well as for proteins 
involved in internalization pathways. Depending on the EGF dose, the EGFR can be 
internalized through the CME pathway, or via the NCE pathway, with distinct signaling 
outcomes: CME is crucial to sustain EGFR signaling, while NCE is essential for EGFR 
degradation in the presence of high EGF doses, safeguarding cells against excessive signaling 
(Sigismund, Algisi et al. 2013). The existence of two distinct EGFR internalization routes 
raises the question: how does the cell sense the signal and target the EGFR to the correct 
internalization pathway? 
Of note, the switch between CME and NCE occurs over a narrow range of EGF 
concentrations (1-10 ng/ml), and it has been proposed that this fine modulation is transmitted 
to the cell in a pY-based cooperativity mechanism (Sigismund, Algisi et al. 2013). The 
molecular determinants for distinguishing between the CME and NCE internalization 
pathways have been elucidated by our group in a study that demonstrated that the EGFR 
ubiquitination pattern is responsible for committing the receptor to the different 
internalization routes (Sigismund, Woelk et al. 2005). At low doses of EGF, the receptor is 
not ubiquitinated and is internalized through CME, whereas at higher ligand concentrations 
the receptor becomes ubiquitinated and, concomitantly, the NCE internalization pathway is 
activated (Fig. 14). At this point, the receptor is internalized both through CME and NCE, 
with a ratio that is about 60 and 40% respectively (Sigismund, Argenzio et al. 2008). Both 
CME and NCE direct the EGFR to EEs, where its fate is decided: either it is recycled back to 
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the PM or it is destined to degradation via the LEs and lysosomes (Fig. 15). Thus, 
distinguishing between the two endocytic pathways is essential for understanding EGFR 
biology, since both pathways have profound and distinct effects on receptor fate, and hence 
on downstream signaling. 
5.1 - CME sustains EGFR recycling to the cell surface and prolonged 
EGFR signaling 
The first EGFR internalization route to be characterized was the CME, through which the 
receptor is rapidly removed from the cell surface and internalized via clathrin-coated pits. The 
phosphorylated receptor is recognized by CME adaptors that recruit the clathrin apparatus and 
drive pit formation (Fig. 15, see also Introduction Section 4.2). In particular, a direct 
interaction between the phosphorylated EGFR and the µ2 subunit of the adaptor protein AP2 
has been observed (Sorkin, Mazzotti et al. 1996). Apart from AP2, other adaptors play a role 
in EGFR endocytosis, namely EPS15/EPS15L1 and epsins (Carbone, Fre et al. 1997; 
Sigismund, Woelk et al. 2005), which, however, also have a role in EGFR-NCE. It has also 
been found that Grb2 and Cbl are necessary for CME of the EGFR (Jiang, Huang et al. 2003; 
Stang, Blystad et al. 2004). Since Cbl-mediated ubiquitination of the EGFR was not necessary 
Figure 14: EGFR ubiquitination and 
EGFR-NCE activation occur in the same 
EGF concentration interval. Dose-response 
curves of EGFR-NCE (black) and EGFR 
ubiquitination (red) in HeLa cells. Cells were 
stimulated with increasing doses of EGF and 
ubiquitination was measured. NCE activation 
was measured with an iodinated 
internalization assay at the indicated EGF 
concentrations. (From Sigismund, Algisi et 
al. 2013) 
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for its internalization via CME (Huang, Goh et al. 2007), Cbl and Grb2 may be involved in 
CME via a distinct mechanism independent of EGFR ubiquitination. 
In the presence of low EGF concentrations, EGFR is internalized almost exclusively 
through the CME route, and preferentially destined to recycling to the PM (around 70%), 
although there is a minor component that is directed to degradation (around 30%) (Sigismund 
2008). CME-dependent recycling could represent an important aspect of EGFR signaling, 
conferring to the receptor spatial and temporal specificity; CME represents a way to redirect 
the receptor to precise membrane locations where a specific signal is required. Continuous 
Figure 15: EGFR endocytosis and endosomal sorting. Following ligand binding, EGFR can undergo 
clathrin-dependent endocytosis (CME, right) or clathrin-independent endocytosis (NCE, left). In both 
cases, endocytic vesicles derived from both clathrin-dependent and -independent pathways fuse with 
early endosomes (EEs). From here, ubiquitinated receptors are sorted into late endosomes (LEs) and 
intraluminal vesicles (ILVs) of multivesicular endosomes (MVEs) and subsequently targeted for 
lysosomal degradation. In contrast, non-ubiquitinated receptors are recycled to the plasma membrane. 
Ubiquitin is an essential signal for endosomal sorting of EGFRs into the ILVs of MVEs. Components of 
the endocytic machinery, including Eps15, epsins, and the ESCRT components, contain ubiquitin-
binding domains (UBDs) that have been implicated in recognizing and sorting ubiquitinated receptors 
either at the plasma membrane or at endosomes. The ESCRT-I and -II components (not shown) 
assemble in super-complexes and have been proposed to organize buds at the endosomal membrane. 
The ESCRT-III (not shown) complex associates with ESCRT-II and forms polymers that drive 
membrane scission and ILV biogenesis. Deubiquitinating enzymes (DUBs) catalyze the removal of 
ubiquitin from receptors before their translocation into the ILV, without allowing cargo to escape. 
(Adapted from Haglund and Dikic 2012) 
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recycling would also allow for multiple cycles of signaling and could also protect the receptor 
from degradation in conditions of limited ligand availability. Indeed, recycling of the receptor 
to the PM is a way to achieve sustained signaling. 
CME was also found to be necessary for downstream EGFR signaling: in fact, some 
downstream signaling pathways, such as AKT and ERK, require intact CME machinery 
(Sigismund, Argenzio et al. 2008; McMahon and Boucrot 2011). In addition, the execution of 
complex biological functions, such as EGFR-activated DNA synthesis, depends on functional 
CME (Sigismund, Argenzio et al. 2008). An interpretation of these findings could be that the 
initial phase of signaling, or the peak-phase, is endocytosis-independent and probably occurs 
at the PM, whereas the later decay-phase requires CME. 
5.2 - NCE is preferentially coupled to EGFR degradation 
Functional ablation of clathrin in HeLa cells has been shown to have little effect on EGFR 
degradation, implying that CME is not the major pathway responsible for receptor 
downmodulation and degradation (at least in the model system under scrutiny; Sigismund, 
Algisi et al. 2013). Indeed, an alternative cholesterol-dependent NCE internalization pathway 
for the EGFR has been detected in the same cells following stimulation with high EGF dose 
under CME-deficient conditions (i.e., lacking clathrin or AP-2; Sigismund, Argenzio et al. 
2008). Inhibition of this pathway using cholesterol-interfering drugs such as filipin, showed 
that NCE directs around 90% of the EGFRs that are internalized through this pathway to 
degradation, thereby resulting in downmodulation of EGFR signaling. 
Despite recent efforts, the EGFR-NCE pathway has not yet been fully elucidated and its 
existence is still questioned by some researchers in the field. In our laboratory, we have 
directed much effort towards the characterization of the EGFR-NCE pathway and the 
molecular mechanisms that govern it. EGFR-NCE that gets activated at high EGF doses and 
responsible for receptor degradation, is apparently distinct from other forms of clathrin 
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independent endocytosis, as evidenced by the peculiar dependence on dynamin 1/2 and Cdc42, 
but not other known genetic NCE determinants (Sigismund, Argenzio et al. 2008; Sigismund, 
Algisi et al. 2013; Caldieri, Barbieri et al. 2015). However, the lack of knowledge of the 
precise molecular determinants involved in EGFR-NCE has prevented in the past years, the 
use of molecular genetics tools to selectively inhibit this pathway, and thus hampered the 
study of the role of EGFR-NCE in cellular homeostasis. 
To address this knowledge gap, our group has attempted to characterize the NCE 
molecular players using an integrated approach based on immunopurification of EGFR-NCE 
vesicles, SILAC-based mass spectrometry, and RNA interference (RNAi)-based validation 
screening (Caldieri, Barbieri et al. 2015). In this work, novel regulators of EGFR-NCE have 
been identified and validated. Among the regulators of the pathway, the ER-resident protein 
Reticulon-3 (RTN3) was identified, suggesting a role of the ER in EGFR internalization. This 
finding led to the discovery that EGFR-NCE represents a completely novel form of 
endocytosis that requires the formation of specific contacts between the PM and the cortical 
ER, mediated by RTN3 (Fig. 16). This novel NCE pathway has been termed ER-mediated 
endocytosis (ERME;  Caldieri, Barbieri et al. 2015). By knocking down RTN3 expression in 
Figure 16: A novel model for EGFR 
endocytosis and the involvement of the 
ER. At high doses of EGF, EGFR is 
internalized both through CME and 
NCE. The proposed NCE pathway 
ERME is mediated by tubular structures 
that, differently from clathrin-coated 
pits, require contact sites between the 
plasma membrane and the endoplasmic 
reticulum (ER-PM) in order to progress. 
The establishment of these contact sites 
is Reticulon-3 (RTN3)-dependent. By 
inhibiting EGFR entry via NCE, RTN3 
KD affects subsequent EGFR targeting 
to the lysosomal compartment and 
delays EGFR degradation. (Adapted 
from Caldieri, Barbieri et al. 2015) 
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HeLa cells, we confirmed that this specific NCE pathway is the major endocytic pathway 
responsible for EGFR degradation and long-term attenuation of EGFR signaling. Thus, this 
pathway might serve as a crucial negative regulator of EGFR signaling in response to 
excessive stimulus. It’s worthy to note that hereafter we refer to NCE as the specific EGFR 
clathrin independent, RTN3 dependent pathway described in this section. 
5.2.1 - EGFR ubiquitination and EGFR-NCE are mechanistically linked 
As stated above, the switch between CME and NCE occurs over a narrow range on EGF 
concentrations (1-10 ng/mL). Notably, EGFR ubiquitination also occurs in this EGF 
concentration range (Sigismund, Algisi et al. 2013). Indeed, the EGFR-Ub and the EGFR-
NCE curves are almost superimposable (Fig. 14), indicating that EGFR ubiquitination 
correlates with NCE activation. This notion is supported by the finding that only the EGFR-
NCE pathway displays a threshold-controlled dose-response curve over the EGF 
concentration range, while both EGFR-CME and EGFR-total internalization display 
completely different behaviors, not matching that of EGFR ubiquitination (Sigismund, Algisi 
et al. 2013). In addition, EGFR mutants that affect EGFR ubiquitination also affect the 
capacity of the mutants to be internalized through NCE (Sigismund, Algisi et al. 2013). The 
fact that EGFR ubiquitination and NCE activation only occur at high EGF concentrations 
suggests that this pathway serves to prevent overstimulation of the cell in the presence of 
excess ligand by directing receptor to degradation. 
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6 - EGFR and other RTKs in cancer 
 
In general, RTKs have been shown not only to be key regulators of normal cellular processes, 
but also to have a critical role in the development and progression of many types of cancer 
(Zwick, Bange et al. 2001). The first connection between RTKs and human cancers was made 
in 1984 (Ullrich, Coussens et al. 1984), when the predicted viral-erbB (v-erbB) mRNA 
oncogene product, which was identified in chickens infected with avian erythroblastosis virus, 
was found to be homologous to the amplified EGFR gene in human A431 epidermal 
carcinoma cell line. This discovery connected, for the first time, an animal oncogene with a 
human gene that encodes a cell-growth-controlling membrane protein. 
In the same study, the EGFR gene was found to be amplified and rearranged in the cell 
line under study, resulting in the expression of a receptor with a truncated extracellular 
binding domain (Ullrich, Coussens et al. 1984). Since this discovery, the link between RTKs 
and cancer became increasingly evident and now it is well known that aberrant RTK signaling 
is critically involved in human cancer and other hyperproliferative diseases (Gschwind, 
Fischer et al. 2004, see also Section 6.1.1).  
 As with other types of oncogenes, oncogenic activation of RTKs can occur through several 
mechanisms, including gene amplification, protein overexpression, amino acid deletions and 
mutations. These alterations result either in the expression of a constitutively active form of 
the receptor or of a non-degradable receptor. Deletions and mutations can occur within the 
extracellular region, as well as in the catalytic domain or in the juxtamembrane region, 
resulting in a constitutive active RTK (for a recent review of EGFR mutations in lung cancer 
see Siegelin and Borczuk 2014). Additionally, mutations in the TM domain of the EGFR can 
also result in ligand-independent kinase activation, as reported for the other ErbB family 
member, ErbB2 (HER2; Bargmann, Hung et al. 1986). Somatic and germline mutations that 
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are associated with distinct inherited and spontaneous human cancer syndromes, have been 
observed in at least ten different RTK families (Robertson, Tynan et al. 2000). 
In many cases, alterations affect the ability of the RTK to be properly ubiquitinated and 
downregulated, thereby causing sustained signaling, as in the case of the EGFR and the MET 
receptor (Kon, Kobayashi et al. 2014). The most frequent genetic alterations, in these cases, 
consist of mutations that affect the region encoding the intracellular domain of RTKs, usually 
encompassing the binding region for Cbl (as in the case of MET receptor), the major E3 
ligase involved in RTK ubiquitination (Sigismund, Confalonieri et al. 2012). An alternative 
mechanism for preventing receptor downmodulation is proposed to be the occlusion of 
relevant binding sites on the EGFR, for instance by heterodimerization with other ErbB 
family members that renders the EGFR inaccessible to effectors, such as Cbl (Shtiegman, 
Kochupurakkal et al. 2007, see also page 60).  
 Another way by which RTK functionality can be deregulated is to establish an autocrine 
growth factor loop, as frequently described for the EGFR and the IGF-IR (Smith, Derynck et 
al. 1987; Kaleko, Rutter et al. 1990; Saeki, Salomon et al. 1995). This mechanism of 
oncogenic transformation occurs when an RTK is aberrantly expressed or overexpressed in 
the presence of its cognate ligand, or when overexpression of the ligand occurs in the 
presence of its associated receptor. In many solid tumors it has been shown that elevated 
levels of both growth factor receptor and its ligand are expressed concomitantly (Salomon, 
Normanno et al. 1995; Scala, Saeki et al. 1995).  
6.1 - ErbB family receptors and cancer 
Over the past two decades, it has become evident that the ErbB family members play an 
important part in the initiation and maintenance of several solid tumors. This has led the 
scientific community to invest much effort into the development and expansion of specific 
ErbB inhibitors for cancer therapies. In the following paragraphs, the role of ErbB receptors 
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in human cancer will be briefly discussed, whereas in Section 6.2 an overview of the possible 
intervention strategies and therapies targeting ErbB receptors will be given. 
6.1.1 - EGFR in human tumors 
Since the milestone discovery in 1984, when the sequence of EGFR was recognized to be 
closely related to the sequence of the v-erbB oncogene, many studies have been dedicated to 
characterizing EGFR deregulation in cancer. EGFR is now known to be deregulated in a 
number of tumors, including a variety of lung tumors, breast, prostate and ovarian carcinomas, 
gliomas and others (Arteaga and Engelman 2014). There are different ways through which 
EGFR can be involved in neoplastic transformation or in cancer progression, as outlined 
above for RTKs in general. These mechanisms include EGFR gene amplification or mutation, 
genetic rearrangements, and production of different spliced variants. The subsequent changes 
in EGFR expression are often correlated with poor prognosis in patients and usually 
determine increased activity of the EGFR, which is able to be activated both in a ligand-
dependent and -independent manner. 
Overexpression of EGFR is frequently found in non-small cell lung cancer (NSCLC), 
head and neck cancer, glioma, esophageal cancer, and colorectal cancers (Yarden and Pines 
2012), as well as in bladder, cervical, ovarian, kidney, and pancreatic cancer (Zwick, Bange et 
al. 2001). One important mechanism leading to EGFR overexpression is EGFR gene 
amplification, with more than 15 copies per cell reported in certain tumors (Velu 1990). 
Moreover, mutations in regulatory regions of the gene (e.g. the promoter) can be responsible 
for EGFR increased expression levels (Hudson, Thompson et al. 1990; Hou, Johnson et al. 
1994). In general, elevated levels of EGFR expression are associated with the late stages of 
disease progression and often correlate with high metastatic rate and increased tumor 
proliferation (Nicholson, Gee et al. 2001; Selvaggi, Novello et al. 2004; Zimmermann, 
Zouhair et al. 2006). 
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Mutations affect different mechanisms of EGFR regulation (Fig. 17 and Table III), 
leading to enhanced EGFR activity. These mutations can be single base mutations or larger 
genetic rearrangements. In gliomas, for example, EGFR amplification is often accompanied 
by structural rearrangements that cause in-frame deletions in the extracellular domain of the 
receptor. This is the case for an oncogenic mutation that deletes exons 2–7 in the receptor 
ectodomain, denoted EGFR variant III (EGFRvIII), that is found in up to 60% of 
glioblastomas (Nishikawa, Ji et al. 1994) and in other types of cancer, including lung, breast, 
ovarian and prostate cancer (Fig. 17) (Wikstrand, Hale et al. 1995; Gan, Cvrljevic et al. 2013). 
EGFRvIII exhibits constitutive dimerization, impaired downregulation, and aberrant tyrosine 
kinase activity, all resulting in enhanced tumorigenicity (Nishikawa, Ji et al. 1994). EGFRvIII 
Figure 17: Oncogenic EGFR variants. Cartoon shows the positions of key EGFR mutations/variants in the 
corresponding domains. Large rearrangements of the extracellular domain of the EGFR, as well as single base 
mutations in the juxtamembrane or intracellular domains, can cause deregulated EGFR-dependent signaling 
activity.EGFR vI, EGFR vII, and EGFR vIII represent the three major types of deletion mutations in the 
extracellular region. Of these mutant forms, EGFR vIII is the most common mutation in gliomas. V689M and 
L703F mutations are localized in the EGFR juxtamembrane (Huang, Nijman et al. 2006) region and were 
identified as constitutively active in NSCLC patients. JM seems to play an activating role, enhancing the 
formation of the asymmetric dimer and promoting allosteric activation of the acceptor kinase. 
The most prevalent EGFR mutations occur in the kinase domain of the receptor: the small in-frame deletion 
around the conserved LREA motif of exon 19 and the L858R point mutation in exon 21, account for more 
than 90% of all EGFR kinase mutations. Point mutations G719 account for approximately another 5% of 
EGFR mutations. These EGFR mutations activate the EGFR signaling pathway and promote EGFR-mediated 
pro-survival and anti-apoptotic signals through down-stream targets. In contrast to the activating mutations, a 
point mutation T790M was identified as a secondary mutation responsible for acquired resistance to EGFR 
inhibitors, accounting for more than 50% of primarily EGFR TKI- sensitive lung tumors that become resistant 
to EGFR inhibitors. Other resistance mutations, such as D761Y and L747S, have been reported but seem to be 
rare. Finally, two kinds of deletion mutants in the C-terminal domain have been reported in gliomas: EGFR 
vIV and vV. These mutants seem to be constitutively active. (Adapted from Zhang, Stiegler et al. 2010) 
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is not the only variant resulting from a deletion mutation in the extracellular region; two other 
major variants exist (EGFRvI, EGFRvII, originally discovered in gliomas). However, 
EGFRvIII remains the most common mutation in gliomas (Zhang, Stiegler et al. 2010).  
Somatic activating mutations in EGFR have been discovered in the last 10 years in a 
subset of NSCLCs (Fig. 17) (Lynch, Bell et al. 2004; Paez, Janne et al. 2004; Pao, Miller et al. 
2004). Like the EGFRvIII mutation, these mutations enhance EGFR activity, causing ligand-
independent firing and/or boosting receptor-dependent signaling up to 50-fold over the basal 
unliganded receptor activity (Yun, Boggon et al. 2007). One kind of somatic mutation that 
boosts EGFR-dependent signaling acts through impairment of Cbl binding. This mutation is 
represented by the EGFR L834R (or L858R, accordingly to whether the numbering system 
includes the signal peptide) mutant (Fig. 17) (Shtiegman, Kochupurakkal et al. 2007) and was 
identified in NSCLC patients. Although the L834R mutation does not directly disrupt the Cbl 
binding site on the receptor (pY1045), which shows a normal - or even increased - 
phosphorylation, it causes reduced Cbl recruitment to the EGFR and defective EGFR 
ubiquitination (Shtiegman, Kochupurakkal et al. 2007). The authors proposed that this 
reduction in Cbl recruitment could be due to occlusion of its binding site through the 
formation of a heterodimer between L834R-EGFR and ErbB2, which appears to form even in 
the absence of ligand stimulation (for L834R mutant see also Discussion Section 7, page 163). 
Impairment of Cbl-mediated ubiquitination of the EGFR causes persistent activation of 
downstream signaling molecules, including Ras, MEK and ERK signaling effectors (Kon, 
Kobayashi et al. 2014). 
Another very potent mechanism for constitutive EGFR activation in a variety of human 
cancers is the autocrine/paracrine stimulation via growth factor loops. The most prominent 
ligand, which is involved in autocrine growth receptor activation is TGFα, whose 
coexpression with the EGFR is frequently observed in glioblastomas and squamous cell 
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carcinomas of the head and neck, as well as in lung, pancreas, ovarian and colon cancers 
(Grandis, Chakraborty et al. 1998; Yarden 2001). 
The abovementioned mechanisms are all frequently associated with different types of 
cancer, and the identification and characterization of these non-physiological alterations is 
fundamental to the development of an effective anti-cancer therapy and to discover new 
druggable targets. Even though this thesis is focused on the study of the EGFR, it is 
interesting to highlight how the ability of the EGFR to heterodimerize with the other ErbB 
receptors, in particular ErbB2, plays an important role in cancer. 
6.1.2 – ErbB2/HER2 
The involvement of ErbB2 in cancer was first inferred from a study on its rat orthologous Neu 
(Schechter, Stern et al. 1984). ErbB2 is typically amplified in human cancers, such as breast, 
ErbB receptor Alteration Cancer type References 
EGFR Mutation (L834R, 
etc.) 
Lung NSCLS  (Lynch, Bell et al. 
2004; Paez, Janne et al. 
2004; Pao, Miller et al. 
2004) 
EGFR EGFR-vIII Glioma (Sugawa, Ekstrand et al. 
1990) 
EGFR Amplification Lung NSCLC, head and 
neck, glioma, esophageal, 
colorectal 
(Yarden and Pines 
2012) 
ErbB2 (HER2) Amplification Breast, gastric, esophageal Cancer genome atlas 
network 2012 
ErbB2 (HER2) Mutation Breast, lung, gastric, 
bladder, endometrial 
Cancer genome atlas 
network 2012 
ErbB3 (HER3) Mutation Breast, gastric (Jaiswal, Kljavin et al. 
2013) 
ErbB4 (HER4) Mutation Melanoma, lung NSCLC, 
medulloblastoma 
(Prickett, Agrawal et al. 
2009; Gilbertson, 
Hernan et al. 2001) 
TGFα  Overexpression Prostate, lung, pancreas, 
ovary, colon, head and neck 
(Yarden and Sliwkowski 
2001) 
Neuregulin1 Overexpression colorectal, head and neck (Wilson, Lee et al. 2011; 
Yonesaka, Zejnullahu et 
al. 2011) 
Table III: Alterations of ErbB Receptors and Ligands in Human Cancer. (Adapted from Arteaga and 
Engelman 2014) 
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ovarian, gastric and esophageal tumors (Table III; Arteaga and Engelman 2014). In 
approximately, 30% of breast cancers ErbB2 was found to be amplified 2- to 20-fold and was 
associated with poor prognosis (Slamon, Clark et al. 1987). This was the first time that an 
oncogenic alteration had been associated with poor prognosis in cancer patients, suggesting a 
causal relationship to cancer. Additional evidence linking ErbB2 with cancer progression 
comes from the improvement in survival of patients with ErbB2-amplified early-stage breast 
cancer treated with the ErbB2 antibody Trastuzumab (Gajria and Chandarlapaty 2011).  
As previously discussed, ErbB2 is an orphan receptor, meaning no ligands have been 
identified that bind to and activate the receptor. The mechanism of activation of ErbB2 is 
indeed peculiar: it acts as a co-receptor for the other EGFR family members (Fig. 4, 
Introduction Section 2.4). The mechanism underlying the oncogenic potential of 
overexpressed ErbB2 may relate to the increased potential for heterodimer formation. In 
particular, the specific EGFR ligands or the neuregulins (that bind ErbB3 or ErbB4) are able 
to induce heterodimer formation between a high-affinity ligand binding receptor and ErbB2. 
ErbB2 possesses the strongest tyrosine kinase activity among the ErbB receptors (Moasser 
2007), and the heterodimers that is forms are pathophysiologically relevant since a plethora of 
signaling pathways, including MAPK, PI3K, Ras and Src, are activated by such heterodimers 
and appear to be important for tumor growth (Prenzel, Zwick et al. 2000; Arteaga and 
Engelman 2014). 
ErbB2-containing heterodimers are also characterized by a higher affinity for ligands with 
respect to the other heterodimeric receptor complexes, owing to slow rates of growth factor 
dissociation (Aria-Romero 2010). Moreover, ErbB2-containing heterodimers undergo slow 
endocytosis, and are more frequently recycled back to the cell surface (Sorkin, Di Fiore et al. 
1993). These features contribute to the generation of potent mitogenic signals from ErbB2-
containing heterodimers, through the simultaneous and prolonged activation of multiple 
signaling pathways.  
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6.2 - Possible drugs targets and therapy 
In the last decades, the increasing knowledge of RTK structure and the activation mechanisms, 
as well as of the signaling pathways they control, allowed the development of target-specific 
drugs and new anti-cancer therapies. Approaches towards the prevention or interference of 
deregulated RTK signaling include the development of selective compounds that target either 
the extracellular ligand-binding domain or the intracellular tyrosine kinase domain or 
substrate-binding region (Fig. 18). 
6.2.1 - Monoclonal antibodies 
One of the most successful classes of targeted therapies designed to selectively kill tumor 
cells are monoclonal antibodies (mAbs) directed against the extracellular domain of RTKs. At 
the end of last century, recombinant antibody technology made immense progress in the 
design, selection and production of newly engineered antibodies (Farah, Clinchy et al. 1998; 
Hudson 1999). This research field has since been accelerated by the generation of humanized 
antibodies for targeted cancer therapies, which are now widely used in the clinic (Nelson, 
Figure 18: Schematic representation of 
EGFR and ErbB2 inhibitors. In the 
cartoon, EGFR or ErbB2-addicted cancer 
cells are treated with an ErbB small-molecule 
inhibitor (tyrosine kinase inhibitor; TKI) or 
monoclonal antibody, resulting in 
suppression of downstream signaling. EGFR 
homodimers (left) and EGFR-ErbB2 
heterodimers (right) are shown. Adapted 
from Arteaga and Engelman 2014) 
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Dhimolea et al. 2010). 
Anti-RTK mAbs work by blocking the ligand:receptor interaction, and therefore inhibiting 
ligand-induced RTK downstream signaling and/or increasing receptor internalization and 
downregulation. Alteration of the intracellular signaling pattern inside the targeted tumor cell 
may lead to growth inhibition and/or apoptosis (Zwick, Bange et al. 2001). The most widely 
used EGFR-neutralizing mAbs are Cetuximab and Panitumumab (Table IV). These 
antibodies specifically bind to the extracellular domain of the EGFR, thereby preventing 
ligand binding (Bou-Assaly and Mukherji 2010; (Dubois and Cohen 2009), and are most 
effective in cancers that express ligand-activated, wild-type EGFR. They have also been 
proposed to enhance EGFR endocytosis and downregulation (Doody, Wang et al. 2007); 
however, the exact mechanism of their action is still under investigation. 
Cetuximab, commercialized as Erbitux, is an approved treatment for head and neck 
squamous cell carcinomas and colorectal cancer as indicated by the information provided by 
the company that produced it (MerkSerono, www.merckserono.com). It has also been 
Drug Type of molecule Mechanism of action Notes 
Trastuzumab Humanized IgG1, 
binds 
juxtamembrane 
domain IV 
inhibits ectodomain cleavage and 
ligand-independent ErbB2-
containing dimers; ADCC and 
adaptive immunity to ErbB2 
 
Cetuximab 
human-murine 
chimeric IgG2, binds 
ligand-binding 
domain 
inhibits ligand-dependent 
activation of EGFR  
Panitumumab 
human IgG1, binds 
ligand-binding 
domain 
inhibits ligand-dependent 
activation of EGFR  
Lapatinib small molecule  reversible, ATP-competitive TKI  
Erlotinib small molecule  reversible, ATP-competitive TKI  
Afatinib small molecule  
irreversible, ATP-competitive 
TKI  
Neratinib small molecule  
irreversible, ATP-competitive 
TKI 
Trials in patients 
with tumors 
expressing ErbB2 
mutants are 
ongoing. 
 
Table IV: ErbB receptor inhibitors. Mechanisms of action and key clinical trials for the principal clinical-
grade ErbB targeted therapies. (Adapted from Arteaga and Engelman 2014) 
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evaluated as a first-line treatment for advanced NSCLC in clinical trials, with the result that 
combination of chemotherapy plus Cetuximab improves overall survival in advanced NSCLC 
patients with respect to chemotherapy alone (Yang, Liu et al. 2014). Panitumumab is 
commercialized as Vectibix and to date is approved for the treatment of patients with 
metastatic colorectal cancer (Table IV; Arteaga and Engelman 2014).  
In the case of ErbB2, the best-characterized and most widely used blocking antibody is 
Trastuzumab, approved for the use in breast cancers since early 2000s (Slamon and Pegram 
2001) and more recently used also for HER2-positive advanced gastric or gastro-esophageal 
junction cancer (Bang, Van Cutsem et al. 2010). 
6.2.2 - Tyrosine kinase inhibitors (TKIs) 
Another effective approach to inhibiting aberrant RTK signaling is to use small molecule 
inhibitors that selectively interfere with the intrinsic tyrosine kinase activity of the EGFR. 
Kinase inhibition is achieved by two alternative mechanisms: by competing with ATP for 
binding to the catalytic site or by blocking the catalytic activity of the receptor. These 
mechanisms block receptor autophosphorylation and thus activation of downstream signal 
transducers. Two EGFR-targeting reversible small molecule inhibitors, Gefitinib 
(commercialized as Iressa) and Erlotinib (commercialized as Tarceva) received fast-track 
approval from the US Food and Drug Administration (FDA) as treatment for patients with 
advanced NSCLC who had failed to respond to conventional chemotherapy (Table IV; 
Sharma, Bell et al. 2007). These molecules were designed to act as competitive inhibitors of 
ATP binding to the active site of the EGFR (Barker, Gibson et al. 2001; Wakeling, Guy et al. 
2002), so that receptors are inhibited at lower concentrations of the drug resulting in a 
favorable therapeutic index. Early clinical data showed that 10% of patients with NSCLC 
responded to Gefitinib or Erlotinib, followed by the observation that sensitivity to Gefitinib 
and Erlotinib strongly correlated with the presence of a new class of somatic activating 
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mutations in the EGFR kinase domain (Lynch, Bell et al. 2004; Paez, Janne et al. 2004; Pao, 
Miller et al. 2004), including the L834R substitution (see page 60). This finding can be 
explained by the fact that EGFR kinase domain mutations result in hyper-activation of the 
kinase, so conferring a dependence of the tumor cells on the mutated kinase. The treatment of 
TKI-sensitive cells with these targeted therapies appears to cause a form of ‘oncogenic shock’, 
which is proposed to result from the gradual degeneration of downstream mitogenic signals, 
leading to a temporary predominance of apoptotic signals (Sharma, Bell et al. 2007). 
EGFR lung cancers carrying the primary activating mutations often develop a secondary 
mutation T790M that confers resistance to the TKI. Following the identification of this 
secondary mutation (Pao, Miller et al. 2005) there was a huge effort to develop an inhibitor of 
the T790M EGFR mutant and thus overcome resistance. This effort led to the development of 
second-generation EGFR inhibitors, such as Afatinib (Table IV). Although these second-
generation drugs are able to inhibit the T790M EGFR mutant, they do so at concentrations 
that also inhibit wild-type EGFR. Thus, treatment with these inhibitors induces severe side-
effects, such as acneiform-like rash and diarrhea (Hirsh 2011). 
Another approach to inhibition of ErbB kinases has been to develop irreversible inhibitors 
(reviewed in Sharma, Bell et al. 2007). These inhibitors are able to form a covalent bond with 
a crucial Cys residue in the active site of the enzyme: Cys797 in EGFR, and Cys805 in ErbB2 
(Singh, Dobrusin et al. 1997; Fry, Bridges et al. 1998). Since only EGFR and ErbB2, among 
the ErbB receptors, have cysteine residues at these corresponding positions, these irreversible 
inhibitors show very high specificity towards these two enzymes and are thus called dual 
inhibitors for their dual specificity. Interestingly, resistance to irreversible dual inhibitors does 
not develop as quickly as it does with reversible inhibitors such as Gefitinib and Erlotinib. 
Indeed, the irreversible EGFR inhibitors CL-387785 (Discafani, Carroll et al. 1999) and 
Canertinib (Smaill, Rewcastle et al. 2000) can overcome resistance to L834R-mutated EGFR 
harboring the T790M mutation, whereas the reversible EGFR and ErbB2 inhibitor Lapatinib 
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was ineffective in this regard (Carter, Wodicka et al. 2005; Kobayashi, Ji et al. 2005). 
Similarly, a small subset of NSCLCs that express the EGFRvIII (see Introduction Section 
6.1.1) are also insensitive to Gefitinib and Erlotinib, but show sensitivity to the irreversible 
TKI Neratinib (Ji, Zhao et al. 2006) that is currently in phase I/II clinical trials for NSCLC 
patients (Table IV). Therefore, several independent lines of evidence underscore the use of 
irreversible ErbB inhibitors, especially for situations in which reversible inhibitors of EGFR 
lose efficacy (Sharma, Bell et al. 2007). 
During the development of this project, we took advantage of Getifinib, the competitive 
reversible inhibitor of ATP-binding, to study the role of phosphatases in the early steps of 
EGFR activation upon kinase inhibition (see Results Section 4). 
  
INTRODUCTION 
 68 
7 - Modeling biological networks 
 
As mentioned earlier, one big challenge in studying complex signaling pathways is the step of 
deciphering the exact mechanisms that underlie the translation of an extracellular signal to a 
specific cellular outcome. In particular, when dealing with RTKs, the situation becomes more 
complex, since pathways that rely on the activation of RTKs are highly complex and 
interconnected. Cell biology and biochemistry provide tools to study local and short-range 
interactions within biological networks, but are subjected to technical limitations and not 
suitable to study long-range connections. Computational modeling aims to bridge this gap by 
revealing hidden functional aspects and topological properties (Enuka, Feldman et al. 2015). 
Mass action modeling, also known as mechanistic computational modeling, is the main 
approach used to model layers of the ErbB network. Mass action modeling is based on 
ordinary differential equations (ODEs) through which it is possible to express the overall rate 
of change in the concentrations of cellular components. The rate equations that form the 
model are connected; this means that a change in the concentration of one component causes 
a change in another component.  
The dynamics of the signaling cascade is modeled by an ordered set of rate equations. 
Rate equations generally have the form: 𝑑𝐶𝑑𝑡 = 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 − 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 
which states that the change in concentration of a certain component over time is dependent 
upon the rate of generation minus the rate of consumption of the component. The generation 
and consumption terms can be either a constant or a function of the concentration of cellular 
components, such as mRNAs, proteins, and small molecules. Usually, the set of ODEs is too 
much complicated for an analytical solution. Therefore, mechanistic models are solved using 
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numerical methods that are based upon two parameters that must be either measured or 
estimated for every species in the model, namely, initial concentrations and rate constants. 
When experimental data for these parameters are missing, it is necessary to estimate their 
values. When parameters must be estimated, simulation techniques are used to ensure that the 
final output is robust against variations in these parameters. 
The modeling process is a recursive procedure where a first model is built based on 
current knowledge. From this first version of the model, new hypotheses are derived. Later, 
these hypotheses are examined using available tools (e.g. wet lab experiments, analysis of 
data available in the literature, databases, etc.), and finally the model is validated or else 
rejected. In the case where the model is validated, the regulatory mechanisms that were 
forecast by the model are confirmed. In contrast, if the model is rejected, the model must 
undergo a refinement process.  
7.1 - ErbB receptors: a multi-layered signaling network 
Although the ErbB network possesses a relatively high level of complexity in terms of its 
players and interactions, it is however suited to the development of computational models. 
The ErbB network topology consists in three layers: (1) the input layer, (2) the signal 
processing layer and (3) the output layer. 
The input layer is the part of the system where the ligand activates the receptor and, as 
previously discussed, it consists of several extracellular ligands, as well as 4 receptors, of 
which 3 can bind a ligand, whereas only one is an orphan receptor, able to heterodimerize 
with the other receptors (see Introduction Section 1). The different receptor-ligand complexes 
that are formed upon receiving a stimulus, drive distinct biological outcomes (Yarden and 
Sliwkowski 2001). The four receptors can assemble into several kinds of homo- and hetero-
dimers and the situation becomes more complicated due to the fact that each receptor has at 
least nine tyrosine residues that can be phosphorylated. Moreover, each receptor displays 
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distinct functional properties which depend on ligand affinity, increasing the complexity of 
this network.  
The ErbB signal processing unit is composed of several kinase cascades. The first kinase 
in each cascade is able to phosphorylate, and thereby activate, the successive kinase in the 
cascade. Interestingly, although the processing unit is composed of components that are 
shared among several signaling pathways, the system is still able to signal through the correct 
pathway to produce the correct output. An example of this is the case of the EGF and the 
nerve growth factor (NGF). While the former activates ErbB receptors, the latter activates the 
TrkA receptor, but both signals are funneled to the MAPK module. However, while EGF 
transiently activates ERK, which is the last step in the enzymatic cascade of the MAPK 
module, NGF causes sustained activation of ERK, leading to profoundly different outputs. In 
particular, transient activation on ERK by EGF leads to proliferation, while sustained 
activation by NGF induces differentiation (Marshall 1995). A possible explanation for such a 
different output in a system that utilized the same players was given by the hypothesis of the 
Figure 19: a “bow tie” or “hourglass” network. A useful concept that has emerged is that of a 
“bow tie” architecture of robust networks, linking the input layer of ligands and receptors to the 
output layer of biological outcomes, in which modularity and redundancy are important 
components. (Adapted from Meyts 2015) 
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presence of different feedback loops governing this processing layer. Indeed, if cells were 
stimulated with EGF, the MAPK network exhibits a negative feedback loop between ERK 
and RAF (two players of the same network module), while with NGF stimulation, ERK 
positively signals backwards to RAF through PKC, thereby re-feeding the enzymatic cascade, 
resulting in a switch-like response of ERK activation (Birtwistle, Hatakeyama et al. 2007). 
Villasenor et al. recently gave another possible mechanism by which cells can 
differentiate between EGF and NGF stimuli (Villasenor, Nonaka et al. 2015). Their study is 
based on the evidence that phosphorylated receptors are removed from the PM and packaged 
in endosomes. With the use of a mathematical model, they were able to determine that 
different endosomes contain the same mean amount of phosphorylated EGFR (pEGFR). By 
increasing EGF dose, cells respond to higher EGF concentrations by increasing the number of 
endosomes, keeping the average number of pEGFR almost constant in each endosome. This 
mechanism is referred to as an ‘analogue-to-digital conversion’ that ensures a robust signal 
and can regulate the signaling of the activated receptors in both space and time. 
Moreover, the authors also found that changing how the pEGFR is distributed between 
endosomes modifies how the cells decipher the signal. Indeed, different growth factors either 
increase or decrease the number and size of endosomes in various cell types: this is the case 
of NGF or HGF in PC12 or primary mouse hepatoblasts, respectively (Villasenor, Nonaka et 
al. 2015). In NGF or HGF treated cells, a prolonged Erk signaling was observed and the 
authors proposed that this sustainment of signaling is due to the presence of endosomes that 
are smaller in size but more numerous. In contrast, in the same cell lines they observed that 
EGF determines a transient ERK activation, likely due to the presence of larger endosomes. 
The picture that they outlined is that the pEGFRs contained in smaller endosomes are 
protected from phosphatases and surrounded by a favorable signaling environment, whereas 
pEGFRs that reside in bigger endosomes are shorter-lived and dephosphorylated faster. 
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In the ErbB network, the kinetics of the processing unit downstream of the receptor is a 
major determinant of cell fate because the different network modules that can potentially exist 
(like positive or negative feedback loops) in the processing layer, determine a number of 
different signals, later transmitted to the output layer. The output layer receives information 
from the processing unit and directs specific transcriptional responses that determine cell fate. 
While much progress has been made in our understanding of the ErbB network, specifically at 
the input and signal processing unit layers, the output layer still lacks quantitative mechanistic 
models. Modeling of the output layer would require more detailed data than is currently 
available in terms of metabolic, biochemical, and transcriptional processes (Enuka, Feldman 
et al. 2015). 
7.1.1 - Positive and negative feedback circuits  
Autocrine and paracrine loops are important positive feedback circuits that act at the input 
layer, enhancing the ErbB network from the very first stimulus, i.e., ligand binding. In fact, 
activation of this network causes transcription of multiple ErbB ligands, such as TGFα and 
HB-EGF (Schulze, Lehmann et al. 2001; Brankatschk, Wichert et al. 2012), which then re-
feed into the network. Another important feedback loop, in this case a negative circuit, is the 
endocytosis of activated receptors. Ligand-receptor complexes are indeed internalized through 
distinct mechanisms that overall result in either recycling or degradation in lysosomes. 
At the border between the input layer and the signaling processing unit, phosphatases 
importantly impinge on EGFR activity and on that of the other ErbB receptors. Indeed, 
phosphoreceptors can undergo dephosphorylation both at the PM and at later intracellular 
compartments (Ostman and Bohmer 2001; Roda-Navarro and Bastiaens 2014), and are thus 
negatively regulated by this class of enzymes. In a work by Kleiman et al. it was highlighted 
how phosphorylated ErbB receptors are short-lived with half-lives of a few seconds (Kleiman, 
Maiwald et al. 2011). By exploiting mathematical modeling, combined with the use of 
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phosphatase inhibitor drugs, the authors observed that a rapid phosphoturnover occurred both 
on PM-resident receptors, as well as on multiple adaptor proteins and signaling kinases, such 
as AKT and MAPK. Thus, the complexes formed on the cytoplasmic tail of activated 
receptors and the downstream signaling cascades that they regulate, are highly dynamic and 
antagonized by potent phosphatases. 
For what concerns the signaling processing unit, a major attenuator of signals within this 
layer is dephosphorylation by specific phosphatases. NRG-stimulated signaling offers an 
example of the complex role of phosphatases along this signaling pathway. NRG binds to 
ErbB4, stimulating signals that involve activation of the MAPK and AKT phosphorylation 
cascades. These two pathways are interconnected since activation of the AKT pathway 
decreases the level of ERK activation. The protein phosphatase 2A (PP2A) has contradicting 
effects on ERK signaling: it can negatively regulate the MAPK cascade (by 
dephosphorylation of MEK) and can simultaneously enhance the MAPK cascade by 
dephosphorylating AKT (Enuka, Feldman et al. 2015). 
7.2 - Existing EGFR models 
Computational models of the EGFR have been useful in the past to understand complex 
biological behaviors of receptor systems. At the end of last century, two complementary 
approaches were used in different attempts to model EGFR activity. Several groups focused 
their efforts on the ligand-induced endocytosis of EGFR (Sorkin, Waters et al. 1991; Wiley, 
Herbst et al. 1991; Reddy, Wells et al. 1998). These models mainly concentrated on receptor 
trafficking, without including mechanistic details of downstream signaling. This kind of 
approach did not consider qualitative differences in receptor signaling from the different 
cellular compartments, either the PM or endosomes. 
In contrast, other models focused on the acute response that is characteristic of ligand-
activated EGFR, jumping to the signaling processing layer without considering internalization 
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events. An example of such a modelling approach is the development of an EGFR network 
model to describe signal transduction events down to the Ras activation (Kholodenko, Demin 
et al. 1999). This model included a set of experimentally verified rate constants of the 
biochemical reactions that participate in signal transduction. Another example is given by a 
model by Kholodenko that presented a detailed outline of ERK activation cascades after 
EGFR activation (Kholodenko, Kiyatkin et al. 2002), but always disregarding the endocytosis 
component and the compartmentalization of the signaling receptors. 
The need to implement both the input layers and the signaling processing unit into a single 
model, came at the beginning of this century. Understanding the lack of information that was 
produced by modeling only different layers, different groups proposed a series of models that 
were trying to contemplate more aspects of EGFR activation and signaling. In 2003, Wiley et 
al. proposed a model that attempted to give a comprehensive understanding of the EGFR 
signaling network, including both trafficking and signaling events (Resat, Ewald et al. 2003). 
By using a multicompartment model, the authors investigated the distribution of the receptors 
among cellular compartments, as well as their potential signal transduction characteristics (as 
schematized in Fig. 20).  
The authors ended up with a model consisting of hundreds of distinct endocytic 
compartments and about 13,000 reactions/events that occur over a broad spatio-temporal 
range. Interestingly, in this model physiochemical aspects of ligand-receptor interactions, 
such as pH-dependent binding in different endosomal compartments were incorporated. To 
determine the utility of the model for biologically relevant predictions, they simulated and 
confirmed experimentally the differential activation of the EGFR by either EGF or TGFα 
ligands. It turned out that TGFα-stimulated receptors preferentially signal from the PM, 
whereas EGF-stimulated receptors produce a signal that is biased towards the endosomal 
compartment. The model was also able to predict the kinetics and magnitude of 
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downregulation of EGF- or TGFα-stimulated receptors. Overall, this work suggested that 
EGFR trafficking controls the modulation and diversification of the signaling cascade that has 
been shown to be dependent upon the ligand that activates the receptor. 
In 2009, the non-linear dependence of downstream signaling on receptor activity was 
highlighted by a computational model from Lauffenburger and Sorger (Chen, Schoeberl et al. 
2009). This model included all the four receptors of the ErbB family, the activity of two 
ligands (EGF and HRG), and first- or second-order reactions to include protein endocytosis 
and degradation. Moreover, the model aimed to understand the readouts of the AKT and ERK 
pathways given different concentrations of the two ligands as input. The authors found that 
Figure 20:  An EGFR model that integrates both internalization and signaling. A - The diagram shows 
the compartments involved in receptor trafficking. EGFR can be internalized through a ligand induced 
pathway, where clathrin-coated pits direct the receptor to early endosomes (EEs), or through a constitutive 
pathway where random non-coated (smooth) vesicles are formed at the PM. Vesicles can recycle back to the 
PM with different rates. EEs converge into late endosomes, whereby the receptor is mainly degraded and only 
a few non-stimulated receptors can escape lysosomal degradation and be recycled to the PM. B - The signal 
transduction model that was integrated in this work, was adapted from Kholodenko et al. (Kholodenko 1999). 
From the monomeric form of the EGFR (R) a subsequent series of reactions lead to the formation of the 
phosphorylated receptor (RP) and to the activation of signaling cascades that converge at the level of Ras 
activation. (Adapted from Resat, Ewald et al. 2003) 
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their model, comprising all the four ErbB receptors, but designed to encompass the 
internalization events in a simplified approach, was able to recapitulate the activities of the 
AKT and MAPK modules. In particular, the model predicted, and experiments confirmed, 
that the system shows an ultrasensitive behavior: due to signal amplification, as the signal 
descends down the MAPK cascade, the stimulus/response curve becomes steeper and the 
relationship between EGFR activation and ERK phosphorylation is nonlinear.  
Another interesting model that integrates both EGFR activation and internalization is the 
work by Resat group (Shankaran, Zhang et al. 2012), where authors focused their attention on 
the integration of EGFR compartmentalization and the activity of phosphatases. The major 
features of their model were the following: I) less than 40% of EGFR are phosphorylated at 
any time-point, even after stimulating cells with saturating ligand doses; II) the rate of 
receptor dephosphorylation at the PM is comparable to that in the EEs; III) dephosphorylation 
of the receptor in the LEs, which determines signal extinction, is an important component of 
the cellular response and takes place before lysosomal degradation. 
Thus, the EGFR modeling field is constantly updating and integrating novel discoveries 
and experimental evidence into pre-existing models with the aim of recapitulating in-silico a 
complete scenario of EGFR-dependent signaling. Such an approach is important as it could 
help shed light on EGFR-related dysfunctions and pathologies.  
RATIONALE	  of	  the	  PROJECT	  
 77 
Rationale of the project 
 
EGFR-dependent signal transduction is a key molecular chain of events important in 
determining cell fate and growth. EGFR biology is a very complex system, the complexity of 
which starts already at the PM, where diverse ligands can interact with and activate the 
receptor. Moreover, heterodimerization of the EGFR with other ErbB receptors increases the 
number of possible states of the EGFR at the PM and contributes to diversification of the 
downstream biological responses. 
Endocytosis has also emerged as a crucial regulator of the EGFR signaling response, since 
it is widely accepted that internalized receptors continue to signal from intracellular 
compartments. In addition, the internalization route is critical in the regulation of receptor fate. 
Indeed, EGFRs can be internalized through CME, which is fundamental for sustaining 
signaling, or via NCE, which is essential for receptor degradation. This latter endocytic 
pathway is activated only when high doses of EGF are applied to cells, thus, safeguarding 
them against excessive signaling. In particular, NCE activation occurs over a very narrow 
interval of EGF concentrations and is mechanistically linked to EGFR ubiquitination, which 
follows a threshold response over the same range of EGF doses. The link between an 
analogical variable (i.e., the linear input of EGF concentrations) and the digital output (i.e., 
ubiquitination threshold and NCE activation) needs to be clarified. 
A number of modeling approaches aimed at understanding ErbB receptor signaling, 
particularly that of the EGFR, are present in literature. Until now, more effort has been placed 
on implementing aspects of the output layer and the signaling processing unit, covering many 
aspects of EGFR activation and signal transduction. However, EGFR ubiquitination has 
received scarce attention. In the present thesis, we have integrated this novel aspect with 
previously published models to obtain a detailed model for EGFR activation at the PM. 
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In order to deal with the system complexity, we have adopted an integrated research 
approach, combining wet-lab experiments and mathematical modeling. We designed an Early 
Activation Model (EAM) that integrates all the EGFR dynamics occurring at 2 minutes after 
EGF stimulation. The novelty that we introduced in our model was to add the EGFR 
ubiquitination component to the system, as a function of EGFR phosphorylation. Although 
the aim of this thesis project was not to build the mathematical model itself, but rather to 
combine experimental evidence and modeling issues in a parallel progression towards model 
development, throughout the next sections, I have tried to give an in-depth overview of the 
processes leading to the construction of the EAM. Although I did not tackle the mathematical 
side of the modeling, I have discussed the preceding more-simplified models (MPM and 
MPM-B), which were developed before reaching the final model, the EAM. The final model 
provides an extensive description of the mechanisms that contribute to the creation of the 
threshold given increasing EGF concentrations, from the dissection of the phosphorylation 
events to the mechanism of EGFR ubiquitination. 
We proceeded in modeling EGFR activation by taking advantage of the many existing 
models of EGFR activation and dependent signaling (see Introduction Section 7), while also 
taking into account the ubiquitination component of the system that has so far received scarce 
attention. This integrated approach aimed to decipher the biological rules underlying the 
generation of the ubiquitination threshold, but also to generate novel and unexpected 
predictions of the behavior of the EGFR system that could contribute to aberrant EGFR 
signaling, as observed in cancer.  
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Materials and methods 
Solutions 
Phosphate-buffered saline  
NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4 10 mM 
KH2PO4 2 mM 
 
8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g of KH2PO4 were dissolved in 800 
ml of distilled water. The pH was adjusted to 7.4 with HCl and the volume was brought to 1 
litre with distilled H2O. 
Tris-HCl (1 M) 
121.1 g of Tris base were dissolved in 800 ml distilled H2O. The pH was adjusted to 7.4, 7.6 
or 8.0 with HCl, and distilled H2O was added to bring the volume up to 1 litre. 
Tris-buffered saline (TBS) 
NaCl 137 mM 
KCl 2.7 mM 
Tris HCl, pH 7.4 25 mM 
 
8 g of NaCl, 0.2 g of KCl and 3 g of Tris base were dissolved in 800 ml of distilled H2O. The 
pH was adjusted to 7.4 with HCl and distilled H2O was added to bring the volume up to 1 litre. 
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10X SDS-PAGE running buffer 
Glycine 192 mM 
Tris HCl, pH 8.3 250 mM 
SDS 1% 
 
10X Western transfer buffer 
Glycine 192 mM 
Tris HCl, pH 8.3 250 mM 
 
For 1X western transfer buffer, the 10X stock was diluted 1:10 with ddH2O and 20% v/v 
methanol or ethanol. 
 
50X TAE (Tris-Acetate-EDTA)  
Tris base 2 M 
Acetic acid 1 M 
EDTA, pH 8 10 mM 
 
The pH was adjusted to 8.5 with HCl and distilled H2O was added to bring the volume up to 1 
liter. 
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Protein buffers 
1X JS buffer 
HEPES, pH 7.4 50 mM 
NaCl 150 mM 
Glycerol 10% 
Triton X-100 1% 
MgCl2 1.5 mM 
EGTA 5 mM 
1X RIPA buffer 
Tris HCl, pH 7.6 50 mM 
NaCl 150 mM 
NP-40 1% 
SDS 0.1% for standard RIPA 
1% for RIPA 1% SDS 
0% for RIPA w/o SDS 
Deoxyxholic acid 0.5% 
EGTA 5 mM 
 
500X Protease inhibitor cocktail from Calbiochem, sodium pyrophosphate pH 7.5 20mM, 
sodium fluoride 250 mM, PMSF 2 mM, and sodium orthovanadate 10 mM were added to the 
buffer just before use. 
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1X Laemmli buffer 
SDS 2% 
Tris HCl, pH6.8 62.5 mM 
Glycerol 10% 
Bromophenol blue 0.1% 
β.Mercaptoethanol 5% (v/v) 
 
SDS-PAGE sample buffer was prepared as a 5X stock solution and stored at -20°C, protected 
from light. 
Reagents and antibodies 
Human recombinant EGF was from INALCO. 125I-EGF was from Perkin Elmer. Doxycycline 
hydrocloride was from SIGMA. 
Antibodies were:  
• an in-house polyclonal anti-EGFR against aa 1172-1186 of human EGFR; 
• a monoclonal anti-EGFR (m108 hybridoma, directed against the extracellular domain of 
human EGFR, ATCC); 
• anti-pY (4G10, Millipore); anti-Ub (P4D1, Santa Cruz Biotechnology, used in all anti-Ub 
IBs); 
• anti-Ub FK2 (BIOMOL, used in all ELISA assays); 
• anti-EGFR phospho-specific antibodies (pY1045, pY1068, Cell Signaling); 
• anti-tubulin and anti-Grb2 (Santa Cruz Biotechnology); 
• anti-Cbl polyclonal (Santa Cruz Biotechnology, used in IB) and monoclonal (BD, used in 
IF) antibodies. 
RNAi oligos 
Oligos used in experiments reported in the figures in the Results Section 7.1 
• EGFR human (Invitrogen): CCGCAGCAUGUCAAGAUCACAGAUU 
• Negative control siRNA: the negative control used in our assays was All Stars from 
Qiagen. 
MATERIALS	  and	  METHODS	  	  
 83 
Cloning techniques 
Agarose gel electrophoresis 
DNA samples were loaded on 0.8%-1% agarose gels along with DNA markers (1 kb DNA 
Ladder, NEB). Gels were made in TAE buffer containing Gel Red (Biotium), according to 
manufacturer’s instructions, and run at 100 V until desired separation was achieved. DNA 
bands were visualized under a UV lamp. 
Minipreps 
Individual colonies were used to inoculate 3 ml LB (containing the appropriate antibiotic) and 
grown overnight at 37°C. Bacteria were transferred to Eppendorf tubes and centrifuged for 5 
minutes at 16,000xg using a 5415 R centrifuge. Minipreps were performed with the Wizard 
Plus SV Minipreps Kit (Promega) following manufacturer’s instructions. The plasmids were 
eluted in 30 µl nuclease free H2O. 
Diagnostic DNA restriction 
Between 0.5 and 5 µg DNA were digested for 2 hours at 37°C with 10-20 units of restriction 
enzyme (New England Biolabs). For digestion, the volume was made up to 20-50 µl with the 
appropriate buffer and distilled H2O. 
Large scale plasmid preparation 
Cells containing transfected DNA were expanded into 250 ml cultures overnight. Plasmid 
DNA was isolated from these cells using the Qiagen Maxi-prep kit according to 
manufacturer’s instructions. 
Transformation of competent cells 
An aliquot of competent cells TOP10 (Invitrogen) were thawed on ice for approximately 10 
minutes prior to the addition of plasmid DNA. Cells were incubated with DNA on ice for 30 
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minutes and then subjected to a heat shock for 45 seconds at 42°C. Cells were returned to ice 
for an additional 5 minutes. Then, 900 µl of LB medium was added and the cells were left at 
37°C for further 60 minutes before plating them onto agar plates with the appropriate 
antibiotic. Plates were incubated overnight at 37°C. 
Constructs and plasmids  
N-terminal HA-tagged human c-Cbl WT [kindly provided by Y. Yarden - Weizmann Institute, 
Israel (Levkowitz, Waterman et al. 1998)] were subcloned into pBABE-puro, pGEX-6P (GE 
Healthcare) or pSLIK (Invitrogen) vectors, through restriction enzyme digestion (New 
England Biolabs) and ligation (New England Biolabs), starting from original pcDNA. All 
clones were sequence verified. 
EGFR mutants were generated by site-directed mutagenesis of the human EGFR cDNA and 
sub-cloned into the pBABE-puro retroviral vector. All clones were sequence verified. 
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Cell culture 
Cell culture media 
HeLa cells were grown in GlutaMAX™-Minimum Essential Medium (MEM, Gibco 
Invitrogen), supplemented with 10% Fetal Bovine Serum South American (FBS SA, 
Invitrogen), sodium pyruvate 1 mM (Euroclone), non-essential aminoacids (Euroclone), and 2 
mM glutamine.  
Murine fibroblastic NR6 cells, Phoenix helper cell were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Lonza), supplemented with 10% Fetal Bovine Serum South 
American (FBS SA, Invitrogen) and 2 mM glutamine.  
NIH 3T3 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Lonza), 
supplemented with 10% Calf Serum South American (Invitrogen) and 2 mM glutamine. NIN 
cells stably expressing human EGFR were cultured with supplemental 2.5 ug/ml puromycin; 
NIN cells stably expressing also human c-cbl were cultured with supplemental 200 ug/ml 
neomycin. 
WI38 were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Lonza), supplemented 
with 10% Fetal Bovine Serum North American (FBS NA, Invitrogen) and 2 mM glutamine.  
CASKI cells were grown in RPMI (Lonza) medium supplemented with 10% Fetal Bovine 
Serum North American (FBS NA, Invitrogen) and 2 mM glutamine. 
BT20 cells were grown in GlutaMAX™-Minimum Essential Medium (MEM, Gibco 
Invitrogen), supplemented with 10% Fetal Bovine Serum North American (FBS NA, 
Invitrogen) sodium pyruvate 1 mM (Euroclone), non-essential aminoacids (Euroclone), and 2 
mM glutamine.  
CHO cells were grown in  Ham's F12 supplemented with 10% Fetal Bovine Serum South 
American (FBS SA, Invitrogen). 
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Transfections 
RNAi transfections were performed using LipofectAMINE RNAi MAX reagent from 
Invitrogen, according to manufacturer’s instructions. Oligos for c-Cbl and Cbl-b mRNA 
silencing were designed with BLOCK-iT™ RNAi Designer from Invitrogen. Cells were 
subjected or double (in both suspension and adhesion) transfection, treated with 10 nM RNAi 
oligo and analyzed 5 days after transfection.  
Retroviral and lentiviral infection 
Human EGFR WT was stably expressed in NIH 3T3 cells by retroviral infection. Briefly, 
vuses were produced by transfecting the Phoenix helper cell line with 5-10 µg of DNA. 48 
hours after transfection, supernatant was collected and passed through a 0.45 µm filter. After 
the addition of 8 µg/ml polybrene (Hexadimethrine bromide, Sigma), the supernatant was 
added to NIN 3T3 cells plated on 10 cm cell culture dishes. Two cycles of infection were 
repeated, after which the medium was replaced with standard HeLa medium (see above “Cell 
culture media”). 48 hours after infection, selection of infected cells was performed by adding 
puromycin 
Single clones were isolated and characterized for EGFR surface expression levels and 
homogeneity by immunofluorescence (IF) (Fig. 41). Briefly, cells were fixed in 4% 
paraformaldehyde and stained (prior to permeabilization) with the monoclonal anti-EGFR 
antibody that recognizes the extracellular domain (m108). Cells were then incubated with 
Alexa488-conjugated secondary antibody (Molecular Probes) and stained with DAPI. Clones 
expressing different levels of surface EGFR, assessed by saturation binding with 125I-EGF, 
were selected for further analysis (Figure 8A, right panel). 
These clones were subsequently infected with an inducible lentiviral construct carrying cDNA 
encoding human Cbl (pSLIK-neo vector). This construct was engineered starting from a Cbl 
cDNA kindly provided by Y. Yarden (Weizmann Institute, Israel). All clones were sequence-
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verified. Stable bulk populations were obtained after 10 days of neomycin treatment (200 
µg/ml). Upon doxycycline treatment (0.5 µg/ml for 16 h), Cbl was expressed at levels ~80-
100–fold greater than those of the endogenous protein and displayed a homogeneous 
expression level (assessed by IF, Fig. 44). The same clones infected with the empty vector 
were treated with doxycycline in the same way and used as control.  
EGF treatment was for 2 min at 37oC. Under these conditions, EGFR internalization is 
negligible and the observed phosphorylation and ubiquitination events occur primarily at the 
PM. 
The EGFR mutants were stably expressed in NR6 and CHO cells and were generated as 
described for NIH 3T3 cells. EGFR surface expression in the transfectants was assessed by 
saturation binding with 125I-EGF. 
Protein production and purification 
GST-fusion protein production 
List of the GST-proteins used: 
- c-Cbl: full length (Homo sapiens); 
- Grb2: full length (Homo sapiens); 
Rosetta cells transformed with the indicated GST-fusion construct were picked from 
individual colonies and, used to inoculate 50 ml LB (containing ampicillin at 25 µg/ml and 
cloramphenicol at 34 ug/ml). Cultures were grown overnight at 37°C. The 50 ml overnight 
culture was diluted in 1 litre of LB and was grown at 37°C until it reached an OD of 
approximately 0.6. Then, 1 mM IPTG was added and the culture was grown either at 37°C for 
theree hours or at 18°C overnight. Cells were then pelleted at 4000 x g for 10 minutes at 4°C 
and pellets were resuspended in GST-lysis solution (20 ml/liter of bacteria). Samples were 
sonicated 5 times for 20 seconds each on ice and were pelleted at 14000 x g for 30 minutes at 
4°C. 600 µl – 1ml of Glutathione Sepharose 4B (GE Healthcare) beads (1:1 slurry), 
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previously washed 3 times with PBS and once with GST-lysis buffer, was added to the 
supernatants and samples were incubated for either 4 hours or overnight at 4°C with rocking. 
Beads were washed once in PBS containing 1% triton, followed by 2 times in PBS alone. 
Beads were finally resuspended in 1:1 volume of GST-maintenance solution and kept at -
80°C. 
 
GST-lysis solution  
HEPES, pH 7.5 50 mM 
NaCl 200 mM 
EDTA 1 mM 
Glycerol  5% 
NP-40 0.1% 
Protease Inhibitors (Calbiochem) 1:500 
 
GST-maintenance solution 
Tris, pH 7.4 50 mM 
NaCl 100 mM 
EDTA 1 mM 
Glycerol  10% 
DTT 1 mM 
Protease Inhibitors (Calbiochem) 1:500 
Cleavage of GST-fusion proteins 
GST-fusion proteins were cleaved with PreScission Protease (provided by the IFOM 
Biochemistry Unit). 1 unit of enzyme for 100 µg of fusion protein was added to the beads in 
the presence of GST-maintenance solution and incubated either overnight at 4°C or for 4 
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hours at room temperature. After cleavage the supernatant containing the cleaved protein was 
collected. 
Protein procedures 
Cell lysis  
After washing with PBS 1X, cells were lysed in JS or RIPA buffer directly in the cell culture 
plates using a cell-scraper and clarified by centrifugation at 16,000 xg for 20 min at 4ºC using 
a 5415 R centrifuge. Protein concentration was measured by the Bradford assay (Biorad) 
following manufacturer’s instructions. 
For the DELFIA assays and some IP assay, lysis was performed in RIPA buffer containing 
1% SDS, followed by clarification for 1 h at 120,000 g and dilution to a final SDS 
concentration of 0.2%.  
1% SDS lysis 
For this lysing procedure prepare two independent solutions (see Protein Buffers section): 
- RIPA 2% SDS 
- RIPA w/o SDS 
Wash cells on ice with cold PBS, twice and let cells dry well. Add lysis buffer 2% SDS and 
ultracentrifuge cells at 45000 rpm at 4’C. Discard pellet, collect the supernatant and dilute 1:5 
the lysate in RIPA w/o SDS to reach a concentration of 0.2% SDS. If performing an IP, keep 
SDS at a concentration of 0.2% also during IP and wash steps. 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made from a 30%, 37,5:1 mix of acrylamide: 
bisacrylamide (Sigma). As polymerization catalysts, 10% ammonium persulphate (APS) and 
TEMED were used. 
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Separating gel mix 
 Gel % 
 6 8 10 
Acrylamide mix (ml) 2 2.7 3.3 
1.5 M Tris HCl, pH 8.8 (ml) 2.5 2.5 2.5 
ddH2O (ml) 5.3 4.6 4 
10% SDS (ml) 0.1 0.1 0.1 
10% APS (ml) 0.1 0.1 0.1 
TEMED (ml) 0.01 0.01 0.01 
TOTAL (ml) 10 10 10 
 
Stacking gel mix 
Acrylamide mix (ml) 1.68 
1 M Tris HCl, pH 6.8 (ml) 1.26 
ddH2O (ml) 6.8 
10% SDS (ml) 0.1 
10% APS (ml) 0.1 
TEMED (ml) 0.01 
TOTAL (ml) 10 
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Western Blot (WB) 
Desired amounts of proteins were loaded onto 1-1.5 mm thick SDS-PAGE gels for 
electrophoresis (Biorad). Proteins were transferred in western transfer tanks (Biorad) to 
nitrocellulose (Schleicher and Schnell) in 1X Western transfer buffer (supplemented with 
20% methanol or ethanol) at 30 V overnight or 100 V for 1 hour for small gels and at 30 V 
overnight or 0.8 A for 2 hours for large gels. Ponceau staining was used to determine the 
efficiency protein transfer onto the filters. Filters were blocked for 1 hour (or overnight) in 
5% milk or BSA in TBS supplemented with 0.1% Tween (TBS-T). After blocking, filters 
were incubated with the primary antibody, diluted in TBS-T 5% milk or BSA, for 1 hour at 
room temperature, followed by three washes of ten minutes each in TBS-T. Filters were then 
incubated with the appropriate horseradish peroxidase-conjugated secondary antibody diluted 
in TBS-T for 30 min. After the incubation with the secondary antibody, the filter was washed 
3 times in TBS-T (10 minutes each) and the bound secondary antibody was revealed using the 
ECL method (Amersham) or ChemiDoc MP system (Biorad). 
Anti-Ub western blot 
After SDS-PAGE, proteins were transferred on a PVDF (polyvinylidene fluoride) membrane 
(Immobilion P, Millipore), previously activated by incubation in 100% MeOH for 5 minutes 
at room temperature. Ponceau staining was avoided since it might interfere with antibody 
recognition. After transfer, filters were subjected to a denaturing treatment in a dedicated 
solution for 30 minutes at 4ºC. This treatment denatures Ub and facilitates the recognition of 
latent Ub epitopes by anti-Ub antibody resulting in intensification of the anti-Ub signal. After 
extensive washing in TBS-T buffer, filters were blocked overnight at 4ºC in 5% BSA 
(dissolved in TBS-T). After blocking, filters were incubated with the antibodies against Ub, 
diluted in TBS-T 5% BSA, for 1 hour at room temperature, followed by 3 washes of 10 
minutes each in TBS-T. Filters were then incubated with the anti-mouse horseradish 
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peroxidase-conjugated secondary antibody, diluted in TBS-T 3% BSA, for 30 minutes at 
room temperature. After incubation with the secondary antibody, the filter was washed 3 
times in TBS-T (10 minutes each) and the bound secondary antibody was revealed using the 
ECL method (Amersham). 
 
Denaturing solution 
Guanidinium Chloride 6 M 
TRIS, pH 7.4 20 mM 
PMSF (freshly added) 1 mM 
β-Mercaptoethanol (freshly added) 5 mM 
 
Immmunoprecipitation 
Lysates prepared in JS (for co-IP) or in RIPA/RIPA 1% SDS (for IP) buffer were incubated in 
the presence of specific antibodies (about 1-2 µg/mg of lysates) for 2 hours at 4ºC with 
rocking. Protein G Sepharose beads (Zymed) were then added, and samples were left for an 
additional hour at 4ºC, rocking. Immunoprecipitates were then washed 4 times in the 
appropriate lysing buffer. Proteins were eluited in Laemli buffer 2x. IP and were performed 
starting from 500 µg of lysates, with the appropriate antibodies. Co-IP assays between Cbl 
and EGFR mutants in NR6 cells were performed starting from 1 mg (for EGFR WT and 
Y1045/68/86+) or 2 mg of lysate  (for the 1045+ mutant), for each condition. Washes were 
then performed in JS buffer (for EGFR WT and the 1045/68/86+ mutant) or in JS buffer 
containing a 5-fold reduced amount of Triton X-100 (0.2%) for the 1045+ mutant. 
Immunoblotting (IB) was performed as described previously. 
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Determination of the number of Cbl and Grb2 molecules 
To calculate the number of Grb2 or Cbl molecules in HeLa (Fig. 35), NIH (Fig. 41) or 
CASKI/BT20 (Fig. 42) cell lysates, we compared signal intensities in anti-Grb2 or anti-Cbl 
IB of increasing amounts of cellular lysate with known amounts of purified Grb2 or Cbl 
protein. From the signal comparison and taking into account Avogadro’s number, we 
calculated the number of Grb2 and Cbl molecules/µg of lysate. After an additional correction 
for the number of HeLa or NIH-EGFR cells corresponding to 1 µg of lysate (measured in the 
same experiment), we obtained the total number of Grb2 and Cbl molecules/cell. To calculate 
the number of active Cbl molecules (Cbl pY), we IP Tyr phosphorylated Cbl, using the anti-
pY antibody, from increasing amounts of lysate (prepared in RIPA buffer containing 1% 
SDS) from cells stimulated with EGF (100 ng/ml) for 2 min. Immunoprecipitates were then 
IB with anti-Cbl and the signal intensities of the anti-Cbl bands were compared with the 
signal intensities of anti-Cbl bands in IB cellular lysates and purified Cbl protein. We 
corrected the obtained values for the efficiency of IP (estimated >90%), and obtained the % of 
Cbl in the lysate that is phosphorylated (active) upon stimulation with EGF (100 ng/ml) for 2 
min. 
Assays with 125I-EGF  
Saturation binding assay 
Cells were serum starved in binding buffer (MEM or DMEM, BSA 0.1%, Hepes pH 7.4 20 
mM) for at least 2 hours. Serum starved cells were then incubated on ice for 6 h in the 
presence of 125I-EGF (100 ng/ml: 10 ng/ml 125I-EGF plus 90 ng/ml cold EGF) in serum-free 
medium supplemented with 0.5% BSA. Samples were cooled on ice for 30 minutes and 
incubated at 4°C with mix containing 125I-EGF. After 6 hours, cells were washed 3 times in 
PBS, and solubilized in 300 µl 1 M NaOH. After correction for the hot/cold dilution, the 
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number of receptors on the surface was deduced from the specific activity of the labeled 
ligand. Non-specific binding was measured in the presence of a 300-fold excess of cold EGF, 
and was never > 3-10% of the total counts. 
Immunofluorescence studies 
Cells were plated on glass coverslips pre-incubated with 0.1% gelatin in PBS at 37°C for 30 
minutes. Cells were fixed in 4% paraformaldehyde (in 1X PBS) for 10 minutes, washed with 
PBS and permeabilized in 0.1% Triton X-100, BSA 0.2% in 1X PBS for 8 minutes at room 
temperature. To prevent non-specific binding of the antibodies, cells were then incubated with 
1X PBS in presence of 2% BSA for 30 minutes at room temperature. Next, cells were 
incubated for 1 hour with primary antibody in 1X PBS in presence of 0.2% BSA (anti-EGFR 
m108 or anti-c-Cbl BD), washed 3 times with 1X PBS and incubated for 30 minutes with 
fluorescently labeled secondary antibodies (Amersham). After 3 washes with PBS, nuclei 
were DAPI-stained for 5 minutes and washed again 3 times with 1X PBS. Coverslips were 
immediately mounted with moviol and examined under a wide-field fluorescence microscope 
(Olympus). Images were further processed with the ImageJ software. To detect only surface 
EGFR (anti-EGFR m108) permeabilization step was avoided.  
ELISA assays for EGFR ubiquitination and phosphorylation  
For the ELISA-based assays shown in Figure 8 and Supplementary Figure 7, we used the 
DELFIA (Dissociation Enhanced Lanthanide Fluoroimmunoassay) technology from Perkin 
Elmer. This technology is based on sandwich-recognition of a target protein by a capture 
antibody and a detection antibody. The capture antibody is immobilized on a solid surface 
(microwells) directly through non-covalent bonds. After the addition of the analyte 
(appropriate cellular lysate), the detection of signals relies on a lanthanide (Europium)-
conjugated antibody that is able to produce a fluorescent signal upon enhancement with acidic 
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enhancement buffer. Plate preparation, analyte incubation and antibody detection were 
according to the manufacturer’s instruction. Briefly, microwells plates were coated with the 
capturing antibody (see below). Blocking was performed for 2 h with BSA 2% in PBS. 25-50 
µg of lysates from HeLa or NR6 cells, stimulated with the indicated concentration of EGF, 
were incubated overnight at 4ºC. Lysates were prepared in RIPA/1% SDS buffer and diluted 
to 0.2% SDS before incubation step. After three washes, wells were incubated with primary 
antibodies, diluted at 1 µg/ml in assay buffer, for 1 h at RT. After three washes, anti-mouse or 
rabbit Europium-labeled secondary antibodies (1 µg/ml in assay buffer) were added for an 
additional hour. After three washes and treatment with enhancement solution, fluorescence 
was measured with EnVision instrument (excitation at 340 nm and emission at 615 nm). 
 
Capturing and detecting antibodies differed depending on whether a forward or reverse 
approach was performed (see Supplementary Figure 2A-B for a scheme of the two 
procedures): 
 Capturing antibodies Detecting antibodies 
Forward 
ELISA 
Home made polyclonal anti-
EGFR directed against aa 1172-
1186 of human EGFR (5 µg/ml) 
Monoclonal antibodies against Ub 
(FK2), pY (4G10), pY1068, or 
EGFR (m108), all diluted at 1 µg/ml 
Reverse 
ELISA 
Monoclonal antibodies against 
Ub (FK2, 5 µg/ml), pY (4G10, 5 
µg/ml), pY1068 (1 µg/ml), 
pY1086 (1 µg/ml) or EGFR 
(m108, 1 µg/ml) 
Home ade polyclonal anti-EGFR 
directed against aa 1172-1186 of 
human EGFR (1 µg/ml) 
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Densitometry and statistical analysis 
Quantification of blot was performed with Photoshop. Error bars in the plots represent the 
standard deviation of the mean. All statistical analyses were performed using Excel. 
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RESULTS 
1 - A quantitative assay to follow EGFR ubiquitination and 
phosphorylation 
We have previously shown that, when treated with increasing doses of ligand, cells showed a 
peculiar behavior: EGFR-Ub increased sharply over a narrow range of EGF concentrations, 
being minimal at 1 ng/ml and nearly maximal at 10 ng/ml, both in epithelial cells (HeLa) and 
in fibroblasts (NR6-EGFR cells; Fig. 8, page 33). On the other hand, EGFR-pY, which is a 
readout for receptor activation, displays a gradual and linear increase over the same range of 
EGF concentrations (1-10 ng/ml EGF). These data were obtained by western blot analysis, 
which is a powerful technique that allowed us to explore receptor ubiquitination under 
different conditions (Sigismund, Algisi et al. 2013). However, western blot analysis is a semi-
quantitative assay and has several limitations, the major one being its low dynamic range due 
to sensitivity and saturation problems. Before proceeding with the integration of EGFR-pY/-
Ub data into a mathematical formalism, we needed a more sensitive and quantitative high-
throughput assay to detect receptor ubiquitination and phosphorylation. 
To this aim, we set-up a quantitative ELISA-based immunoassay, DELFIA (Dissociation-
Enhanced Lanthanide Fluorescent ImmunoAssay; Perkin Elmer), which employs a 
fluorescent molecule instead of chemoluminescence. This assay takes advantage of the unique 
chemical properties of lanthanide-labeled biomarkers, to create an assay that performs well in 
terms of sensitivity, wide dynamic range and stability. In common with the ELISA technique, 
DELFIA is based on sandwich-recognition of the target protein using a capture antibody and 
a detection antibody. The capture antibody is immobilized directly onto a solid surface (e.g. a 
suitable microwell plate). After the addition of the sample and binding of the target protein to 
the capture antibody, the detection antibody is added. This antibody binds to an exposed motif 
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on the target protein and is either directly conjugated to a lanthanide or is, in turn, recognized 
by a lanthanide-conjugated species-specific secondary tracer antibody. The lanthanide tracer 
is then detected following enhancement with an acidic enhancement buffer, which results in 
the production of a fluorescent signal (for a schematic representation see Fig. 21A).  
Our assay utilizes europium (Eu), a member of the lanthanide chelates. During the assay, 
Figure 21: Schematic representation of DELFIA assay. A. DELFIA assay takes advantage of a lanthanide 
chelate, in this case Europium (Eu) conjugated to a specific antibody. The native lanthanide chelate is 
essentially non-fluorescent throughout the assay. Upon addition of a specific DELFIA Enhancement Solution, 
lanthanide ions are released, forming fluorescent chelates that are stably protected inside a micelle. B. In the 
“forward” approach, microwell plates were coated with a polyclonal anti-EGFR antibody (intracellular domain, 
anti-EGFR intra), which captures the receptor from the lysate (1). After incubation of the lysate, the main 
fraction of the EGFR remains bound onto the plate (green dimeric protein in the scheme). Detection of EGFR-
Ub, EGFR-pY or total EGFR was performed with primary monoclonal antibodies directed against Ub (anti-Ub: 
FK2), pY (anti-pY: 4G10), or the EGFR extracellular domain (anti-EGFR extra: m108) (2), followed by 
europium labeled secondary antibodies [(Eu)-labeled secondary Ab] (3). C. In the reverse approach, microwell 
plates were coated with monoclonal antibodies directed against Ub (anti-Ub: FK2), pY (anti-pY: 4G10) or the 
EGFR extracellular domain (anti-EGFR extra: m108) that capture EGFR-Ub (1), EGFR-pY (2) or total EGFR 
(3), respectively. Detection was performed with a polyclonal anti-EGFR antibody recognizing the intracellular 
domain (anti-EGFR intra) followed by a Eu-labeled secondary antibody. 
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the native lanthanide chelate is essentially non-fluorescent. However, after the binding 
reaction is complete, lanthanide fluorescence is stimulated by the addition of a specific 
DELFIA Enhancement Solution: the lanthanide ions are released in solution at low pH, and 
they rapidly form new, highly stable fluorescent chelates inside a protective micelle with 
components of the Enhancement Solution. Europium fluorescence is amplified 1-10 million 
times by this enhancement step and it develops a signal in 5 minutes that is stable for up to 8 
hours. Fluorescence can be measured with a suitable detector using the factory-set DELFIA 
Europium protocol (excitation at 340 nm and emission at 615 nm). Raw data output from the 
instrument is in the format of a table with a value - representing counts per seconds - for each 
well. This value is a direct measure of the lanthanide fluorescence and is proportional to the 
amount of tracer antibody that has bound to the well, which, in turn, depends upon the amount 
of captured target protein. 
In the “forward assay” approach (Fig. 21B), we immobilized an anti-EGFR antibody that 
recognizes the intracellular domain of the receptor (anti-EGFR intra) onto the solid surface 
(“capture antibody”). Plates were then incubated with cell lysate derived from appropriately 
treated cells (stimulated or not with EGF; see Materials and Methods), in order to capture all 
EGFR molecules present in the lysate. After extensive washes, plates were incubated with an 
anti-ubiquitin mouse antibody (anti-Ub) or an anti-phosphotyrosine mouse antibody (anti-pY) 
(“detection antibodies”), which specifically recognize and bind to epitopes present in the 
modifications under analysis. The addition of the tracer (Eu-labeled secondary Ab) then 
allows the amount of ubiquitinated and phosphorylated receptors in the cell to be measured 
(Fig. 21B). In parallel, detection with an anti-EGFR antibody recognizing the extracellular 
domain of the receptor (anti-EGFR extra), as opposed to the intracellular domain recognized 
by the capture antibody, permits normalization of results with respect to the total amount of 
receptor in each well.  
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A crucial aspect in obtaining a reliable assay was the identification of experimental 
conditions that result in an optimal signal-to-noise ratio. During the set-up of the assay, we 
tested different antibodies and different experimental conditions. To optimize the detection of 
phosphorylated EGFR, we started with a capture antibody (anti-EGFR intra) concentration of 
0.1 µg/well. Different quantities of lysate (ranging from 1 to 100 µg/well) derived from HeLa 
cell that had been serum-starved or EGF-stimulated for 2 minutes, were tested. 
Phosphorylated EGFR was measured using: 
• anti-pY antibody followed by the addition of an anti-mouse Eu-conjugated 
secondary antibody. 
• an anti-pY antibody directly labeled with Eu (pY-Eu). 
The anti-EGFR extra antibody was used as an internal control, to normalize the values 
between serum-starved and stimulated conditions based on the amount of total EGFR in each 
well. 
An example of raw output data from the DELFIA assay is shown in Table V. From these 
data, we can appreciate that both anti-pY antibodies tested returned a significantly higher 
value (higher counts per second) when lysate from ligand stimulated, rather than serum-
starved, cells was analyzed. On the contrary, EGFR levels, as measured by the use of anti 
EGFR antibodies, gave similar counts, reflecting that roughly the same amount of lysate was 
used for each cellular condition. Indeed, throughout all our DELFIA assays, we considered 
EGFR levels as the internal normalization factor. The concentration of lysate that gave the 
best results in terms of signal-to-noise-ratio was 25 µg/well of lysate (see Table V and Fig. 
22A). As expected, total receptor levels did not change between serum-starved and EGF-
stimulated cells, since the receptor after 12 hours of serum starvation followed by 2 minutes 
of EGF stimulation, does not undergo degradation. In contrast, the levels of activated receptor, 
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as indicated by the anti-pY signal, is significantly increased following 2 minutes of EGF 
stimulation. 
Starting from these experimental conditions (0.1 µg/well anti-EGFR intra, 25 µg/well 
lysate), we proceeded with the setting up of the assay by optimizing the detection of 
ubiquitinated  EGFR. We tested three different antibodies that should be able to recognize 
ubiquitinated proteins: the commercially available FK2 antibody and the in-house antibodies 
ZTA10 and AQ17 (Fig. 22B). The latter two failed to recognize the target protein and were 
discarded. Only FK2 gave a good signal-to-noise ratio between serum-starved and stimulated 
cells. In the same experiment, we also considered an additional variable, i.e., the stringency of 
Table V: Typical raw data from a DELFIA assay. The DELFIA assay was performed using cell lysate 
from HeLa cells that had been serum-starved (SS) or treated with 100 ng/ml EGF for 2 minutes. Cell lysate, 
at the indicated amounts, was then added to 96 microwell plates coated with 0.1 µg/well of the capture 
antibody (anti-EGFR intracellular domain). Captured receptor was then detected using different 
combinations of detection and tracer antibodies: i) the anti-phosphotyrosine (αPY) detection antibody 
coupled with the europium-conjugated anti-mouse tracer antibody (αM-Eu); ii) the anti-EGFR extracellular 
domain (αEGFR-extra) detection antibody coupled with the europium-conjugated anti-mouse tracer 
antibody (αM-Eu); iii) the  europium-conjugated anti-phosphotyrosine detection/tracer antibody (αpY-Eu)  
(see Materials and Methods). Results are expressed as counts per second. The highlighted data obtained with 
25 µg/well cell lysate corresponds to data shown in Fig. 22A. 
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our lysis buffer and the concentration of detergents. We tested standard RIPA buffer and 
RIPA buffer supplemented with 1% SDS (see Material and Methods, section Protein buffers). 
The rationale for adding additional detergent to the buffer was to prevent the potential co- 
precipitation of ubiquitinated proteins with EGFR. Furthermore, the FK2 antibody was known 
to perform better in denaturing conditions. 
 
 
 
 
Figure 22: Optimization of experimental conditions for the DELFIA assay. A - Cell lysate, either 
serum starved or stimulated with 100 ng/ml, were analyzed by the forward DELFIA assay. Microwell plates 
were coated with 0.1 µg/well of the capture antibody (anti-EGFR intracellular domain). After lysate 
addiction and incubation (25 ug of lysate/well), captured receptor was then detected using 0,1 ug/well of the 
following antibodies: i) the anti-EGFR extracellular domain (αEGFR-extra 108M) detection antibody 
coupled with the europium-conjugated anti-mouse tracer antibody (αM-Eu); ii) the anti-phosphotyrosine 
(αPY) detection antibody coupled with the europium-conjugated anti-mouse tracer antibody (αM-Eu); iii) 
the europium-conjugated anti-phosphotyrosine detection/tracer antibody (αpY-Eu)  (see Materials and 
Methods).  
 B - The DELFIA assay was performed essentially as 
described in ‘A’. The detection antibodies used were anti-
EGFR extra, anti-pY, and various anti-ubiquitin 
antibodies (FK2, AQ17 and ZTA10, see Materials and 
Methods). Different lysis conditions were also used: 
standard RIPA buffer (RIPA) or 1% SDS RIPA buffer 
(SDS) (see Materials and Methods), as indicated. Colo602 
is a cell line that does not express EGFR, used as a 
negative control. 
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2 - The EGFR Ubiquitination threshold 
We then aimed to validate the EGFR-Ub threshold observed by WB analysis using the 
DELFIA method. First, we confirmed by WB analysis that the EGFR-Ub threshold was 
maintained, and occurred over the same EGF concentration range, when cells were lysed in 
the more stringent RIPA 1% SDS buffer instead of standard RIPA buffer. HeLa cells were 
plated in duplicate at 50% confluency and stimulated with increasing EGF doses. One sample 
was lysed in standard RIPA and the other one was lysed in RIPA 1% SDS buffer. Total cell 
extracts were then immunoprecipitated with an anti-EGFR antibody (see Materials and 
Methods, section Protein Procedures) and analyzed by WB (Fig. 23A). By densitometric 
analysis of the WB, we observed that the presence of 1% SDS had no effect on the EGFR-Ub 
threshold, which occurred over the same EGF concentration range under both conditions (Fig. 
23B), or on phosphorylation, which remained linear with EGF doses.  
Figure 23: EGFR ubiquitination assay in stringent lysis condition. A - To confirm that the Ub threshold 
observed by anti-EGFR IP and WB analysis was due exclusively to EGFR ubiquitination and not to co-
immunoprecipitating proteins, we repeated the experiment shown in Fig. 8A using more stringent lysis 
conditions (WB relative to RIPA buffer are the same as in Fig.8A). HeLa cells were stimulated with EGF for 
2 min at the indicated concentrations and lysates were prepared in 1% SDS RIPA lysis buffer, diluted to 0.2% 
SDS (see Materials and Methods) and subjected to immunoprecipitation (IP) and IB as shown. Also under 
these stringent lysis conditions, the Ub threshold was readily detected and indistinguishable from that 
obtained under standard cell lysis conditions (standard RIPA buffer 0.1% SDS, see Materials and Methods). 
Blot is representative of 3 repeats. B - Quantitation by densitometry analysis of the images relative to 2% SDS 
blots shown in A as % of max (black lines). The red curve shows quantitation of the anti-Ub signal of the 
images obtained with lysates prepared with standard RIPA buffer as shown in A and Fig. 8A. In all figures, 
when comparing curves that did not show significant differences it is shown R, the Pearson correlation 
coefficient. 
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We thus proceeded with DELFIA “forward” assay (Fig. 21B) to analyze EGFR-Ub and -
pY. Again HeLa cells were stimulated with increasing EGF doses for 2 minutes, lysed in 
RIPA 1% SDS and analyzed using the DELFIA assay for the relative levels of EGFR-Ub and 
EGFR-pY (Fig. 24A). With this new approach, we could increase the number of EGF 
concentrations analyzed, particularly at the transition phase (between 1-10 ng/ml). We 
confirmed both the sigmoidicity of EGFR ubiquitination and the hyperbolic behavior for 
phosphorylation (Fig. 24A). Importantly, the EGFR-Ub threshold is positioned between 1 and 
10 ng/ml of EGF, as observed in WB experiments (Fig. 24B and C). 
Additionally, we performed a “reverse assay” in which plates are coated with anti-
Figure 24: Analysis of EGFR ubiquitination and phosphorylation by DELFIA. A-B - Lysates of HeLa 
cells stimulated with the indicated doses of EGF for 2 minutes, were subjected to either forward or reverse 
DELFIA analysis (see Fig. 21B-C), using the indicated detection antibodies (Ub, ubiquitination; pY, 
phosphorylation; pY1068, EGFR 1068 tyrosine specific phosphorylation). Results are shown as % of max. 
With DELFIA analysis we increased the number of EGF concentrations analyzed with respect to WB 
analysis. C - Comparison of the EGFR ubiquitination and phosphorylation curves obtained by forward and 
reverse DELFIA analysis of HeLa cell lysates described in C-D. In all panels, results are expressed as the 
mean ± SD calculated from at least three independent experiments, performed in triplicate. P-values were 
calculated using two-way ANOVA analysis. In all figures, when comparing curves that showed significant 
differences it is shown the relative P-values; when comparing curves that did not show significant 
differences it is shown R, the Pearson correlation coefficient. P-values inside legend boxes (B-C) refer to the 
groups of data indicated. P-values inset in graphs (A-B-C) refer to Ub vs pY groups of data. 
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ubiquitin or anti-phosphotyrosine antibodies and captured EGFR is detected using an anti-
EGFR intra antibody (as schematized in Fig. 21C). The EGFR ubiquitination and 
phosphorylation curves were verified also with this approach and we obtained curves that 
were completely superimposable on those obtained with the forward approach, as shown in 
Fig. 24C.  
Finally, we wanted to verify if the results obtained with the DELFIA assay were 
comparable with data obtained from WB analysis. Densitometric analysis of images of 
digitally acquired blots at different exposures was performed. Despite this procedure being 
subject to a high degree of variability, the comparison of curves (normalized to max) obtained 
with the two methods indicated how the two methods gave similar results (Fig. 25A and B). 
Ubiquitination behavior is in good agreement between the two methods, although it varies at 
the 3 ng/ml data point, which is higher in the DELFIA output compared with the WB analysis 
(Fig. 25A). This might be due to a higher sensitivity of the DELFIA signal. In agreement, the 
standard deviation of DELFIA at this critical point is very low (almost invisible in the chart), 
indicating higher reliability of results compared with the WB analysis. This variation, 
however, does not affect the interpretation of the results, since both methods detect a 
Figure 25: Comparison of EGFR ubiquitination and phosphorylation curves obtained by WB and 
DELFIA. A - Ubiquitination curves obtained by both WB (from Fig.23A) and forward DELFIA analysis 
(from Fig.24C) were superimposed to allow for direct comparison. The asterisk indicates the only point that 
significantly differed in the two curves (*p = 0.01). B - Phosphorylation curves obtained as in A are directly 
compared. In all panels, results expressed as mean ± SD calculated from at least three independent 
experiments. When curves show significant differences, this is indicated with a p-value calculated using 
two-way ANOVA analysis. Instead, when curves that did not show significant differences, we calculated the 
Pearson correlation coefficient (R). 
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threshold positioned within the same range of EGF concentrations. Moreover, the DELFIA 
Ub curve exhibited an even sharper threshold effect than the WB curve.  The EGFR 
phosphorylation curves obtained with the two methods were instead identical at all EGF 
concentrations (Fig. 25B). Overall, we concluded that the DELFIA assay is a reliable method 
for measuring EGFR ubiquitination and phosphorylation.  
3 - Dose response curves of EGFR phosphorylation 
In collaboration with the Systems Biology group in our Institute, we have designed a 
mathematical model based on an ordinary differential equations (ODE) that integrates all the 
overlapping dynamics occurring after two minutes of EGF stimulation. At this time point, the 
phosphorylation and ubiquitination events take place predominantly at the PM, with a 
negligible contribution from events at other endomembranes (Sigismund, Algisi et al. 2013). 
Since EGFR phosphorylation and ubiquitination are causally related, we initially modeled 
EGFR phosphorylation to obtain a quantitative relationship between these two biochemical 
modifications.  
To guide model construction, we performed experimental dose-response curves in HeLa 
cells stimulated with increasing EGF concentrations, and analyzed the dynamics of 
phosphorylation of the individual Tyr residues by WB and DELFIA. The WB analysis was 
performed using different commercially available phospho-EGFR antibodies that specifically 
recognize a single phosphotyrosine in the cytoplasmic tail of the stimulated receptor (Fig. 
26A). Unfortunately, not all the available phospho-specific antibodies worked in the DELFIA 
assay, with only the pY1068 and pY1086 being functional in this experimental setting (Fig. 
26B). The data showed that all the individual phosphosites analyzed followed the same 
gradual increase, with increasing EGF concentration, as global EGFR phosphorylation, 
suggesting that individual EGFR tyrosine residues can be phosphorylated independently of 
each other. 
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Figure 26 - Analysis of phosphorylation of specific EGFR phosphosites following EGF stimulation of 
HeLa cells A. HeLa cells were stimulated with different EGF doses, as indicated, and total cell lysates were 
analyzed by WB using the specified antibodies. pY1045-1068-1086-1173 refer to commercially available 
antibodies (see Materials and Methods, section Reagents) that recognized the indicated phosphosite of 
EGFR. αEGFR was used as control for total receptor levels. Tubulin was used as protein loading control. 
Blots are representative of 3 experimental repeats. Molecular weight markers are shown on the right. B. 
HeLa cells were stimulated with increasing EGF concentrations and total cell lysates were analyzed by 
DELFIA. Only two specific phosphotyrosine antibodies, pY1068 and 86, were functional in the DELFIA 
assay. Results are expressed as mean ± SD calculated from at least three independent experiments. 
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To verify this result, we employed EGFR add-back mutants. EGFR can be phosphorylated 
on nine tyrosine residues in the intracytoplasmic tail (Fig. 27A). We mutagenized all nine 
tyrosines into phenylalanine (a residue that is structurally similar to tyrosine but cannot accept 
a phosphate moiety) thus creating a pY-null EGFR backbone (the 9Y- mutant; Fig. 27A). We 
then added back, singularly or in combination, the three tyrosines that are important in the 
process of EGFR ubiquitination, i.e. Y1045, Y1068, Y1086 to create the add-back mutants 
EGFR-1045+, EGFR-1068/86+ and EGFR-1045/68/86+ (EGFR-3Y+; Fig. 27A). At two 
minutes of EGF stimulation, the add-back mutants exhibited gradual EGF-dependent tyrosine 
phosphorylation (Fig. 27B). For all mutants, we showed that the dose response curves of 
pY1045, pY1068 and pY1086 was the same in the context of the add-back mutants EGFR-
1045+, EGFR-1068/86+ or EGFR-3Y+, as in EGFR wildtype (WT), and was not influenced 
by the number of tyrosine residues present in the EGFR tail. 
These data suggest a simple model for EGFR early phosphorylation, based on the 
independent phosphorylation of each single tyrosine. 
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Figure 27: Add back mutants to study tyrosines important in the process of EGFR ubiquitination A - 
Schematic representation of human wildtype (WT) EGFR, the EGFR-pY null mutant (9Y-), and the EGFR 
add-back mutants EGFR-1045+, EGFR-1068/86+ and EGFR-1045/68/86+ (EGFR-3Y+). The intracellular 
domain (kinase domain and C-terminal tail) of the EGFR is shown, with the position of the relevant 
residues. Critical tyrosine residues involved in Cbl/Grb2 binding are indicated in blue, while the other 
tyrosine residues in the EGFR tail are depicted in grey.  
 B - NR6 mouse cells endogenously devoid 
of EGFR, were transfected to express the 
indicated add-back mutants or the human 
WT EGFR. Cells were then stimulated 
with increasing EGF doses and analyzed 
by WB using antibodies directed against 
the indicated pY sites (pY1045 and 
pY1068). Quantitation of WB experiments 
by densitometry was performed to analyze 
tyrosine phosphorylation of individual 
phosphosites in the EGFR add-back 
mutants as a function of EGF dose. 
Phosphorylation of EGFR-WT is also 
shown in each graph for comparison. 
Results are expressed as absolute values in 
arbitrary units (a.u.) where the max value 
is WT at 100 ng/ml EGF. 
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4 - Role of phosphatases 
It has been recently shown that phosphatases are active already at two minutes after EGF 
stimulation (Kleiman, Maiwald et al. 2011). To confirm these data also in our cellular model 
and experimental setting, we performed experiments with a clinical-grade EGFR kinase 
inhibitor, Gefitinib, in HeLa cells. This drug is a sub-micromolar inhibitor of EGFR TK 
activity and is known to inhibit EGFR autophosphorylation by competing with ATP 
molecules. Gefitinib has been already used in literature (Kleiman, Maiwald et al. 2011) to 
study the kinetics of receptor dephosphorylation by exploiting its strong inhibitory effect on 
EGFR phosphorylation. We first tested the optimal concentration of Gefitinib in HeLa cells to 
inhibit EGFR, in a titration experiment. Cells 
were either treated for two minutes with 100 
ng/ml EGF alone or in combination with the 
inhibitor at different drug concentrations, and  
EGFR phosphorylation was assessed by WB 
analysis (Fig. 28). The inhibitory effect on 
EGFR phosphorylation was already evident at 
the lowest concentration of Gefitinib tested (1 
µM), although a complete inhibition was 
observed at 5 µM. To be consistent with the 
published experiment (Kleiman, Maiwald et al. 
2011), in which Gefitinib was investigated as a 
de-phosphorylation agent for EGFR in different 
cell lines, we chose to stay in line with the 
experimental set up used and to treat cells with 
10 µM Gefitinib. 
Figure 28: Effect of the different doses of 
the TK activity inhibitor Gefitinib on 
EGFR phosphorylation. Top, scheme of the 
experiment: HeLa cells were serum starved 
(ss) and then stimulated with 100 ng/ml EGF 
for 2 minutes in presence or absence of the 
indicated concentrations of Gefitinib. Cells 
were then quickly lysed in RIPA buffer at 
4°C to avoid further dephosphorylation of the 
EGFR during washing steps and assessed by 
WB. Left, scheme of the experiment. Right, 
WB evaluation of the inhibitory effect of 
Gefitinib on EGFR phosphorylation using the 
specific EGFR phosphosite antibody pEGFR-
1068. Total EGFR was also detected and 
tubulin was used as a loading control 
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After having assessed the optimal Gefitinib dose, we stimulated cells with EGF (100 
ng/ml) for two minutes to induce EGFR phosphorylation, and then treated stimulated cells 
with 10 µM Gefitinib or DMSO alone for different lengths of time before processing cells for 
WB analysis (Fig. 29). We confirmed that Gefitinib is able to dramatically decrease EGFR 
phosphorylation in a very short time interval. We also estimated the half-life for EGFR-pY to 
be around 8 seconds in our cell model system (Fig. 29, lower panel), consistent with previous 
observations in H1666, MCF10A, HepG2 and HeLa cells (Kleiman, Maiwald et al. 2011). 
Figure 29: Effect of Gefitinib on 
EGFR phosphorylation. Top, 
scheme of the experiment. Serum 
starved (ss) HeLa cells were 
stimulated with EGF 100 ng/ml and 
after 2 minutes were treated with 
Gefitinib (10 µM) for the indicated 
time before processing samples for 
WB analysis. Parallel DMSO 
treatment was included as a control. 
Middle panel, lysates were analyzed 
by WB using the indicated 
phosphospecific antibodies (anti-
pY1068 and anti-pY1173). anti-
tubulin was used as a loading 
control. Different exposures of the 
blot are shown (low exp and high 
exp). Bottom panel, quantitation of 
the pEGFR-1173 WB shown in the 
middle panel. The half-life of the 
phosphorylated receptor was 
calculated with the formula 𝑡!! = 𝑡 ∗ !"  (!)!"  (!!!!)  where t is the time 
after Gefitinib addition and N is the 
value of EGFR phosphorylation, 
reported to its maximum level. The 
half-life was found to be around 8 
seconds. 
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These data confirm that phosphatases do indeed have a significant role early in the process of 
EGFR activation, being very active already at 2 minutes of EGF stimulation. 
However, to test whether phosphatases are able to counteract the EGFR kinase and 
influence EGFR phosphorylation behavior at 2 minutes after EGF stimulation, we tested the 
EGFR dose response curve upon inhibition in vivo of tyrosine phosphatases with the chemical 
compound sodium orthovanadate (Na3VO4). First, we verified that Na3VO4 was able to 
effectively block phosphatase activity in the cell. Cells were pre-treated for 2 hours with 200 
µM Na3VO4, as already performed in the lab, and then were stimulated with high doses of 
EGF for two minutes. Anti-pY blot on total cellular lysate revealed that total protein 
phosphorylation is increased when cells were treated with EGF plus Na3VO4, compared to 
Figure 30: Effect of phosphatases inhibition by orthovanadate treatment on EGFR phosphorylation. A - 
Left, scheme of the experiment. HeLa cells were serum starved (SS) and treated or not for 2 hours with 200 µM 
sodium orthovanadate phosphatase inhibitor (Na3VO4). DMSO was used as a solvent control. EGF 100 ng/ml 
stimulation was then performed for 2 minutes and total levels of protein tyrosine phosphorylation were analyzed 
by WB, using the anti-total pY antibody on total cellular lysate (right panel). Tubulin was used as a loading 
control. IB is representative of 3 biological replicas. Note that Na3VO4 treatment significantly increased the level 
of total phosphorylated proteins both in the presence or absence of EGF. B - HeLa cells were serum starved (SS) 
and either treated or not with 200 µM Na3VO4 as in A. Cells were then stimulated with EGF at 1, 10 or 100 ng/ml 
for 2 or 10 minutes. EGFR phosphorylation was analyzed by WB using the EGFR-pY1068 antibody (left panel). 
Total EGFR was also detected and tubulin was used as a loading control. IB is representative of 2 biological 
replicas.  Quantitation of the anti-pY1068 WB was performed using densitometry (right panel). 
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EGF alone, suggesting that phosphatases are inhibited by the treatment (Fig. 30A). 
Next, we repeated the experiment, stimulating cells with different EGF doses (i.e. 1, 10, 
100 ng/ml) for 2 or 10 minutes. By WB analysis with anti-EGFR-pY1068 antibody, we 
observed that when phosphatases were inhibited by Na3VO4 treatment, EGFR 
phosphorylation at 2 minutes after stimulation was only slightly increased at 100 ng/ml (Fig. 
30B). The effect was more clear after 10 minutes of EGF stimulation, at which time even at 
10 ng/ml EGF a major effect on the early time-point is evident. At 100 ng/ml EGF, we could 
score a 1.8-fold increase in the levels of phosphorylated EGFR (Fig. 30B, right panel). Our 
data confirmed a role of phosphatases in EGFR phosphorylation, which becomes more 
evident at later time points. 
Therefore, in the formalization of a mathematical model for EGFR activation, we could 
not ignore the activity of phosphatases described above. We thus considered a value for 
EGFR dephosphorylation due to phosphatase activity equal to !"  (!)!!/! = 0.016 s-1 (as reported in 
(Kleiman, Maiwald et al. 2011)), in agreement with the experimental observation. 
5 - MPM: a simple model for early EGFR phosphorylation 
With the aim of obtaining an Multisite Phosphorylation Model (MPM) that takes into 
account only the steps of EGFR phosphorylation and dephosphorylation, we considered the 
enzyme kinetics that EGFR follows. Since kinases respect a standard Michaelis-Menten 
kinetics, we built a schematic representation of the enzymatic reactions that lead to EGFR 
phosphorylation in an active dimer (Fig. 31A). The TK domain of an EGFR moiety binds 
reversibly to the C-terminal tail of a partner EGFR molecule - which carries the 
phosphorylatable tyrosines - with the binding/unbinding rate constants kon and koff, 
respectively. After addition of the phosphate group with rate constant kcat, the TK dissociates 
from the substrate. Experimental measurements of these rate constants were obtained from the 
RESULTS 
 114
literature (Levkowitz, Waterman et al. 1999; Reynolds, Tischer et al. 2003; Grovdal, Stang et 
al. 2004; Zhang, Gureasko et al. 2006; Kleiman, Maiwald et al. 2011; Monast, Furcht et al. 
2012; Endres, Das et al. 2013; Roda-Navarro and Bastiaens 2014; see Appendix 1). To 
simplify this two-step reaction, we modeled phosphorylation as a first-order reaction 
characterized by kkin, the basic rate constant that governs the addition of a phosphoryl group 
in the absence of competing tyrosine. Similarly, we included the subtraction of one phosphate 
group by phosphatases considering the kPTP constant. 
Two limiting regimes (free and saturated) can be identified for the reaction catalyzed by 
kinases (and phosphatases), depending on the stability of the complex between the catalytic 
subunit and its substrate. We wanted to determine which regime the EGFR follows in the first 
2 minutes after stimulation. 
In collaboration with the Systems Biology group, we ran simulations of a receptor that 
carries 9 identical tyrosine residues. These simulations highlighted that: 
• if kinases (or phosphatases) work under free-enzyme regime, each tyrosine contributes 
equally to the rate of the overall EGFR phosphorylation, without considering the 
number of available sites. Therefore, the rate of EGFR phosphorylation decreases 
linearly with the number of tyrosines accessible for phosphorylation (Fig. 31B, black 
solid line). Moreover, tyrosine residues do not compete for the kinase domain and this 
can occur only if the kinase:tyrosine complex is unstable.  
Figure 31 (on the right): Modeling EGFR phosphorylation. A - Schematic representation of the 
enzymatic reactions that lead to EGFR phosphorylation in an active dimer. Top: Michaelis-Menten 
reaction whereby the tyrosine kinase (TK) domain of an EGFR molecule binds reversibly to the C-
terminal tail of a partner EGFR molecule with the binding/unbinding rate constants kon and koff, 
respectively. After adding one phosphate group, the TK domain dissociates from the substrate with the 
rate constant kcat. Bottom, the simplified reaction scheme for Tyr phosphorylation is characterized by 
kkin. B-Two limiting regimes (free and saturated) can be identified for the reaction catalyzed by kinases, 
depending on the stability of the complex between the catalytic subunit of EGFR and its tyrosine target 
substrate. To simulate the reactions schematized in A, kcat and koff were fixed to 10 and 1, respectively, 
and kon was varied. Simulations were performed for an EGFR molecule with 9 identical tyrosines. This 
graph shows the dependence of the rate constant k(α) on the number of pYs (α=0,1,…,8) present in the 
receptor tail, in units of kKIN (the basic rate constant that governs the addition of a phosphoryl group in 
the absence of competing tyrosine residues). For (kon+koff)/kcat=10-2 (blue dashed line), kcat controls the 
rate-limiting step, a condition that we call the saturated-enzyme regime. 
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•  
For (kon+koff)/kcat=104  (black line), kon controls the rate limiting step, a condition that we dubbed the 
free-enzyme regime. For intermediate values (kon+koff)/kcat=10 (red line), there is no single limiting 
step. (refer also to the main text, Results Section 5). C - Wiring diagram of the MPM. Top, 
phosphorylation of individual Tyr residues (blue circles) occurs independently of the phosphorylation 
of the other Tyr residues. This results in a branched wiring diagram, in which each phosphorylation 
event occurs with the same probability. Bottom, EGFR molecules (red circles) with the same total 
number of phosphoryl groups (blue circles) are grouped together to generate a linear chain of 
increasingly phosphorylated EGFRs. Only the three Tyr residues relevant for EGFR ubiquitination are 
shown (i.e., Y1045, Y1068, Y1086).  and  are the rates of addition and subtraction 
of one phosphoryl group from an EGFR molecule that carries α phosphorylated Tyr residues. 
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• in an alternative saturated regime in which the kinase (or phosphatase) is 
predominantly bound to the substrate, the phosphorylation rate of EGFR does not 
change with the number of non-phosphorylated tyrosine residues (Fig. 31B, blue 
dashed line). In this case, each of the 9 residues are phosphorylated at the same rate as 
only one residue, indicating that the phosphorylation rate per tyrosine residue 
decreases with the number of available sites. 
As we discussed previously, we observed that individual tyrosine residues are 
phosphorylated independently of each other (Fig. 27B) suggesting that that they do not 
compete for the kinase domain. This situation supports the scenario in which the rate-limiting 
step is the kinase:tyrosine binding constant and the kinase is expected to be mostly free (free-
enzyme). The same applies for the phosphatases, whose activity at 2 minutes after EGF 
stimulation has been also implemented in our models. We therefore chose for our model the 
free-enzyme regime for both kinases and phosphatases. 
 In the MPM model, the rate constant of EGFR phosphorylation increases with the 
number of tyrosine residues, and this also increases the number of variables in the model. In 
order to reduce the number of variables, we introduced a simplification: receptors with an 
equal number of phosphosites (pYs) [i.e., unphosphorylated EGFR (R0), 1pY-EGFR (R1), 
2pY-EGFR (R2), etc.] were grouped together, regardless of the specific identity of the pY. 
This simplification is justified by the observation that, in the first two minutes of EGF 
simulation, different sites have similar phosphorylation kinetics (Olsen, Blagoev et al. 2006). 
We schematically envisioned our system with a wiring diagram of the MPM (Fig. 31C), in 
which each phosphorylation event occurs with the same probability: EGFR molecules (red 
circles) with the same total number of phosphoryl groups (blue circles) are grouped together 
to generate a linear chain of increasingly phosphorylated EGFRs (Fig. 31C, bottom line). 
Only the three tyrosine residues relevant for EGFR ubiquitination are shown (i.e., Y1045, 
Y1068, Y1086). 
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 To compare the pattern of EGFR phosphorylation reproduced by the MPM with 
experimental data, we required a relationship between EGFR phosphorylation and EGF 
concentration. To keep this model simple, we initially ignored the numerous reactions that 
contribute to EGFR activation - that will be accounted for in a more complex model (the 
Early Activation Model, see Results Section 7) - and considered only a phenomenological law 
to link EGFR phosphorylation and EGF concentration (the “Hill function”, see next Section 
5.1).  
5.1 - The Hill function 
The properties and mode of action of a wide range of enzymes can be studied by the classical 
Michaelis-Menten equation. However, some enzymes display kinetic properties that cannot be 
fully described by this equation. We have recently shown that the dose-response curves for 
EGFR phosphorylation and ubiquitination display different degrees of sigmoidicity 
(Sigismund, Algisi et al. 2013) and both of them can be best approximated by the Hill 
function.  
 The Hill equation was first introduced by A.V. Hill in 1913 to describe the equilibrium 
between oxygen tension and the saturation of hemoglobin (Hill 1913). Since then, the Hill 
equation has been widely used to analyze quantitative drug or ligand–receptor relationships. 
Many biochemical models have exploited the potential of Hill equation to describe non-linear 
dose response relationships. 
The general Hill equation is represented by: 
𝜃 = [𝐿]![𝐶]! + [𝐿]! 
where: 
• [L] is the free ligand concentration 
• C is the ligand concentration occupying half of the binding sites 
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• n is the Hill coefficient and describes biochemical properties, depending on the 
context in which the Hill equation is being used. 
The Hill functions that best reproduce the experimental EGFR phosphorylation and 
ubiquitination curves have Hill coefficients (nH) of 1 and 3, respectively. 
More precisely, to model EGFR phosphorylation, we used the Hill function: 
𝑘!"# = 𝑘!"#!"# [𝐸𝐺𝐹]![𝐸𝐺𝐹]! + 𝐽! 
where: 
• [EGF] is the EGF concentration 
• J is the EGF concentration where 𝑘kin is half-maximal 
n is the Hill coefficient and represents how steeply 𝑘kin increases with 𝐸𝐺𝐹. 
This equation defines a sigmoidal curve in an interval between 0 and 𝑘!"#!"#, which is the 
maximal kinetic activity of EGFRs. 
 From the fitting of the experimental dose-response curves of EGFR-WT and the EGFR-
3Y+ add-back mutant, we identified n and J. Experimental points were obtained both by WB 
densitometric analysis and the DELFIA assay on stimulated HeLa cell lysates. After fitting 
these parameters, the MPM reproduced closely the experimental dose-response curve of 
EGFR-pY (Fig. 32A). 
Since we used the free-regime for EGFR phosphorylation, the result is independent of the 
number of tyrosine residues when the curves are normalized to their maximal value (Fig. 
32B). Moreover, the model correctly attributed a 3-fold increase to the total Tyr 
phosphorylation of EGFR-WT compared to the total Tyr phosphorylation of the EGFR-3Y+ 
mutant, for every value of EGF (Fig. 32C), as expected from a substrate carrying only 3 out 
of 9 accessible catalytic residues. 
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 In conclusion, we have developed a model, the MPM, which faithfully reproduces the 
distribution of EGFR phosphorylated species, as a function of EGF concentration, at two 
minutes of stimulation. 
Figure 32: Modeling EGFR 
phosphorylation: EGFR-WT vs. EGFR-
3Y+. A - A comparison between EGFR-WT 
and -3Y+ phosphorylation, computed by the 
MPM in the free-kinase/free-phosphatase 
regime as a function of EGF (model, solid 
lines), or determined experimentally (dashed 
lines: experimental data taken from Fig.14). 
EGFR phosphorylation was normalized to the 
maximum pY value (pY/pYmax). B - A 
comparison of the ratio of total pY of EGFR-
WT and EGFR-3Y+, as a function of EGF 
concentration (at 2 min), calculated by the 
MPM (dashed line) or determined 
experimentally (exp; solid line, data taken 
from blot in C). C - Dose response analysis 
of Ub and pY of EGFR-WT, and the Y1045+ 
and 3Y+ add-back mutants. NR6 cells stably 
expressing the indicated mutants were 
stimulated for 2 min with increasing 
concentrations of EGF, as indicated. Lysates 
were subjected to IP and IB as shown. The 
ratio of total pY of EGFR-WT vs. EGFR-
3Y+ was determined by densitometry 
analysis and is shown in B. 
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6 - Modeling EGFR ubiquitination 
We then progressed to add to the MPM the processes leading to EGFR ubiquitination. 
This covalent modification is catalyzed by the E3 ligase Cbl, which can bind to the EGFR 
directly through pY1045, or indirectly through the adaptor protein Grb2 that binds pY1068/86 
(see also Introduction Section 3.2, Fig. 33A). As previously elucidated (page 31), Cbl family 
proteins consist of three homologues: c-Cbl, Cbl-b and Cbl-c. By q-PCR analysis, we showed 
that in HeLa cells only c-Cbl and Cbl-b are expressed, the latter being expressed at levels 
~10% of the level of the former (Pascolutti et al, unpublished). With an RNAi approach, we 
demonstrated that c-Cbl is the major E3 ligase responsible for EGFR ubiquitination in HeLa 
cells (Sigismund, Algisi et al. 2013), since the KD of Cbl-b is only able to slightly decrease 
EGFR-Ub levels, whereas KD of c-Cbl is able to abrogate it (Sigismund, Algisi et al. 2013). 
Thus, we described only c-Cbl (hereafter referred to as Cbl) in the model.  
By the use of EGFR phospho-mutants, we have also shown that the binding of Cbl to its 
phosphosites is necessary and sufficient for EGFR ubiquitination, and that the EGF dose-
dependent Cbl:EGFR interaction in vivo displays a threshold-like profile, analogous to that of 
EGFR ubiquitination (Sigismund, Algisi et al. 2013). Based on this evidence, we further 
simplified the model by assuming that ubiquitination is simply proportional to the amount of 
Cbl-bound EGFR. Thus, we modeled EGFR ubiquitination as simply Cbl binding to the 
receptor. 
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was loaded alone as internal control (input). Right: 
quantitation of the amount of Cbl or Grb2 co-
immunoprecipitating (CoIP) with EGFR based on 
densitometry analysis of blots, as shown on the left.C - 
NR6 cells expressing the EGFR-WT, -9Y- mutant and 
the indicated add-back mutants (described in Fig.27A) 
were stimulated or not with EGF. Lysates were 
subjected to IP and IB as indicated, to explore the level 
of ubiquitination of EGFR mutants. Right: quantitation 
of the level of ubiquitination of the different EGFR 
mutants relative to EGFR-WT based on densitometry 
analysis of blots, as shown on the left. In B and C, 
results were normalized to the amount of 
immunoprecipitated EGFR and are expressed as % of 
the values obtained in EGFR-WT cells. Results are 
expressed as the mean ± SD of three independent 
experiments. 
 
Figure 33: Cooperativity between the EGFR phosphosites pY1045 and pY1068/86 in the binding of 
Cbl to the receptor and in EGFR ubiquitination. A - Schematic representation of EGFR ubiquitination, 
as in Fig.7. The intracellular domain (kinase domain, shaded in blue, and C-terminal tail, unshaded) of the 
EGFR is represented as a long tail, where the three fundamental tyrosines (Y1045, Y1068, Y1086) for 
EGFR ubiquitination and Cbl binding are depicted. The E3-ligase Cbl can interact with the receptor directly 
through the phosphorylated-Y1045 or indirectly through the interaction with Grb2 that binds to pY1068 or 
pY1086. The concomitant binding of Cbl through both sites generates stable Cbl/Grb2 binding to the EGFR 
and increases EGFR-Ub. B - Left: CHO cells expressing the EGFR-WT, -9Y- mutant and the indicated add-
back mutants (Fig.27A), were stimulated with EGF (100 ng/ml) for 2 minutes and lysates were subjected to 
IP and WB as indicated,  to investigate the binding of Cbl and Grb2 to the receptor.  10% of the IP lysate  
was  loaded  
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6.1 - Cooperativity 
The experimental analysis of Cbl binding to the EGFR suggested that the interaction 
between EGFR and Cbl is cooperative with the binding of Grb2 to the receptor (Sigismund, 
Algisi et al. 2013). Indeed, if the binding of Cbl to the EGFR were to take place with the same 
affinity regardless of the binding of Grb2, then EGFR-WT and EGFR-Y1045+ should be 
ubiquitinated to the same level and bind to a similar amount of Cbl. We tested experimentally 
this hypothesis by measuring the levels of EGF-induced ubiquitination in the add-back EGFR 
mutants. Add-back mutants were previously introduced (Results Section 3, Fig. 27A); briefly, 
EGFR gene was mutagenized in the 9 tyrosine residues in the intracytoplasmic tail, to obtain 
a pY-null backbone. From this backbone, single or combinations or residues were back-
mutagenized to WT. Through this experimental approach, we established that binding of Cbl 
to the EGFR was reduced by about the 80% in the EGFR-Y1045+ mutant compared with 
EGFR-WT, and absent or negligible in the EGFR-Y1068/86+ mutant (Fig. 33B). In contrast, 
Cbl binding was almost indistinguishable in EGFR-WT and in the EGFR-3Y+ mutant. 
Clearly, we could also score a cooperative effect between pY1045 and pY1068/86 towards 
the association with Cbl, since the binding of the EGFR-3Y+ mutant to Cbl is far stronger 
than the simple sum of the Cbl interaction with pY1045 and with pY1068/86 (see quantitation 
in Fig. 33B, right panel). 
Next, we experimentally determined the ability of the EGFR mutants to be ubiquitinated 
by Cbl. As expected, EGFR ubiquitination was completely abolished when all three tyrosines 
were mutagenized together in the 9Y- mutant (Fig. 33C). Moreover, the presence of 
pY1068/86 was not sufficient to allow EGFR ubiquitination. Ubiquitination of the receptor 
was, however, partially rescued by the presence of pY1045, but only the concomitant 
restoration of the three sites (3Y+) allowed for full EGFR ubiquitination (Fig. 33C). Again, 
there was a clear cooperative effect between the three Cbl/Grb2 binding sites, which allowed 
the EGFR to be fully ubiquitinated (see quantitation in Fig. 33C, right panel). Importantly, 
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the ubiquitination levels of the EGFR mutants reflected the levels of the in vivo binding of 
Cbl to the EGFR (compare Fig. 33B and 33C).  
Based on these observations, we also used the add-back mutants to investigate whether the 
sigmoidal behavior of the interaction between Cbl and the EGFR is maintained when the 
relevant pY sites (i.e. pY1045/68/86) are lost. To this aim, we performed an EGF dose-
response experiment and analyzed the Cbl:EGFR interaction by co-immunoprecipitation (co-
IP) in NR6 cells expressing EGFR-1045+, EGFR-3Y+ and EGFR-WT. The EGF dose-
response curve for the Cbl:EGFR interaction in cells expressing the EGFR-3Y+ mutant 
displayed a threshold behavior similar to that of cells expressing EGFR-WT, whereas the 
EGFR-1045+ mutant showed a non-threshold gradual response over a range of EGF 
concentrations (Fig. 34A). We then aimed to understand whether the sigmoidal behavior of 
EGFR ubiquitination could be re-established going from the EGFR-1045+ mutant to the 
EGFR-3Y+. We compared EGF dose-response curves for ubiquitination of these mutants 
with that of the EGFR-WT by DELFIA analysis (Fig. 34B). We observed that EGFR-WT and 
the EGFR-3Y+ mutant behaved similarly, showing a threshold effect for receptor 
ubiquitination, while the EGFR-1045+ mutant displayed a non-threshold gradual response 
curve, consistent with the presence of one single site for Cbl binding.  
Together, these data point to a scenario in which the EGFR ubiquitination threshold is due 
to a non-linear recruitment of Cbl-Grb2 complex to the EGFR, which in turn is dependent on 
cooperativity between the key phosphosites. A plausible explanation for cooperativity is that 
when Cbl and Grb2 are simultaneously bound to EGFR via their docking phosphosites 
(pY1045 and pY1068/86, respectively), they are in a state of enforced-proximity, which 
increases the chance of the three species (EGFR, Cbl and Grb2) binding to each other in a 
mass action kinetic. The fully bound trimer corresponds in vivo to the fully ubiquitinated 
EGFR. Instead, if Cbl only binds EGFR directly through pY1045, their interaction is not 
stabilized by Grb2 and the EGFR is only partially ubiquitinated. 
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Figure 34: Comparison of the EGF dose-response behavior of Cbl-binding to the receptor and receptor 
ubiquitination in the EGFR mutants. A - Analysis of the ability of EGFR-Y1045+, -3Y (Y1045/68/86+) and -
WT to bind Cbl. NR6 cells stably expressing the Y1045+ mutant, the 3Y+ mutant, or EGFR-WT, were 
stimulated with EGF for 2 minutes at the indicated EGF doses. Lysates were subjected to IP and IB as shown. 
Note that for the 1045+ mutant, we used 2-fold (2x) more lysate because total EGFR-Ub is impaired in this 
mutant. For each blot, quantitation by densitometry is shown on the right, expressed as a percentage of max. B - 
The same samples described in ‘A’ were subjected to the DELFIA assay (forward approach) to assess 
ubiquitination the EGFR mutants, using anti-EGFR intra as the capture Ab and anti-Ub (FK2) as the detection 
Ab. Results are expressed as a percentage of EGFR-WT ubiquitination (arbitrary units, 100 = max WT, left 
panel) or as a percentage of the maximal ubiquitination of each EGFR construct (% of max, right panel). Error 
bars indicate the SD calculated from at least three independent experiments. All p-values were calculated using 
the two-way ANOVA analysis. P-value inset in graphs refer to wt vs phospho-mutants. C - Schematized 
reactions involved in EGFR ubiquitination. Upper reaction: Cbl binds to pY1045 irrespective of whether it is 
free or in a complex with Grb2 (Grb2 is thus represented with a dotted line); middle reaction: Grb2 binds to 
pY1068 (or pY1086, not shown) irrespective of whether it is free or in a complex with Cbl (represented with a 
dotted line); bottom reaction: Cbl and Grb2 bind to each other. On the right: simplification of the consecutive 
reactions that lead to a stable interaction of the   complex Cbl/Grb2 to the EGFR. 
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In our model, we interpreted the presence of cooperativity as follows: Cbl and Grb2 can 
form a complex that binds to the corresponding pYs on EGFR, but they can also bind EGFR 
individually or bind each other forming a dimer. What is fundamental in the system is that the 
Cbl and Grb2 binding rates (to each other and to the EGFR) are increased in the multimeric 
complex. All the possible combinations accounted in the model are depicted in Fig. 34C.  
6.2 - Cbl, but not Grb2, is limiting in the system. 
Assuming that enforced proximity drives cooperativity, we postulated that the binding 
affinity of EGFR and Cbl increases proportionally with the local increase in the availability of 
Grb2 and Cbl on the receptor. Under this scenario, Cbl and Grb2 concentrations become 
important. For what concerns Cbl, it is known that it acts as an E3 ligase in a number of 
cellular complexes and is highly expressed in cells. However, consistent with the notion that 
Cbl binds to >100 different proteins (Schmidt and Dikic 2005; Dikic and Schmidt 2007), we 
have verified that the majority of Cbl is engaged in stable complexes. Performing a size 
exclusion chromatography, Cbl mainly elutes in high molecular weight fractions, with only a 
minor portion of the protein eluting as the free protein (Fig. 35A). 
We also experimentally determined total Cbl levels through a semi-quantitative WB 
analysis. By comparing known amounts of cell lysates with increasing amounts of bacteria-
purified Cbl, we determined that Cbl is expressed in HeLa cells at ~150,000 molecules/cell 
(Fig. 35B, upper panel, see also Table 2 on page 17). This result combined with the size 
exclusion chromatography analysis, strongly suggests that only a minor fraction of Cbl (in the 
free form or engaged in Cbl:Grb2 complexes) is available for direct binding with EGFR. In 
order to estimate the amount of Cbl available for binding to the EGFR, we used the 
phosphorylated form of Cbl (Cbl-pY) as a proxy for the max amount of available Cbl because   
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Figure 35 – The E3 ligase Cbl is limiting in the system. A. Analysis of Cbl and Grb2 elution profiles 
by size exclusion chromatography, performed as described (Penengo, Mapelli et al. 2006, see also 
Materials and Methods). Starting from a cellular lysate of HeLa cells loaded on a size exclusion 
column, consecutive fractions eluting from the column according to their molecular weight were 
collected and subjected to WB analysis. I, input (50 µg). In the Grb2 panels: s.e. and l.e., represent short 
and long exposure, respectively. B. Quantitation of Cbl and Grb2 molecules in HeLa cells. Increasing 
amounts of HeLa cell lysate were subjected to IB and IP as indicated and compared to increasing 
amounts of in vitro purified Cbl (upper and middle panels) or Grb2 (lower panel) proteins. For further 
information about the estimation of Cbl and Grb2 molecules, refer to Table 1 and Matherials and 
Methods, Section Protein Procedures. C. HeLa cells were stably transfected with Cbl-WT (Cbl 
overexpression, OE), Cbl dominant negative (Cbl70Z), or empty vector (Vector). Lysates were 
analyzed by WB as indicated. Tubulin was used as a loading control. Densitometry analysis revealed an 
~7-fold increase in Cbl expression levels in Cbl-OE and Cbl70Z transfectants compared with control 
cells. D. HeLa cells transfected as in C, were treated with EGF at the indicated concentrations for 2 
minutes. Lysates were subjected to IP and IB analysis with the indicated antibodies. 
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I) Cbl is phosphorylated upon binding to the EGFR; and II) only phosphorylated Cbl is 
competent for EGFR ubiquitination (Levkowitz, Waterman et al. 1999; Zhang, Gureasko et al. 
2006). We reasoned therefore that the levels of Cbl-pY at the maximal EGF concentration 
might represent a reasonable approximation of the maximal amount of Cbl available for 
binding to the EGFR. After stimulating with a high concentration of EGF (100 ng/ml) for two 
minutes, the amount of Cbl-pY that was experimentally determined was ~5,000 
molecules/cell (Fig. 35B, middle panel). This result confirmed that the amount of Cbl that is 
available for EGFR binding in the first 2 minutes after EGF stimulation is a minimal fraction 
of total Cbl molecules/cell (around 4%) and thus could be limiting.  
To investigate in more detail the correlation between Cbl levels and EGFR ubiquitination 
in our system, we took advantage of a dominant negative form of Cbl (Cbl70Z) (Yokouchi, 
Kondo et al. 1999), which mimics Cbl downmodulation. We transfected HeLa cells with an 
empty vector as a negative control, with Cbl-WT as a control for Cbl overexpression, or with 
Cbl70Z, and achieved an ~7-fold overexpression of the two Cbl constructs (Fig. 35C). We 
then treated these cells with increasing EGF doses for 2 min. We observed that Cbl 
overexpression or downmodulation (expression of the dominant negative mutant) induced 
either an increase or decrease, respectively, in the levels of EGFR ubiquitination (Fig. 35D). 
This observation corroborates the hypothesis that Cbl is rate-limiting in the EGFR 
ubiquitination process, since the modulation of its total levels affects the net EGFR-Ub output. 
Using an analogous approach to that used for Cbl, we also estimated a total number of 
~1,000,000 Grb2 molecules/cell through the comparison of total cell lysate with bacteria-
purified Grb2 by WB analysis (Fig. 35B - lower panel). Moreover, by size exclusion 
chromatography, we showed that Grb2 elutes as a single monomeric species (Fig. 35A), 
indicating that the majority of the Grb2 molecules are free or form very unstable complexes. 
The in vivo association of Grb2 with the EGFR add-back mutants (Fig. 33B) supports the 
idea that, in living cells, the majority of Grb2 exists in a free form, while Cbl is 
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predominantly present in complexes that also contain Grb2. The EGFR-1045+ mutant, which 
binds directly Cbl but not Grb2, co-immunoprecipitated with similar amounts of Cbl and 
Grb2 (Fig.33B). In contrast, the EGFR-1068/86+ mutant, which binds directly to Grb2 but 
not to Cbl, co-immunoprecipitated with Grb2 as efficiently as EGFR-WT or the 
1045/1068/1086+ mutant, while it did not co-immunoprecipitate with Cbl.  
Therefore, in our model, we assumed that all measured Grb2 is available for binding to 
the EGFR and/or to Cbl. The above results indicate that Cbl is rate-limiting in the EGFR 
ubiquitination reaction, compared with EGFR and Grb2. 
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6.3 - A probabilistic hypothesis  
Cooperativity is necessary, but not sufficient, to generate the threshold. Indeed, the 
concomitant presence of two key phosphorylated tyrosines is also required, and this occurs 
via a purely probabilistic process. Since tyrosine residues on EGFR are phosphorylated 
independently of each other (Fig. 27), this implies that while the probability of individual 
tyrosyne phosphorylation increases gradually with the concentration of ligand, the probability 
of having two, three, or more phosphorylated tyrosine residues on the same EGFR moiety, 
does not. Instead it increases non-linearly. Thus, at low doses of ligand the receptor is 
scarcely phosphorylated so the probability of having two out of three key tyrosines 
phosphorylated is negligible, causing an unstable binding of the Cbl/Grb2/receptor complex. 
Instead, as the concentration of EGF increases, this probability follows an exponential 
growth, allowing a stable (cooperative) binding of the complex and full ubiquitination of the 
receptor (Fig. 36). Summarizing, we have identified three main features to integrate into the model: 
1. Cooperativity between Cbl:Grb2 and the EGFR; 
2. “Competent” Cbl is present at limiting concentrations; 
3. The non-linear availability of EGFR molecules carrying at the same time the two 
key pY (1045 and 1086/86) sites required for Cbl/Grb2 binding, as EGF 
concentrations increase. 
Figure 36: The probabilistic 
hypothesis that contributes to the 
generation of the EGFR-Ub 
threshold. At low EGF, the EGFR is 
scarcely phosphorylated. Increasing 
the EGF concentration results in an 
exponential increase in the probability 
of having two residues phosphorylated 
on the same moiety, therefore, 
allowing a stable interaction of the 
complex Cbl/Grb2 to the receptor and 
permitting full EGFR ubiquitination. 
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6.4 - MPM-B: a model of EGFR ubiquitination 
Before proceeding with the construction of a complete model for EGFR activation, we 
implemented the MPM and used it as an input for the formalization of Cbl and Grb2 binding. 
We obtained a model of EGFR ubiquitination designated as MPM plus Binding (MPM-B). 
We computed the model assuming that all species are at steady state in the absence of EGF; at 
time zero, we simulated the addition of EGF into the system and computed the values of 
EGFR ubiquitination and phosphorylation after 2 minutes. MPM-B accurately reproduced the 
behavior of EGFR-Ub/-pY that was observed in vivo. Moreover, it also reproduced in 
quantitative detail the increase in steepness (Fig. 37A) of the ubiquitination curve vs. the 
phosphorylation curve for EGFR-WT, as shown by the normalized curves. MPM-B also 
faithfully reproduced the experimentally determined dose-response curves for ubiquitination 
in conditions of Cbl overexpression or downmodulation (Fig. 37B-C), both when curves were 
normalized to their max (Fig. 37B) or to WT ubiquitination (Fig. 37C). In this latter case, 
however, simulated and experimental curves were superimposable only if we assumed a 3-
fold increase in Cbl overexpression, instead of the 7-fold increase measured experimentally 
(Fig. 35C). Thus, the model suggests that the 7-fold increase in Cbl expression that was 
obtained experimentally, does not lead to a real 7-fold increase in Cbl available for EGFR 
binding. Rather, the model suggests that only ~1/3 of the overexpressed Cbl molecules are 
capable of binding the receptor, supporting the notion that not all Cbl is available for EGFR 
ubiquitination.  
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Interestingly, if we analyze the experimental ubiquitination curves normalized to the 
same maximum (Fig. 37B), modulation of Cbl levels does not affect the ubiquitination 
threshold. In parallel, the model also showed that alteration of Cbl levels (within a limit), 
despite affecting the absolute amount of EGFR ubiquitination (Fig. 37C), does not affect 
the ubiquitination threshold (Fig. 37B). This lack of effect on the EGFR-Ub threshold is 
Figure 37: The MPM-B reproduces the EGFR phosphorylation and ubiquitination dose-response 
curves. A - Comparison of experimental (exp; dashed lines) and MPM-B modeled (solid lines) 
phosphorylation (pY) and ubiquitination (Ub) dose-response curves for EGFR-WT. Experimental data are 
expressed as normalized to the maximum value for both EGFR-Ub or -pY. Inset shows the ratio of 
ubiquitination to phosphorylation as a function of EGF concentration for experimental and modeled data. 
B-C - Comparison of experimental (dashed lines) and modeled (solid lines) EGFR ubiquitination dose-
response curves under conditions of Cbl overexpression (OE) or downmodulation (Cbl70Z). Experimental 
data were taken from Fig. 21D in which HeLa cells were transfected with empty vector (vector), Cbl-WT 
for overexpression, or the dominant negative Cbl70Z for downmodulation. Data were obtained through 
quantitation of EGFR ubiquitination by densitometric analysis of WBs shown in Fig. 21D. EGFR 
ubiquitination is expressed, for each condition, as normalized to their own maximum (Ub/UbMAX, B) or to 
the maximum value obtained in the empty vector control (Ub/UbWT, C). D - Dependence of EGFR 
ubiquitination [expressed as normalized to the total EGFR concentration (Ub/EGFR)] on the total Cbl 
concentration [expressed as normalized to the total EGFR concentration (Cbl/EGFR)]. The black square 
indicates the amount of total active Cbl that we have experimentally measured (see Section 6.2). 
Calculations were performed using MPM-B and the parameters given in Appendix 1 (with the exception of 
Cbl). 
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not immediately obvious, given the sizable changes in total EGFR ubiquitination upon Cbl 
modulation. Importantly, this condition was verified by the model only when the ratio 
between Cbl available for EGFR binding (estimated as Cbl-pY) and the EGFR surface levels 
was less than 0.2 (Fig. 37D). Notably, this number is in agreement with the number of Cbl-
pY molecules/cell that we estimated experimentally (Fig. 33D).  
7 - The Early Activation Model 
In order to investigate how the EGFR ubiquitination threshold can be modulated, we used 
the MPM-B to identify the parameters that can alter the position of the threshold. To this aim, 
a normalized “sensitivity parameter” for the EGFR ubiquitination threshold xT (the position of 
the Ub-threshold on the x-axis - or the EGF concentration where the Ub or pY curves reach 
their half-maximal value) was derived by dividing or multiplying, by one order of magnitude, 
all the parameters in the model. A parameter was considered as a good candidate for 
experimental verification when it was greater than 1. This analysis identified only one 
parameter, the EGFR phosphorylation rate kKIN, the experimental validation of which would 
be challenging because it represents a sum of reactions that lead to EGFR intracytoplasmic 
tyrosine phosphorylation. 
To identify alternative parameters for experimental validation, we developed the Early 
Activation Model (EAM), which includes the molecular details of EGFR activation. The 
EAM includes the features that were formalized in the MPM-B, as summarized in Section 6: I) 
cooperativity, II) Cbl limiting, III) probabilistic hypothesis. Moreover, in the EAM, we 
replaced the Hill function used to couple EGF concentration and EGFR phosphorylation 
(Result Section 5.1) with more detailed biological rules, such as EGFR opening and closing, 
EGF binding to EGFR, conformational changes in the extracellular domain and receptor 
dimerization. To address these additional reactions, we started from previously proposed 
models (Klein, Mattoon et al. 2004; Macdonald and Pike 2008). Obviously, the EAM carries 
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more parameters than MPM-B; for many of these, we defined a reasonable range of values, 
thanks to the vast amount of experimental and modeling data available in literature (Appendix 
1). After implementation of the new model, we fitted the dose-response curves for EGFR 
phosphorylation and ubiquitination with the EAM. Importantly, we obtained results very 
similar to those obtained with the MPM-B: also the EAM quantitatively accounts for the 
ubiquitination threshold observed in vivo at 2 minutes of EGF stimulation (Fig. 38), 
reproducing the molecular circuitry underlying EGFR-Ub in silico. 
7.1 - The EGFR-Ub threshold is sensitive to surface EGFR levels 
The EAM was explored to highlight parameters whose alteration might affect the positioning 
of the threshold over the range of EGF concentrations used. The identification in silico of 
those parameters would be advantageous in designing experiments aimed at understanding 
how cells control their EGF-mediated responses and how this control might be subverted in 
pathological conditions. 
 
 
  
Figure 38: The EAM 
reproduces the 
EGFR 
phosphorylation and 
ubiquitination 
curves. Comparison of 
experimental data 
(exp; dashed lines) and 
modeled (solid lines) 
phosphorylation and 
ubiquitination dose-
response curves for 
EGFR-WT. Inset 
shows the ratio of 
ubiquitination to 
phosphorylation as a 
function of EGF 
concentration for 
experimental and 
modeled data. 
Experimental data as 
in Fig.37. 
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eters  
Figure 39: Downmodulation of EGFR levels shifts the ubiquitination dose-response curve. A - EAM 
parameters were varied 10-fold and the sensitivity coefficient S for the EGFR ubiquitination threshold position 
xT was computed. Only parameters whose variation resulted in a sensitivity coefficient of at least 0.1 are 
reported. B - HeLa cells were subjected to EGFR knockdown (KD) with an anti-EGFR siRNA oligo, whereas 
control cells were transfected with mismatched oligos. Cells were treated for 2 minutes with EGF as indicated 
and IP and IB were performed as shown. Quantitation of EGFR ubiquitination by densitometry is shown in C. 
Blots are representative of at least 3 independent experiments. C - Model predictions and experimental data 
(based on blots in B) of the ubiquitination threshold in EGFR-KD (KD) or control (WT) HeLa cells. In the 
simulation of the EGFR-KD, the decrease in EGFR levels was assumed to be 4.2-fold, as determined in 125I-
EGF saturation binding assays performed on the KD cells (not shown). EGFR ubiquitination is expressed, for 
each condition, as normalized to the maximum value obtained in that condition (Ub/Ubmax). Results are 
expressed as the mean ± SD calculated from at least 3 experiments D - Left and middle panels, EGFR-Ub and 
-pY dose-response curves upon downmodulation of EGFR measured by DELFIA. HeLa cells were treated an 
in B. Again, results are expressed as the mean ± SD calculated from at least 3 experiments. Right panel, WB 
analysis was performed using the indicated antibodies to verify efficiency of EGFR KD. Note that Cbl levels 
do not change upon EGFR KD. Tubulin was used as a loading control. This blot control is representative of 3 
independent experiments. 
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The position of the threshold was revealed to be robust, with only two parameters 
identified that could affect the positioning of the threshold (Fig. 39A). One candidate 
parameter whose modification affected significantly the positioning of the Ub threshold was 
again the EGFR phosphorylation rate, kKIN, in agreement with MPM-B. Additionally, the total 
number of EGFRs, RT, emerged as a good candidate. Compared to kKIN, RT has the significant 
advantage of being easy to manipulate. Thus, we validated the predictive power of the model 
by attenuating the expression of EGFR in HeLa cells via incomplete KD (Fig. 39B), 
achieving an ~4-fold decrease in EGFR levels (from ~3×105 to ~7×104 EGFRs/cell, measured 
by 125I-EGF saturation binding assay). Stimulation with increasing EGF doses for 2 minutes 
resulted in a shift of the ubiquitination curve to a position that was remarkably similar to that 
shown in simulations in which the EGFR levels were reduced 4-fold (Fig. 39C), shifting the 
curve towards higher EGF concentrations. HeLa EGFR-KD cells were also assessed by 
DELFIA assay, achieving again a shift of the EGFR-Ub threshold towards higher EGF 
concentrations (Fig. 39D, left panel), while no effect was observed on the EGFR-pY (Fig. 
39D, center panel).  
In conclusion, guided by the EAM, we were able to establish that the total number of 
surface EGFRs is a key parameter in the control of the position of the ubiquitination threshold. 
We also confirmed this prediction experimentally, thereby endorsing the predictive power of 
the model. This prediction might have important implications on how the Ub threshold - and 
the switch between CME and NCE - controls biological output. 
8 - Challenging the model: changing EGFR and EGF levels  
Having highlighted the importance of the number of EGFRs per cell, we wanted to investigate 
in more detail the behavior of EGFR-Ub/-pY over a range of different receptor levels - 
spanning from physiological levels (<105 EGFRs/cell) to pathological levels detected in 
human tumors (>106 EGFRs/cell) - and over different EGF concentrations. This issue is 
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highly relevant to cancer since overexpression of EGFR in human tumors is frequently 
accompanied with the overproduction of its ligands, which can act on the receptor in an 
autocrine or paracrine fashion (Arteaga 2002; Zandi, Larsen et al. 2007). 
The EAM was interrogated about the behavior of EGFR-Ub and -pY upon variation of 
EGFR levels per cell and at different EGF concentrations, generating an advanced prediction 
of EGFR-Ub/-pY patterns (Fig. 40). At all EGF doses, the average EGFR ubiquitination per 
receptor (red line, normalized to the maximum ubiquitination obtained at 100 ng/ml EGF) 
displayed a bell-shaped curve, indicating that ubiquitination increases as a function of EGFR 
surface expression, until a maximum is reached, after which it decreases. Interestingly, the 
peak is progressively shifted towards lower EGFR surface levels, as the EGF concentration 
increases. In contrast, the average phosphorylation per receptor (black line, normalized to the 
maximum phosphorylation obtained at 100 ng/ml EGF) behaved differently, with the 
phosphorylation peak progressively shifting towards higher EGFR surface levels, as a 
function of EGF concentration. This behavior has important consequences: in the 
physiological range of EGFR levels, the system responds to increasing EGFR activation (i.e. 
pY) with a congruent increase in EGFR-Ub levels, at all EGF doses. However, when EGFR 
levels exceeded the physiological range, and for EGF concentrations above 1 ng/ml - two 
conditions frequently associated with cancer – EGFR-Ub decreases much more rapidly than 
its pY and the Ub/pY curves became uncoupled.  
 We experimentally tested this prediction by measuring EGFR ubiquitination and 
phosphorylation dose-response curves in cell lines expressing increasing amounts of EGFR. 
We followed two parallel approaches to verify this prediction: first, in order to eliminate 
biological variability, we took advantage of an isogenic background, i.e. NIH cells, in which 
we reintroduced the EGFR at different levels (Result Section 8.1); in parallel, we validated 
the prediction also in normal vs. cancer cells with increasing surface receptor levels (Result 
Section 8.2). 
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8.1 - Isogenic background approach to validate the EGFR-Ub/pY 
uncoupling prediction 
To perform experiments in a homogeneous genetic background, we used NIH-3T3 fibroblasts, 
which express low levels of endogenous EGFR (~104 EGFRs/cell) transfected with a 
retroviral expression vector (pBABE) encoding human EGFR-WT. We then selected three 
NIH-EGFR clones expressing different surface levels of EGFR (as assessed by saturation 125I-
EGF binding assay, Fig. 41A) representative of: 
• the physiological condition (~7 x 104 EGFRs/cell, EGFRphy cells); 
• moderate overexpression (~2 x 105 EGFRs/cell, EGFRm-ov cells);  
• high overexpression (~6 x 105 EGFRs/cell, EGFRh-ov cells). 
Figure 40 - Advanced prediction for EGFR-Ub and -pY as a function of EGF concentration and 
surface EGFR number. Relative phosphorylation (pYT/EGFRT, black lines) and ubiquitination 
(UbT/EGFRT, red lines) levels of the EGFR, as given by the EAM, for the indicated EGF concentrations. 
The gray area represents the physiological range of EGFR levels. Dashed lines indicate the maximum levels 
of phosphorylation and ubiquitination. Curves are plotted as normalized to the individual maximum of either 
phosphorylation or ubiquitination obtained at 100 ng/ml of EGF. 
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The three clones displayed homogenous expression of the receptor at the single cell level (Fig. 
41A). 
To better characterize this cell line in terms of absolute amounts of the key players in the 
system - Cbl and Grb2 - we calculated the number of total Cbl, Cbl-pY and Grb2 in NIH-
EGFRh-ov cells in condition of high EGFR levels, in which the ratio between Cbl and 
receptors/cell could be critical. The analysis showed that NIH cells express similar levels of 
the key players of the Ub reaction as HeLa cells: 800,000 Grb2 molecules/cell and 130,000 
Cbl molecules/cell. Considering only the active form of Cbl (Cbl-pY), its level decreased to 
6,000 molecules/cell, thus Cbl remained limiting in the Ub reaction under these conditions 
compared to the number of EGFRs/cell (Fig. 41B, Table VI). We also verified, by size 
exclusion chromatography, whether Cbl, in NIH cells, exists mostly as a free monomer, or as 
part of macromolecular complexes. Again, we observed that the majority of Cbl fractionates 
at high MW, indicating that it is mostly engaged in macromolecular complexes, and that it is 
not commonly found as a monomer in cells (Fig. 41C). 
We then proceeded to test the model predictions (Fig. 40). To this aim, the selected NIH 
clones were stimulated for 2 minutes al 37°C with 1, 10, 100 ng/ml of EGF, and their Ub and 
pY levels were measured by DELFIA assay. This quantitative assay allowed us to measure 
EGFR ubiquitination and phosphorylation in a relatively high number of samples in the same 
experiment, in contrast to WB analysis. Importantly, the NIH clones were able to recapitulate 
the Ub/pY bell-shaped curves reported by the model prediction, as reported in Fig. 41D, 
where the experimental data were superimposed onto the model simulation. In particular, the 
experimental data confirms the progressive uncoupling of the phosphorylation and 
ubiquitination dose-response curves with increasing EGFR surface levels.  
Figure 41 (next page): Experimental validation of the EAM prediction reveals how EGFR-Ub and -pY 
are uncoupled at high EGFR number. A - NIH-3T3 cells were stably transfected with a vector carrying WT 
EGFR. NIH clones were selected expressing different numbers of EGFRs/cell (from lowest to highest: NIH-
EGFRphy, physiological EGFR; NIH-EGFRm-ov, medium overexpression; NIH-EGFRh-ov, high overexpression). 
Representative images of immunofluorescence (IF) analysis of EGFR surface levels (see Materials and 
Methods) in the indicated NIH-EGFR clones is shown. Continues in the next page… 
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Nuclei were stained with DAPI (blue). Bar 18 µm. Bottom, number of surface EGFRs/cell, as measured by 
125I-EGF saturation binding assay (see Materials and Methods). B - Quantitation of the number of Grb2 
and Cbl molecules in NIH3T3 cells overexpressing EGFR. Increasing amounts of NIH-EGFRh-ov (NIH3T3 
clone with the strongest EGFR overexpression) cell lysate were subjected to IP/IB as indicated and 
compared with increasing amounts of in vitro purified Grb2 (top panel) or Cbl (middle panel) proteins. To 
estimate the ratio between the total and the phosphporylated  form of Cbl, we IP increasing amount of NIH-
EGFRh-ov cells (as indicated) and compared them to increasing amount of total lysate. Additional 
information about the estimation of Cbl and Grb2 molecules can be found in Table VI and Materials and 
Methods. C - NIH-EGFRh-ov cell lysate was subjected to size exclusion chromatography (see Materials and 
Methods). Sequential fractions eluting from the column were collected and analysed by WB to identify 
fractions containing Cbl and Grb2.  D - Advanced model for EGFR-Ub and -pY as in Fig.40. Red squares 
and black circles represent experimental measurements of EGFR-Ub and -pY behavior, respectively, 
obtained by DELFIA assay on NIH-EGFR clones with increasing numbers of EGFRs/cell and stimulated 
with the indicated EGF doses.  Experimental data are reported as mean ± SD from at least three independent 
experiments. 
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Table VI - Amount of critical players involved 
in the EGFR ubiquitination reaction in HeLa 
and NIH-EGFRh-ov cells. The number of surface 
EGFR molecules in HeLa cells and NIH3T3 cells 
overexpressing EGFR at high levels (NIH-EGFRh-
ov) was measured by 125I-EGF saturation binding 
(see Materials and Methods). Data are expressed as 
number of surface EGFRs/cell, results are 
expressed as the mean ± SD calculated from at 
least three independent experiments. To calculate 
the total number of Grb2 and Cbl molecules (Grb2 
tot and Cbl tot, respectively), we compared signal 
intensities of anti-Grb2 or anti-Cbl bands in IB of 
increasing amounts of cellular lysate with known 
amounts of purified Grb2 or Cbl protein (see Fig. 35B and 41B). To calculate the number of active Cbl 
molecules (Cbl-pY), we IP Tyr phosphorylated Cbl, using an anti-pY antibody, from increasing amounts of 
cellular lysate derived from cells stimulated with EGF (100 ng/ml) for 2 min (see Fig. 35B and 41B). 
Immunoprecipitated proteins were then IB with anti-Cbl. The amount of Cbl in the IPs was then compared with 
the amount in total cellular lysates and with known amounts of purified Cbl protein (see Materials and Methods). 
The IBs in Fig. 35B and 41B from which these calculations derived, are representative of at least three 
independent experiments. Results are expressed as mean ± SD calculated from at least three independent 
experiments. 
 
8.2 - Non-isogenic background approach to validate the EGFR-Ub/pY 
uncoupling prediction 
We extended our analysis and tested the non-obvious prediction generated by the EAM in 
normal vs. cancer cells. We performed a screening of different cell lines, taking into 
consideration the EGFR levels/cell along with the expression of other proteins directly 
involved in the EGFR ubiquitination process (i.e. Cbl and Grb2; Fig. 42A). We selected for 
further analysis a number of tumor cell lines displaying increasing amounts of EGFR (HeLa, 
CASKI, BT20; in this latter line EGFR is amplified), compared to a normal fibroblast cell line 
(WI38; Table VII), while having similar levels of Cbl and Grb2 (Fig. 42A, B).  
Cells were stimulated for 2 minutes al 37°C with 100 ng/ml of EGF, and their Ub and pY 
levels were measured by the DELFIA assay. We also included in the experiment the three 
NIH clones with increasing EGFR levels as an internal reference. Data obtained by DELFIA 
analysis were plotted normalized to the NIH-EGFRphy (Fig. 42C). Importantly, we could 
confirm the dramatic reduction in EGFR ubiquitination at high EGF concentrations, going 
from normal to cancer cell lines with increasing numbers of EGFRs/cell, while EGFR 
phosphorylation remained constant. 
 
N. of molecules / cell (x 103) 
HeLa WT NIH-EGFRh-ov 
EGFR 250 (± 50) 200 (± 50) 
Grb2 tot 1000 (± 260) 800 (± 120) 
Cbl tot 150 (± 25) 130 (± 8) 
Cbl-pY 5.2 (± 0.75) 6 (± 1.5) 
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Overall, uncoupling of EGFR-Ub and -pY curves was observed by two independent 
approaches - using an isogenic background or a set of different cell lines - validating the 
EAM prediction and leaving us with the open question as to why this uncoupling is observed.  
It is important to highlight that in our model, designed for HeLa cells, the edge where Cbl 
becomes limiting is when the ratio between Cbl-pY and surface EGFRs is less than 0.2 (Fig. 
37D). We verified that this was the case both in CASKI and BT20. To this aim, we performed 
a quantitative WB analysis to calculate the number of total Cbl and Cbl-pY per cell (Fig. 42D, 
see Methods). Results are reported in Table VII and show that the levels of total Cbl are 
similar in all cell lines; more importantly, the fact that Cbl-pY is limiting is verified both in 
CASKI and BT20 cells (Cbl-pY/EGFRs <0.2).  
 
 
 
 
 
Cell 
line Origin 
EGFRs/cell 
(x 103) 
Cbl 
tot/cell 
(x 103) 
Cbl-
pY/cell 
(x 103) 
Cbl-pY/ 
EGFRs 
WI38 Normal lung fibroblasts 80 n.a. n.a. n.a. 
HeLa Cervix adenocarcinoma 250 150 5.2 0.02 
CASKI Cervix epidermoid carcinoma 400 190 2.7 0.0067 
BT20 Breast carcinoma 1200 210 15 0.0125 
Table VII – Origin of the cell lines used in the non-isogenic approach for the EAM validation. 
The indicated cell lines were characterized for the number of surface EGFRs/cell by saturation 125I-
EGF binding assay (see Materials and Methods). For the high EGFR expressing cell lines (CASKI 
and BT20), where Cbl levels may be critical for EGFR-Ub, we calculated the number of total Cbl 
(tot Cbl) and active Cbl (Cbl-pY) molecules/cell by comparing the signal intensities of the anti-Cbl 
bands in IBs of total lysates and anti-pY IPs, with the signal of the purified Cbl protein as in Fig. 
35B and 41B, as previously described (see also Table VI and Materials and Methods). Last column 
indicates the ratio of Cbl-pY molecules to EGFR molecules/cell. Note that, in our model, tailored 
for HeLa cells, Cbl becomes limiting when Cbl/EGFRs/cell reaches ≈0.2. Calculation of Cbl and 
pY-Cbl molecules are from blot in Fig. 42D. 
RESULTS 
 142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Uncoupling of EGFR-Ub/-pY at high EGFRs/cell was confirmed by a non-isogenic strategy. A - 
A panel of cell lines was investigated by IB to assess the levels of the key players in the EGFR ubiquitination 
machinery. Lysates from the indicated cell lines were IB as shown. Asterisks indicate cell lines with levels of 
Cbl/Grb2 comparable to HeLa cells, but with different EGFR levels (see Table VII), which were selected for the 
Ub/pY analysis performed in C. B - EGFR and Cbl levels were evaluated by IB in the indicated cell lines at 
steady state or upon stimulation with 100 ng/ml EGF for 2 minutes. Tubulin was used as loading control to 
evaluate that Cbl levels are unchanged in the different samples. C - Relative EGFR ubiquitination (left, 
Ub/EGFRT, red line) or phosphorylation (right, pY/EGFRT, black line), as given by the EAM, for 100 ng/ml 
EGF, normalized to their respective maximum. The gray area represents the physiological range of EGFR levels. 
Red dashed line indicates the maximum level of ubiquitination. Squares represent experimental measurements of 
EGFR ubiquitination (left) or phosphorylation (right), obtained by the DELFIA assay in the indicated NIH-
EGFR clones (red) or cell lines (black). Note that cell lines used display increasing amounts of EGFR at the cell 
surface, going from physiological receptor levels to strong EGFR overexpression. Experimental data are 
reported as mean ± SD from at least three independent experiments. D - Increasing amounts of CASKI (upper) 
or BT20 (middle) cell lysate were subjected to IP/IB as indicated, and compared with increasing amounts of in 
vitro purified Cbl protein to obtain an estimate of the number of Cbl molecules per cell (see Table VII and 
Materials and Methods) 
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9 - Recoupling of EGFR phosphorylation and ubiquitination 
The presence of bell-shaped curves in the model prediction can be explained by the saturation 
of the reactions leading to both phosphorylation and ubiquitination when the number of 
EGFRs increases and EGF concentration remains constant. When EGFRs increase above 
physiological levels, low doses of EGF are diluted among the receptors and the average 
phosphorylation per receptor decreases, possibly due to impairment of dimer formation at the 
PM due to competition with the many unbound 
inactive EGFRs. Similarly, as phosphorylated 
EGFRs decrease, also the fraction of ubiquitinated 
EGFRs decreases. However, at high EGF 
concentrations and especially at non-physiological 
levels of EGFR, the ligand is no longer diluted and 
the average phosphorylation per receptor does not 
decrease. Ubiquitination, however, decreases also in 
this case because it requires Cbl, which we have 
shown to be rate-limiting compared to EGFR and 
Grb2 and which becomes saturated by the many 
activated EGFRs. Therefore, despite the increase in 
potentially “ubiquitinatable” EGFRs, the fraction of 
actual ubiquitinated receptor decreases at high EGF 
under conditions of EGFR overexpression, while 
EGFR-pY is maintained.  
 In support of this interpretation, we attempted 
to re-establish ubiquitination under conditions of 
Figure 43 - Modeling EGFR-Ub under 
conditions of Cbl overexpression. Relative 
EGFR ubiquitination levels (Ub/EGFRT), as 
given by the EAM, at 100 ng/ml of EGF 
under control (red line) or Cbl 
overexpressing (Cbloe; red dashed line) 
conditions. The gray area represents the 
physiological range of EGFR levels. Cbl 
overexpression was modeled as a 100X 
increase. Data were normalized to the 
maximum ubiquitination in each condition.  
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EGFR overexpression in silico, by increasing the levels of Cbl of 100 times. Cbl 
overexpression resulted in a partial restoration of EGFR ubiquitination (Fig. 43). 
To experimentally test the prediction of the uncoupling between EGF-Ub and -pY 
behaviors, we transfected the NIH clones with a lentiviral inducible vector (pSLIK) that 
drives the overexpression of Cbl upon doxycycline treatment. We checked clones for Cbl 
expression levels by: i) WB to assess that overexpression was comparable between different 
NIH-EGFR clones (Fig. 44A) and ii) single cell IF analysis to control the homogeneous 
expression of the proteins among cells (Fig. 44B). An overnight treatment with 0.5 µg/ml of 
doxycycline was sufficient to induce an ~80-100 times increase in Cbl expression compared 
to endogenous levels, as calculated by quantifying different amounts of cell lysate by 
densitometric analysis (Fig. 44C). NIH clones -/+ Cbl were stimulated for 2 minutes with 100 
ng/ml of EGF, and their Ub and pY levels were measured by the DELFIA assay. EGF 
treatment of NIH-Cbl overexpressing clones resulted in the complete restoration of EGFR 
ubiquitination in the EGFRm-ov cells and in a 50% increase in ubiquitination in the EGFRh-ov 
cells, in perfect agreement with model prediction (Fig. 44D). We conclude that the levels of 
Cbl, in conditions of EGFR overexpression, are critical to guarantee the correct coupling of 
EGFR phosphorylation and ubiquitination. 
 
 
 
 
 
 
  
Figure 44 (next page): EGFR-Ub and -pY upon Cbl overexpression. A - NIH clones (EGFRphy, EGFRm-ov 
and EGFRh-ov) infected with empty vector or with a lentiviral vector driving inducible Cbl overexpression, 
were treated with doxocycline (0.5 µg/ml for 16 h), as indicated above each lane, to induce expression of the 
transgene. Lysates were analysed by IB as shown. B - Immunofluorescence staining of Cbl in the NIH clones 
infected with empty vector (Vector) or upon Cbl overexpression (Cbloe); comparable exposures are shown. 
Note that endogenous Cbl is not detected at this exposure, while it gives a punctuate pattern at higher 
exposures (data not shown). Clones with Cbloe showed homogeneous Cbl expression level in >95% of the 
cells (Cbl, red; nuclei, DAPI blue). C - Increasing amounts of total cellular lysate from NIH-EGFRh-ov cells 
expressing endogenous Cbl (Cbl wt) or overexpressing Cbl (Cbloe), were examined by IB using an anti-Cbl 
Ab, followed by densitometric quantitation. Cbl overexpression was calculated to reach ~100 times the 
expression of endogenous Cbl by densitometric analysis. This result is a mean of at least three independent 
experiments. D - Relative EGFR ubiquitination in WT conditions or upon Cbl overexpression as presented in 
Fig.43. Squares represent experimental measurements (obtained by DELFIA assay) of EGFR-Ub NIH clones 
(phy, m-ov and h-ov) infected with empty vector (Vector, red) or with inducible Cbl overexpression vector 
(Cbloe, black). Results are expressed as the mean ± SD calculated from at least three independent 
experiments. E. Relative EGFR phosphorylation in WT conditions or upon Cbl overexpression as given by 
the EAM. EGFR-pY is not predicted to be altered upon Cbl overexpression (gray line represents the WT 
condition in model curves, Cbl OE is not reported because it is coincident with EGFR-pY in the WT 
background). Gray circles represent experimental measurements (obtained by DELFIA assay) of EGFR-pY 
NIH clones empty vector, whereas black circles represent experimental data upon Cbl overexpression. 
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Discussion 
 
In this study, we started from our previous observation that when HeLa cells are stimulated 
with increasing EGF doses, ubiquitination of the EGFR follows a threshold behavior, being 
minimal at low doses, maximal at high doses and presenting a rapid increase in an EGF 
interval centered between 1 and 10 ng/ml of EGF. Importantly, in this same interval of EGF 
concentrations, NCE is activated, and experimental evidence indicated that ubiquitination is 
essential for the internalization of the EGFR through this pathway (see Introduction Section 
3.2). NCE targets the majority of EGFRs to degradation, thus downregulating EGFR 
signaling under conditions of high ligand concentration. Given the biological importance of 
the activation of this internalization route, in this project, we aimed to understand the 
molecular mechanisms underlying threshold generation and NCE activation. To this end, in 
collaboration with the Andrea Ciliberto’s group at IFOM, we expressed as mathematical 
formalism all the reactions leading to EGFR activation and ubiquitination, attempting to 
describe at the molecular level the input layer of our system. Each step in the development of 
the model was supported either by the literature or by direct experimental validation. Thanks 
to this side-by-side use of modeling and experiments, we have uncovered a novel mode of 
EGFR-dependent signal transduction that does not follow a simple linear input->output 
relationship. This finding provides a mechanistic explanation of how the ubiquitination 
threshold is generated as a function of ligand concentration. The model, designed as such, was 
able to predict non-obvious behaviors of normal vs. cancer cells that have been 
experimentally validated. 
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1 - Qualitative to quantitative analysis of EGFR ubiquitination and 
phosphorylation 
To build a mathematical model of EGFR activation and ubiquitination, we needed to obtain 
reliable quantitative data of EGFR phosphorylation and ubiquitination following stimulation 
with ligand. Quantitative data better deal with a mathematical formalism. 
Initially, the EGFR ubiquitination and phosphorylation patterns were characterized by 
WB analysis. Qualitative experimental data were translated into quantitative data by image 
processing and densitometric analysis of the WB images. However, this procedure did not 
guarantee perfect reproducibility in data acquisition. Moreover, exposure times and signal 
saturation introduced additional levels of variability in the data. For instance, depending on 
the exposure time, some signals might reach saturation while others are still in the linear 
phase; this results in over-estimation of the latter signals. By analyzing dose-response curves 
from different sets of WB data, we found that the highest variability was, as expected, in the 
transition phase (i.e., inside the 1-10 ng/ml EGF interval; for a significant example see Fig.25. 
During this phase, the system is instable and highly sensitive to small experimental alterations 
(e.g. small variations in EGF concentration, incubation time, and signal saturation). For these 
reasons, although we obtained WB data that was in good agreement with the threshold model, 
we decided to develop a quantitative assay to measure EGFR phosphorylation and 
ubiquitination in order to reduce experimental variability.  
As described in the Results Section 1, we developed a reliable quantitative EGFR 
ubiquitination/phosphorylation assay. This assay is based on the ELISA method and was 
developed using the DELFIA technique (Perkin Elmer). We now routinely use this assay in 
our laboratory to measure ubiquitination and phosphorylation levels of EGFR upon different 
perturbations. DELFIA was found to be a specific assay, as determined by the absence of 
signal in cells devoid of endogenous EGFR (colo602 cells, see Fig. 22B), and very 
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reproducible (from both technical and biological replicas, see error bars in Fig. 23 and 24). 
Indeed, the standard deviations (SD) derived from DELFIA outputs were much lower with 
respect to WB outputs for both ubiquitination (Fig. 25A) and phosphorylation (Fig. 25B) of 
the receptor. Importantly, we confirmed the existence of a threshold for receptor 
ubiquitination, which is generated between 1 and 10 ng/ml of EGF. The two Ub curves 
obtained by WB and DELFIA analysis display a similar pattern. However, with DELFIA the 
Ub curve was slightly shifted to the left (to lower EGF concentrations) relative to the curve 
obtained by WB. This difference is due almost exclusively to differences in the 3 ng/ml EGF 
data point, which is higher in the DELFIA output compared to the WB analysis. A likely 
explanation for the different results is the higher sensitivity and higher dynamic range of the 
DELFIA signal. In addition, the SD of DELFIA at this critical point is very low (almost 
invisible in the chart), indicating higher reliability. Of note, the phosphorylation curves 
obtained with the two assays were almost identical, and we were also able to show that 
phosphorylation of pY1068 follows similar hyperbolic behavior in DELFIA as the one 
observed by WB (Fig.  24B).  
Thus, we developed a sensitive and reliable quantitative assay based on DELFIA 
technology to measure EGFR ubiquitination and phosphorylation. Using this assay we 
generated reliable data for inclusion in our models. 
2 - Role of phosphatases in counteracting EGFR kinase activity at 
early vs. late time points 
Prior to the modeling of EGFR ubiquitination, we focused our efforts on reproducing the 
behavior of EGFR-pY observed in vivo, developing a simple model to account for EGFR 
phosphorylation at two minutes of EGF stimulation. We considered EGFR phosphorylation 
kinetics as a fast enzymatic reaction (Olsen, Blagoev et al. 2006; Kleiman, Maiwald et al. 
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2011), in which the catalytic domain of the one receptor moiety trans-autophosphorylates the 
cytoplasmic tail of the second receptor moiety in the EGFR homodimer. To take into account 
the potential contribution of phosphatases in the system, we investigated experimentally their 
impact on EGFR phosphorylation.  
It had already been reported in literature that phosphatases have an important role in 
determining the overall EGFR phosphorylation levels (Monast, Furcht et al. 2012). In a panel 
of human tumor lines, including H1666, HeLa and HepG2 cells along with non-transformed 
MCF-10A cells, Kleiman and colleagues showed that active EGFR presents a 
phosphorylation peak 10 minutes after EGF stimulation, which progressively decreases to 
background levels within 2 hours (Kleiman, Maiwald et al. 2011). Total EGFR levels also 
decreased with time after EGF treatment, indicative of EGF-dependent receptor degradation. 
To study the role of phosphatases in the same panel of cell lines, the authors blocked EGFR 
kinase activity using the clinical-grade kinase inhibitor Gefitinib (see Results Section 4), and 
observed a rapid decrease in total EGFR phosphorylation, along with a decrease in 
phosphosite-specific receptor phosphorylation. The half-life of the phosphorylated receptor 
was estimated to be approximately 10-15 seconds, depending on the cell line used, indicating 
a very fast turnover for EGFR phosphorylation. Thus, the authors concluded that total EGFR 
phosphorylation levels is the result of a balance between phosphorylating and 
dephosphorylating events, and that receptors cycle between EGFR and EGFR-pY forms. 
Considering these findings, we investigated the action of phosphatases in our cell model 
system. The aim of our experiments was to assess the activity of phosphatases at 2 minutes 
after EGF stimulation, since the published work focused mostly on the 10 minutes time point 
(Kleiman, Maiwald et al. 2011). Using the inhibitor Gefitinib, we observed that phosphatases 
are very active already at 2 minutes after EGF stimulation (Results Section 4); abrogation of 
the EGFR kinase activity post-EGF treatment, caused a rapid and complete impairment of 
EGFR phosphorylation. We calculated the dephosphorylation constant kPTP of the receptor at 
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2 minutes after EGF stimulation, which is in agreement with previously published data 
(Kleiman, Maiwald et al. 2011 in Supplementary Material). To fully understand whether 
phosphatase activity has a critical role in counteracting kinase activity at 2 minutes after EGF 
stimulation, we used the chemical compound sodium orthovanadate to inhibit phosphatase 
activity in vivo, while leaving the EGFR kinase activity unaltered. We found that phosphatase 
inhibition caused a 10-20% increase in EGFR phosphorylation levels at 2 min, while at later 
time points (i.e. 10 minutes) it had a bigger effect. Thus, kinase activity is much stronger than 
phosphatase activity at 2 minutes, compatible with efficient and fast EGFR phosphorylation at 
the PM. This point is important for the generation of the EGFR ubiquitination threshold. 
Indeed, EGFR ubiquitination follows a threshold behavior only when the ratio between 
kKIN/kPTP does not exceed a certain value, otherwise the system would be unbalanced towards 
phosphatase activity. Such an imbalance would translate into an insufficient level of EGFR 
phosphorylation that, especially in presence of high ligand concentration, would result in 
insufficient ubiquitination of the receptor.  
It is also interesting to speculate what may happens at later time-points, when 
phosphatases appear to be more active. A recent study has demonstrated that mean EGFR-pY 
content is constant among endosomes, a compartment that is reached by active EGFR once it 
has been internalized (Villasenor, Nonaka et al. 2015). The authors explained this observation 
by suggesting that, although increasing EGF concentration results in increased levels of total 
phosphorylated EGFR, there is a balanced partition of EGFR-pY molecules between cellular 
endosomes, regardless the EGF dose. Increasing the number of endosomes, rather than 
varying their content, is one way to achieve this balanced partitioning. Indeed, when 
endosome dynamics and number were altered by knocking down components of the 
endosome tethering and fusion machinery, an alteration in the intracellular signaling events 
due to an unbalanced partitioning of EGFR-pY among endosomes was observed. It has been 
proposed that such a finely-tuned compartmentalization of EGFR-pY in endosomes is 
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achieved via the activity of phosphatases in the endosomes. A simple mechanism through 
which this could happen is that the EGFR dephosphorylation rate increases as the EGFR-pY 
content per endosome increases. In such a scenario, phosphatase activity might be activated 
by the kinase itself in an autoregulatory loop.  
Our data are in agreement with such a scenario where phosphatase activity increases after 
the initial steps of EGFR activation, with the specific aim of regulating downstream events 
such as signaling. Although phosphatases are accounted for in our early model, they do not 
substantially contribute to the generation of the EGFR-Ub threshold. However, their more 
prominent role at the endosomal level must be taken into account when generating a time-
resolved model of EGFR activation (see Ongoing work and future directions), which will 
include EGFR endocytosis and signaling along with data formalized in previous models 
(Kleiman, Maiwald et al. 2011; Villasenor, Nonaka et al. 2015). 
3 - Mechanisms underlying the ubiquitination threshold 
The ubiquitination threshold is essentially determined through a mechanism of “coincidence 
detection” of two Tyr residues in the EGFR by the Grb2:Cbl complex. In this mechanism, two 
components are essential: 1) cooperativity and 2) probability.  
1) Cooperativity necessitates that a combination of multiple phosphorylated tyrosines is 
required for Cbl recruitment. Cbl is the E3 ligase responsible for EGFR ubiquitination and it 
operates in collaboration with the adaptor protein Grb2 (see Results Section 6). Indeed, Cbl 
can bind directly to the receptor through the pY1045 or indirectly through Grb2 that interacts 
with the pY1068/86 on the receptor. Only the cooperative binding of the Cbl:Grb2 complex 
through both phosphorylated sites allows for full EGFR ubiquitination (see Results Section 
6.1). This scenario has been verified through different lines of evidence:  
I. the interaction of Cbl to the EGFR-pY is dependent upon the presence of its binding site, 
pY1045, and on Grb2 binding sites, pY1068/86. Indeed, Cbl binding to the receptor is 
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impaired in mutants that carry only pY1045 or pY1068/86 (Fig. 33): their abrogation 
(singularly or in combination) strongly reduces the Cbl/EGFR interaction (Fig. 33B); 
II. we also observed that Cbl is recruited to the activated EGFR in a threshold-controlled 
fashion, when all the three key pYs are present (Fig. 34A, middle and lower panels), 
whereas if only the Y1045 site is present, the Cbl:EGFR complex forms with a linear 
pattern over increasing EGF concentrations (Fig. 34A, upper panel); 
III. the interaction between Cbl and the receptor is reflected in the pattern of EGFR 
ubiquitination (Fig. 33C). The abrogation of pY1045 and pY1068/86 results in total 
impairment of EGFR-Ub, while the presence of pY1045 alone determines a strong 
reduction in EGFR ubiquitination, which gradually increases with increasing EGF 
concentrations. In contrast, the presence of all the three binding sites is able to fully rescue 
the EGFR-Ub threshold. 
2) The probability component represents a mechanism for generating a non-linear output 
(threshold for EGFR-Ub) from a linear input (EGF concentration). As already mentioned, 
phosphorylation of two key pYs is necessary and sufficient for full EGFR ubiquitination and - 
since Tyr residues on EGFR are phosphorylated independently of each other - the 
concomitant phosphorylation of two Tyr residues occurs via a purely probabilistic process. 
This implies that while the probability of individual Tyr residues undergoing phosphorylation 
increases gradually with the concentration of ligand, the probability of having two, three, or 
more phosphorylated Tyr residues does not. Indeed, multiple phosphorylation events will be 
insignificant at low EGF concentrations and will increase abruptly after reaching a critical 
concentration of EGF (Fig. 36).  
In further support of the probabilistic hypothesis, we already published direct 
experimental proof that the concomitant presence of pY1045 and pY1068 on the same 
receptor moiety increases sharply and non-gradually as a function of ligand (Sigismund, 
Algisi et al. 2013). Indeed, the probability of having two given sites (pY1045 and either one 
DISCUSSION 
 154
of Y1068 or Y1086) phosphorylated on the same EGFR molecule increases non-linearly as a 
function of ligand concentration, and becomes significant only when a critical EGF 
concentration is reached. Therefore, we could envision a situation in which – at high doses of 
ligand – the simultaneous presence of the two binding sites (pY1045 and pY1068/pY1086) 
allows for efficient recruitment of the Cbl:Grb2 complex. 
We translated this phenomenon into the model, formalizing the probabilistic hypothesis 
whereby the concomitant presence of the two key phosphorylated tyrosine residues (for the 
binding of Cbl:Grb2 complex) increases non-linearly as a function of the EGF concentration 
(see Results Section 6.3). This probabilistic mechanism guarantees that such a combination 
arises naturally only at high EGF concentrations.  
Cooperativity and probability were both implemented in the early model, to obtain the 
MPM-B consisting of two modules: phosphorylation (MPM) and Cbl:Grb2 binding (B). 
MPM-B faithfully reproduced the EGFR-Ub and -pY dose response curves observed in vivo 
(Fig. 37A). 
4 - Additional mechanisms that could contribute to the ubiquitination 
threshold 
In developing the MPM-B, we used standard mathematical formulations to represent the 
chemical reactions that lead to EGFR activation. For example, phosphorylation was described 
as a standard multisite chain of reactions, Grb2 and Cbl binding was represented as simple 
mass action, and cooperativity/probability were also formalized. In order to decrease model 
complexity and simulation time, we were forced to introduce some simplifications, such as 
the fact that in the free regime of phosphorylation of Tyr residues, each residue can be 
phosphorylated independently of each other; this allowed us to restrict the analysis to the 
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three critical Tyr residues. For the EGFR ubiquitination reaction, the model traces back only 
Cbl binding to the EGFR. 
For what concerns the choice of parameters, many of them were either well constrained or 
were experimentally estimated. EGFR activation was modeled by introducing a 
phenomenological function based on the Hill equation, which avoided the introduction of 
many parameters that describe the series of events in EGFR activation. Phosphorylation was 
characterized by fitting the dose-response curves. The binding of the Cbl:Grb2 complex to the 
EGFR relied on protein concentrations that were carefully measured and binding affinities 
that were indirectly determined by fitting ubiquitination dose-response curves under various 
experimental conditions, within well-defined experimental constrains taken from previous 
published studies (Appendix 1).  
 Given this series of simplifications, it is not unexpected that the minimalism of the 
model came at a price. Despite the overall agreement, there are areas in which we noticed 
some discrepancies between modeled and experimental data. First, the experimental EGFR 
ubiquitination curves always showed a higher degree of sigmoidicity than the in silico 
simulations, suggesting that the analogical-to-digital conversion operating in real-life is even 
more efficient than in the modeled predictions. Thus, the model requires further optimization, 
and this will be the focus of future investigations. 
Second, the overexpression of Cbl does not reproduce model predictions in exact 
quantitative terms. In HeLa cells, we achieved an overexpression of Cbl to levels 
approximately 6-8 times those of endogenous Cbl, but in the model we used an 
overexpression of 2-fold. In this case, model predictions and experiments can be made to 
agree quantitatively only if we assume that only 1/3 of the overexpressed Cbl molecules are 
capable of binding to the activated EGFR. In the case of Cbl overexpression in NIH cells, we 
were able to reach a higher level of overexpression (around 100 times), but this resulted in a 
partial re-coupling of EGFR-Ub and pY. 
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A possible explanation of the discrepancy between the model and experimental data with 
regard to Cbl, might be that in our model we lack some parameters of the Cbl regulatory 
network. For example, Cbl phosphorylation upon EGF stimulation is the event that triggers 
Cbl activation as a functional E3 ligase (Dou, Buetow et al. 2012). In our model, we did not 
consider this feedback loop, whereby EGFR activation is responsible for Cbl activation. We 
can speculate that the lack of this level of information may subtract sharpness from the 
modeled ubiquitination curve. Moreover, Cbl can homodimerize and heterodimerize with 
other Cbl family members, such as Cbl-b (Peschard, Kozlov et al. 2007), and is also subjected 
to multiple levels of regulation within the cell. Those different levels of regulation include for 
instance, lysosomal and proteasomal degradation as well as  interaction with other proteins 
that bind Cbl and subtract it from the pool able to ubiquitinate the EGFR (Ryan, Davies et al. 
2006). This was partially confirmed in our study by size exclusion chromatography 
experiments, in which Cbl was observed mainly engaged in large complexes (Fig. 35A). 
Finally, the activity of DUBs might counteract the activity of the Cbl E3 ligase at the PM. 
Indeed, it is known that some DUBs are active at the level of the endosome (Clague, Liu et al. 
2012), although no DUBs have thus far been shown to operate on EGFR at the PM. If PM-
active DUBs were to be identified, their activity could be implemented in our model of early 
EGFR activation.  
Cbl phosphorylation, dimerization and counteraction by DUB activity, although not 
essential for the generation of the EGFR-Ub threshold, might help to refine the mathematical 
abstraction of the system in a future more comprehensive model. 
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5 - The ubiquitination threshold is robust but sensitive to variations in 
the number of EGFRs  
The threshold effect predicted by the MPM-B was robust to changes in parameter values, a 
property that was corroborated by experiments in living cells. In particular, Cbl 
overexpression and the expression of a Cbl dominant negative mutant (Cbl70Z, modeled as 
down-regulation, Fig. 35D) did not displace the threshold, both in the modeled response and 
in experimental settings. Of note, this condition is verified only if Cbl is overexpressed within 
a certain level, in particular when the ratio between the amount of active Cbl and the number 
of EGFR molecules does not exceed 0.2. 
To identify those parameters whose alteration might change the position of the EGFR-Ub 
threshold, we had to expand the MPM-B to create the EAM. The EAM includes the molecular 
details of EGFR activation (i.e. EGF binding, EGFR conformational changes, dimerization, 
and trans-phosphorylation), which were hidden in the MPM-B behind the phenomenological 
relationship between EGF and EGFR activation, given by the Hill equation (see Results 
Section 5.1). The addition of new biological laws that connect EGF concentration to EGFR 
activation, led to a higher degree of complexity in the model. Strikingly, EAM proficiently 
reproduced the patterns of EGFR-Ub and -pY (Fig. 38). The EAM also displayed a 
significant robustness to changes in the parameters and the increased complexity of the model 
permitted the generation of an interesting prediction: the position of the EGFR-Ub threshold 
can be shifted to higher EGF concentrations by decreasing the number of surface EGFRs. We 
also experimentally verified this prediction in HeLa cells by EGFR KD, achieving a shift of 
the Ub threshold towards higher EGF concentrations (Fig. 39B-C). Thus, the surface number 
of EGFRs is a key parameter in the control of the position of the ubiquitination threshold. We 
hypothesized that this happens because the reduction of receptors at the PM decreases the 
capability of EGFRs to dimerize and to be activated. 
DISCUSSION 
 158
Results from a study by Mellman and colleagues, in which they investigated the time for 
dimer formation upon EGF stimulation support our hypothesis (Chung, Akita et al. 2010). 
Unliganded EGFR continuously fluctuate between monomer and dimer states. Pre-formed 
dimers can be made through the transient interaction of two monomers, but only the binding 
with the ligand is able to stabilize the dimer form and activate the trans-phosphorylation of 
the two intracellular tails. This means that in the absence of the EGF, the koff of the dimer 
dominates over the kkin of the kinase domain. Moreover, the EGF-induced EGFR dimerization 
time, which contributes to the generation of the kon parameter, is dependent upon the local 
concentration of EGFR pre-formed dimers, at least in EGFR overexpressing cells (Chung, 
Akita et al. 2010). At the single cell level, there are differences in the dimer time formation 
between the periphery, where EGFR dimers are formed in a shorter time interval, and the 
center of the cell, where the time for dimer formation is longer. This observation explains the 
higher probability of finding a dimer at the periphery of the cell with respect to the center 
(Chung, Akita et al. 2010). However, in certain EGFR cell lines that do not overexpress the 
receptor or where EGFR expression is knocked down, the difference in dimer time formation 
between the periphery and center of the cell was lost and the overall time for dimer formation 
turned out to be significantly longer with respect to overexpressing cells (Chung, Akita et al. 
2010). The hypothesis drawn from these data was that cells with increased surface EGFRs 
form dimers faster than those which have decreased EGFR surface levels, probably due to 
simple mass action dynamics. Moreover, even in presence of EGF, dimers are formed and 
disrupted continuously, and the rate of dimer formation is dependent upon EGFR surface 
number (Chung, Akita et al. 2010). 
These findings are in agreement with our observations: we saw that by decreasing the 
EGFR number, the ubiquitination threshold is shifted towards higher EGF concentrations. 
This shift has important implications to how EGFR ubiquitination and its threshold pattern 
control biological output by governing the switch between CME and NCE. The EGFR-Ub 
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threshold shift is perhaps due to the fact that the probability of EGF-bound dimers to form is 
reduced under conditions of decreased EGFR, and only by increasing EGF concentration can 
we restore a scenario in which more stable dimers are formed, resulting in phosphorylation of 
the three key Tyr residues and thus allowing EGFR ubiquitination.  
An implied effect of the EGFR-Ub threshold shift is that as EGFRs decrease on the 
surface because of downmodulation and degradation, and under conditions of high EGF 
concentration, the threshold for NCE internalization is progressively shifted towards higher 
EGF doses. This directs an increasing proportion of EGFRs to CME and thus towards 
recycling rather than degradation. In turn, this would lead to a final equilibrium in which a 
certain amount of EGFR is still preserved at the PM, thereby allowing the persistence of 
signaling required for generating a biological output. This mechanism therefore might allow 
for proper signal maintenance over a wide range of ligand concentrations, which is achieved 
by a balance between EGF-dependent signaling and degradation.  
6 - An important non-obvious prediction: uncoupling of EGFR-Ub/pY 
Given the importance of surface EGFR at the PM in determining the extent of receptor 
ubiquitination, we challenged the EAM to predict the behavior of both EGFR-Ub and -pY 
upon the variation of surface receptor levels, but also EGF doses. The prediction that was 
generated by the model displays a complex behavior (Fig. 40, see also Results Section 8) and 
appears to have evolved in such a way that the maximal response is in the physiological range 
of EGFR levels. At all EGF concentrations, the average EGFR ubiquitination per receptor 
showed a bell-shaped curve, indicating that ubiquitination increases as a function of EGFR 
surface expression until a peak is reached, after which it decreases. Indeed, the EGFR-Ub 
peak is progressively shifted towards lower EGFRs, as EGF concentration increases. Thus, at 
low EGF concentrations (1 ng/ml), the peak values for EGFR ubiquitination and 
phosphorylation per receptor were essentially coincident (Fig. 40, left panel), while at higher 
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EGF concentrations (10-100 ng/ml), ubiquitination saturated at lower EGFR levels compared 
with phosphorylation (Fig. 40, middle and right panel). Since EGFR ubiquitination is coupled 
to the internalization of the receptor through the NCE pathway (Sigismund, Argenzio et al. 
2008; Sigismund, Algisi et al. 2013), this means that over the wide physiological range of 
EGFR levels, which spans one order of magnitude, the cell is well equipped to react to 
increased signaling with increased receptor degradation, to protect itself from overstimulation. 
Instead, at supra-physiological EGFR levels and for EGF concentrations above 1 ng/ml - two 
conditions frequently associated with cancer - the ubiquitination of the receptor decreases 
much more rapidly than receptor phosphorylation and the two curves are uncoupled. This 
would translate into a faster attenuation of NCE-mediated degradation with respect to 
signaling. 
This prediction was experimentally confirmed in cell lines through two parallel 
approaches: the first approach used an isogenic background model system, while the second 
employed a panel of cell lines. In the first approach, we managed to express human EGFR at 
different levels in the murine NIH-3T3 cell line, in order to achieve a homogeneous tool in 
which to study EGFR-Ub and –pY (see Results Section 8.1). By exploiting the NIH clones, 
we validated the non-obvious prediction generated by the EAM, and confirmed the 
uncoupling of the ubiquitination and phosphorylation curves (Fig. 41D). We also confirmed 
the prediction in the panel of normal and tumor cell lines that express increasing amounts of 
surface EGFR, mimicking the progression towards a more aggressive phenotype (Rimawi, 
Shetty et al. 2010). Thus, our results might harbor relevant implications for tumors displaying 
overexpression of the EGFR. 
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7 - Modeling EGFR ubiquitination in cancer 
Our findings are highly relevant to human cancers since the EGFR is frequently 
overexpressed and/or amplified in tumors, either alone or in combination with its ligands (for 
a recent review see (Arteaga and Engelman 2014). EGFR has been shown to be 
overexpressed in a wide variety of cancers and, for some cancers, its overexpression is 
suggested to be a risk factor for poor prognosis and is associated with a more aggressive 
clinical progression, such as in lung, breast, ovarian, bladder, esophageal, cervical, and head 
and neck cancers (Spano, Lagorce et al. 2005 and references therein). 
In many cancer types, overexpression of EGFR is accompanied by aberrant autocrine 
production of EGFR ligands, including EGF, TGFα, AREG, BTC, EREG, EPGN and HB-
EGF (P, Rhys-Evans et al. 2000; Schneider and Wolf 2009, see also Introduction Section 2.2). 
Interestingly, also risk factors such as tobacco smoking, which is one of the main factors 
contributing to the development of many types of cancer, increases the expression of some 
EGFR ligands, for example TGFα and AREG in oral epithelial cells.  
In NSCLC, it has been found that EGFR overexpression is often accompanied by 
overexpression of TGFα ligand, constituting an autocrine loop able to start signaling cascades. 
This distinctive trait is frequent in early stage NSCLC, but is not associated with differences 
in survival, suggesting a role for the EGFR/TGFα loop in tumor formation, rather than in 
tumor progression (Rusch, Klimstra et al. 1997). In addition, head and neck squamous cell 
carcinoma (HNSCC) frequently displays overexpression of EGFR and its ligand, especially 
EREG (Jedlinski, Ansell et al. 2013), and high EGFR expression levels have been associated 
with a more aggressive phenotype, poor prognosis, and resistance to cancer therapy (Ang, 
Berkey et al. 2002). 
Multiple anti-EGFR antibodies and small molecule tyrosine kinase inhibitors targeting the 
EGFR have been developed; up to now, the main EGFR-targeted therapy in use comprises the 
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two tyrosine kinase inhibitors Erlotinib and Gefitinib for treatment of NSCLC and the 
monoclonal antibody Cetuximab, approved for the treatment of NSCLC (Yang, Liu et al. 
2014), advanced HNSCC (Loeffler-Ragg, Schwentner et al. 2008) and colorectal cancer. 
For what concerns treatment response based on ligand expression, data are divergent: in 
HNSCC, for example, EREG mRNA expression was found to be low in cell lines resistant to 
Cetuximab treatment, suggesting it could be a predictive marker of Cetuximab response. This 
finding can be explained by the hypothesis that cells overexpressing both EGFR and its 
ligands depend on signaling through this RTK for maintenance of viability and/or growth and 
will therefore respond well to EGFR-targeted therapy. In the same direction, in colorectal 
cancer, high ligand expression of AREG and EREG identified a subgroup of KRAS WT 
patients who had a high probability of responding to Cetuximab compared with KRAS WT 
patients with low ligand expression. Conversely, in some cases, ligand overexpression is 
associated with a lack of treatment response. For example, AREG overexpression correlates 
with Gefitinib resistance in NSCLC (Busser, Sancey et al. 2010) and overexpression of HB-
EGF has been proposed as a possible mechanism of Cetuximab resistance in HNSCC 
(Hatakeyama, Cheng et al. 2010). The rationale behind these data might be that high levels of 
ligand may compete with the antagonist at the binding site and displace it. 
No matter what the downstream effects are of EGFR and ligand overproduction, these 
data are in agreement with our proposed scenario. Indeed, high EGFR levels, along with 
ligand overexpression, result in a situation in which cells are not able to counteract receptor 
activation and stimulation of signaling cascades with Ub-mediated EGFR downmodulation. 
This determines a set of events that potentially facilitates the onset of cancer. 
Various strategies involving small-molecule inhibitors have been developed to target the 
EGFR system, such as Gefitinib and Erlotinib: two drugs that specifically target the tyrosine 
kinase activity of EGFR (see Results Section 4). The observation that sensitivity to Gefitinib 
and Erlotinib correlated very strongly with a newly discovered class of dangerous somatic 
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activating mutations in the EGFR kinase domain, highlighted the importance of mutationally 
activated kinases as anticancer drug targets (Haber, Bell et al. 2005). Indeed, although WT 
EGFR is able to determine cancer transformation by simple overexpression, another 
mechanism by which a cell might transform into cancer cell is through the mutation of the 
EGFR kinase domain. Kinase domain mutations in EGFR are generally referred to as 
activating mutations, as they result in the increased kinase activity of the receptor, leading to 
hyperactivation of downstream pro-survival pathways (for a review see Zhang, Stiegler et al. 
2010). EGFR kinase domain mutations target four exons (18 – 21), which encode part of the 
tyrosine kinase domain and are clustered around the ATP-binding pocket of the enzyme 
(Kobayashi, Ji et al. 2005; Pao, Miller et al. 2005). Recent studies revealed that these mutants 
are oncogenic in both cell culture and transgenic mouse studies. However, not all the mutated 
EGFRs are necessarily constitutively or fully active, since their degree of ligand 
independence might not be total. 
This is the case of mutation L834R (or L858R if numbering includes the signal peptide) 
that is a partial activating mutant of EGFR, which can be rendered fully ligand-independent - 
and therefore constitutively active - by second site substitutions in EGFR, such as a specific 
mutation in exon 20 (Kobayashi, Ji et al. 2005). In vitro biochemical studies using purified 
recombinant cytoplasmic domains of WT and L834R EGFR have shown that this mutant has 
increased kcat values and an increased Km for ATP, along with decreased KD for homodimer 
formation (Sharma, Bell et al. 2007). Additionally, EGF binds more avidly to mutant L834R 
EGFR expressing cells, and its rate of dissociation from the receptor is retarded (Shtiegman, 
Kochupurakkal et al. 2007). Interestingly, the L834R EGFR mutant shows impaired 
association with Cbl, and consequently compromised ubiquitination (Shtiegman, 
Kochupurakkal et al. 2007). The most direct mechanism for abrogating c-Cbl-mediated 
ubiquitination of L858R would be abrogation of Y1045 phosphorylation in the EGFR, the 
only direct docking site for Cbl (Waterman, Levkowitz et al. 1999). However, data present in 
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literature indicate that Y1045 in the L858R EGFR mutant is still found strongly 
phosphorylated (Shtiegman, Kochupurakkal et al. 2007). The reason why this mutant cannot 
efficiently recruit Cbl is still unclear. One hypothesis that has been put forward is that L834R 
EGFR displays an enhanced propensity to heterodimerize with ErbB2, which would lead to 
the recruitment of several signaling molecules, but not Cbl (Shtiegman, Kochupurakkal et al. 
2007). The reason for the decreased affinity of the mutant for Cbl binding might reside in a 
different conformation of the heterodimers compared to EGFR homodimers, possibly 
masking the Cbl binding site on the EGFR. Further studies are required to clarify this point.  
According to these observations, we challenged our model to predict the behavior of the 
L834R EGFR mutant, which was shown to display increased phosphorylation together with 
decreased Cbl binding and ubiquitination. Indeed, Cbl binding to the L834R EGFR mutant 
corresponded to ~20% of that to WT EGFR at 20 ng/ml EGF, as experimentally shown 
(Shtiegman, Kochupurakkal et al. 2007). Based on parameters present in literature (Shtiegman, 
Kochupurakkal et al. 2007), we introduced the mutant and WT kinetic values into our EAM 
model and produced the simulation for EGFR ubiquitination and phosphorylation. According 
to our model, EGFR is hyperphosphorylated already at low EGF doses, whereas EGFR-Ub 
remains overall at very low values (Fig. 45). In this setting, Ub and pY curves are uncoupled 
already at physiological levels of EGFR (Fig. 45), providing a possible explanation of why 
this mutant is tumorigenic in the absence of receptor overexpression and/or ligand 
overproduction. 
8 - Cbl as the limiting factor  
In the model, both the robustness of the EGFR ubiquitination threshold and the uncoupling of 
activation (that is represented by EGFR-pY) from attenuation (i.e. EGFR-Ub) is due to the 
fact that Cbl is limiting. In all the cell lines used in this work, the total amount of Cbl is 
relatively abundant; however, experiments confirmed that the number of Cbl molecules 
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Figure 45: Predicted behavior of EGFR-Ub and -pY for the L834R mutant, as a function of EGF 
concentration and EGFR number. Relative L834R EGFR phosphorylation (𝑝𝑌/𝐸𝐺𝐹𝑅T, black lines) and 
ubiquitination (𝑈𝑏/𝐸𝐺𝐹𝑅T, red lines) levels, as given by the EAM, are shown for the indicated EGF 
concentrations. The gray area represents the physiological range of EGFR levels. Data are normalized to the 
maximum phosphorylation/ubiquitination of EGFR WT obtained at 100 ng/ml EGF. Dashed lines represent 
mutant curves; continuous lines represent WT curves (the same as in Fig. 27D). 
available for EGFR binding is limited (see Tables VI and VII), in agreement with the fact 
that Cbl is engaged in many different macromolecular complexes in the cell (Fig. 35A and 
Fig. 41C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indeed, Cbl is responsible for ubiquitination of a variety of proteins. It is known that more 
than 150 proteins are substrates of Cbl ubiquitination, including receptors with or without 
intrinsic kinase activity, cytosolic kinases, phosphatases, ubiquitin ligases, adaptors and many 
more proteins, representing a cross section through the signal transduction proteome 
(reviewed in Schmidt and Dikic 2005). This makes it difficult to separate Cbl E3 ligase 
activity and adaptor function, even when focusing only on EGFR endocytosis. In our lab, it 
was observed that Cbl is necessary for EGFR endocytosis through both clathrin-dependent 
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and -independent pathways. For the latter case, we widely discussed the need of EGFR 
ubiquitination for NCE internalization and receptor degradation. For what concerns the CME 
pathway the situation is still unclear, but recent evidence points to an essential role of Cbl in 
the ubiquitination of protein adaptors involved in this pathway (Pascolutti et al, unpublished). 
This finding highlights another important aspect of Cbl availability in EGFR ubiquitination; 
at high doses of ligand, when NCE is turned on, CME is still active and those Cbl moieties 
that act on this internalization route might be subtracted or compete with the ones directly 
involved in EGFR ubiquitination and NCE. This would further reduce the pool of available 
active Cbl moieties able to ubiquitinate the receptor. 
Importantly, one critical element that contributes to the robustness of the ubiquitination 
threshold is the rate-limiting availability of Cbl: increase in Cbl leads to the same proportional 
increase in EGFR ubiquitination for all EGF concentrations. This holds true until the ratio 
between active Cbl/EGFRs is less than ≈0.2. Based on this finding, we can estimate that in 
HeLa cells, the number of active Cbl molecules per cell could reach the level of 50,000 
without affecting the Ub threshold. Paradoxically, this feature also determines the intrinsic 
instability of the balance between EGFR phosphorylation and ubiquitination, which could be 
unmasked at supra-physiological levels of EGFR. NIH cells were again useful to test this 
complex behavior; through Cbl overexpression to levels ~100 times that of endogenous Cbl, 
we managed to partially re-couple EGFR-Ub and –pY as predicted by the model (see also 
Discussion Chapter 4). Thus, the model has been critical in revealing yet another fundamental 
property of the system: i.e., the uncoupling of EGFR ubiquitination and phosphorylation 
depends on the rate limiting availability of Cbl.  
9 - Could this mechanism work for other RTKs? 
The EGFR regulation circuit that we highlighted in this work is peculiar and finely tuned and 
it determines an important biological outcome, especially with respect to cancer-related 
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pathologies. One interesting question that raised is whether other receptors are similarly 
regulated. The MET receptor might be one candidate, since Cbl can also be recruited to this 
receptor following ligand-dependent activation (Peschard, Fournier et al. 2001). 
The MET receptor is another member of the RTK family, important in the control of tissue 
homeostasis under normal physiological conditions. Similarly to the EGFR, MET receptor 
has also been found to be aberrantly activated in human cancers through mutations, 
amplifications or overexpression. For instance, aberrant expression of the MET receptor and 
its ligand, the HGF, has been observed in tumor biopsies of many solid tumors and MET 
signaling has been documented in a wide range of human malignancies (Comoglio and 
Trusolino 2002; Birchmeier, Birchmeier et al. 2003; Peruzzi and Bottaro 2006).  
Structurally, the MET receptor is produced by the proteolytic processing of a common 
precursor into a a/b heterodimer (Fig. 46) (Trusolino and Comoglio 2002). The extracellular 
portion of the MET receptor is responsible for ligand binding and dimerization, whereas the 
TM and juxtamembrane regions link the extracellular side of the MET receptor to the 
intracellular TK domain. This domain contains the catalytic tyrosines that positively modulate 
receptor activity by activating downstream responses 
common to many RTKs, such as the MAPK and AKT 
pathways (Abella, Peschard et al. 2005). Following 
ligand binding, MET undergoes internalization through 
clathrin mediated endocytosis and degradation in a 
Figure 46: Domain structure of MET receptor. The receptor is 
formed by proteolytic processing of a common precursor into a 
single-pass, disulphide-linked a/b heterodimer. The MET receptor 
contains an intracellular tyrosine kinase catalytic domain flanked by 
distinctive juxtamembrane and C-term sequences. This portion of c-
MET contains the catalytic tyrosines Y1234 and Y1235, which 
positively modulate enzyme activity, while the juxtamembrane 
tyrosine 1003 negatively regulates MET by recruiting Cbl. The 
multifunctional docking site in the C-term tail contains tyrosines 
Y1349 and Y1356, which recruit several transducers and adaptors. 
(Adapted from Organ and Tsao 2011) 
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dynamin-dependent poorly-carachterized mode (Hammond, Urbe et al. 2001). 
It is interesting to note that the juxtamembrane domain of MET carries the Tyr 1003, 
whose phosphorylation negatively regulates the receptor by recruiting the ubiquitin ligase Cbl, 
that binds to MET receptor either through its direct binding site (pY1003), or indirectly 
through Grb2 (Peschard, Kozlov et al. 2007), destining the receptor to lysosomal degradation 
(Hammond, Urbe et al. 2001; Abella, Peschard et al. 2005). Indeed, it was observed a 
dependency of MET degradation on its ubiquitination, suggesting that the degradative 
pathway might require receptor ubiquitination, whereas it is not required for its internalization 
(Abella, Peschard et al. 2005). Moreover, MET receptor lacking the Cbl binding site was 
found to be tumorigenic, showing enhanced transforming activity in Rat1 fibroblasts with 
respect to the WT counterpart, likely due to reduced MET degradation and sustained 
phosphorylation (Mak, Peschard et al. 2007). 
Even though MET internalization, in particular clathrin independent pathways, show a 
much lower resolution with respect to EGFR internalization pathways, a recent work by 
McMahon lab was published, proposing a role of the FEME pathway (see Introduction 
Section 4.3) for MET internalization. They showed that at high doses of HGF, stimulation of 
the MET receptor induced in the cell lines under scrutiny the formation of morphological 
structures that are linked with the newly endocytic clathrin-independent dynamin-dependent 
pathway therein described (Boucrot, Ferreira et al. 2015). We can thus speculate the existence 
of multiple entry pathways for the MET receptor, that might depend on ligand concentration 
and receptor ubiquitination.  
MET might be one candidate to extend the study of receptors ubiquitination. Since 
stimulation with increasing doses of ligand seems to determine also in this case the 
engagement of different cellular fates, it would be interesting to elucidate this mechanism. 
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10 - Concluding Remarks 
The EAM represents the input layer and the starting point for the construction of a ‘time-
resolved’ model that will be later generated, taking into account events downstream of EGFR 
activation that take place in the signaling processing unit, such as integration of CME and 
NCE, sorting and intracellular signaling. The ‘time-resolved’ model will allow us to predict 
the most likely mechanisms of selection of a particular endocytic route, the evolution of the 
population of inactive, phosphorylated and ubiquitinated receptors, as well as the intensity of 
the signals transmitted to the downstream pathway regulated by the EGFR. The predictions 
generated by the time-resolved model will have - if validated - important implications for the 
future development of novel cancer diagnostic and therapeutic tools based on the Cbl/EGFR 
balance in cells. 
ONGOING	  WORK	  and	  FUTURE	  DIRECTIONS 
 170
Ongoing work and future directions 
1 - Construction of a quantitative and time-resolved advanced model 
We expect that the EAM is able to explain the EGFR-Ub and -pY early responses, but not the 
downstream biological readouts, such as EGFR endocytosis and biological responses, such as 
signaling and proliferation. To gain a deeper understanding of the biological events following 
EGFR activation, we need to extend our predictions to later time points.  
Receptors residing at the PM represent the first-line sensors of extracellular signals. Not 
surprisingly, therefore, the regulation of their surface levels achieved by internalization has an 
immediate impact on the response of a cell to stimulus from the external environment. There 
are several mechanisms through which endocytosis controls receptor signaling specifically at 
the cell surface, such as the regulation of receptor availability at the PM, by which cells 
control the number of the surface receptors. NCE ligand-mediated endocytosis determines a 
rapid internalization of the EGF:EGFR complex, thus providing a mechanism that may 
directly limit the magnitude and duration of signaling from the PM. We thus hypothesize that 
continuous stimulation with high EGF doses, which targets ~50% of engaged receptors to 
NCE for degradation, is the cause of a long-term reduction in the number of cell surface 
receptors. This negative feedback loop, activated only at high EGF, could be essential to 
prevent excessive signaling and to maintain homeostasis. Loss of this safety feedback loop 
could contribute to pathological conditions, such as cancer, where overexpression of both 
ligands and receptors frequently leads to malignant transformation. 
In line with this, the integration of different endocytic pathways, CME and NCE, is 
predicted to be critical to control the net biological output. Indeed, CME (active at all EGF 
doses) is the recycling/signaling-competent route, while NCE (active only at high EGF dose 
concomitant to CME) is a degradative pathway (Sigismund, Woelk et al. 2005). In 
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pathological conditions, such as cancer, one could predict that alterations in this balance (e.g. 
CME up-regulation or NCE down-regulation) might contribute to aberrant EGFR signaling.  
Another mechanism by which endocytosis controls receptor signaling is through the 
assembly of endosome-specific platforms that result in a differential distribution of signaling 
effectors between the PM and the endosomal compartment. It is widely recognized that 
signaling is not restricted to the PM; as internalization proceeds, activated transmembrane 
molecules, with their tails exposed toward the cytoplasm, are confined and enriched within 
endomembrane organelles, from where they continue to signal. Such structures are bona fide 
signaling platforms that influence the duration, amplitude, and specificity of the downstream 
signals (Gould and Lippincott-Schwartz 2009). Consistent with this view, a growing number 
of signal transduction pathways are reported to require active endocytic machinery, or to 
originate exclusively from different endosomes. The term signaling endosome symbolizes this 
concept and indicates that endosomes (and MVBs) are signaling compartments, which confer 
time- and space-resolution to signals that would otherwise be only partially informative, and 
which add specificity to signaling through a variety of molecular mechanisms. 
A number of specific features of endosomes make them ideal for both signal propagation 
and specificity. Endosomes are characterized by: 
1) a limited volume that may favor the interaction between receptor and ligand when the 
two are internalized in the same vesicle by a mass action kinetic, further sustaining receptor 
activity; 
2) a relatively longer resident time of activated receptors, with respect to the PM from 
which active receptors are rapidly removed as a consequence of internalization; 
3) a scaffold-promoting microenvironment, thanks to their enrichment in particular lipids 
or proteins, such as the PI3P, that are able to assemble specific signaling complexes; 
4) a chemically defined microenvironment characterized by low pH that favors specific 
reactions, such as proteolysis of signaling molecules, deubiquitination of ubiquitinated 
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receptors by DUBs, or dephosphorylation by phosphatases, which are all very active in this 
compartment. 
Finally, endosomes can influence signaling either by sustaining signals originating from the 
PM or by contributing to signal specificity through their provision of a platform for the 
assembly of specific signaling complexes that are prevented at the PM (reviewed in Gould 
and Lippincott-Schwartz 2009 and Scita and Di Fiore 2010). 
These observations highlight the need to construct a full-predictive and time-resolved 
model of EGFR endocytosis and signaling by extending the early model from the first 2 
minutes following EGF stimulation to the triggering process of EGFR internalization, sorting 
and downstream signaling. To this end, we will perform the modeling phases in parallel by: 
• experimentally exploring the EGFR biology in terms of endocytosis, as well as the 
later steps of endosomal sorting and EGF-dependent signaling outputs; 
• formalizing into the model the biological observations that result from these 
experiments, and generating a feedback loop in which modeling and wet lab 
experiments are interconnected in a back-to-back approach.  
1.1 - Converting EAM into a quantitative model 
The EAM is able to adequately account for the early stages of the EGFR activation, 
generating results in good agreement with data and parameters coming from the literature. 
However, the EAM is intrinsically a semi-quantitative model, built on normalized curves for 
both EGFR Ub and pY, and it is not time-resolved. 
To develop a full quantitative model, we are faced with the problem of deconvoluting the 
simplifications that we introduced into the EAM. First of all, the fact that EGFR 
phosphorylation is modeled based on the contribution of only 3 phosphotyrosines (the ones 
relevant to Cbl/Grb2 recruitment), rather than the contribution of the 9 pY residues present in 
the system. In addition, the model was designed in such a way that the three tyrosines become 
ONGOING	  WORK	  and	  FUTURE	  DIRECTIONS	  	  
 173 
phosphorylated independently of each other and follow the same kinetics of phosphorylation. 
Although these properties were validated experimentally (in the case of independency, 
Fig.27) or taken from literature (in the case of time kinetics Olsen, Blagoev et al. 2006), we 
acknowledge that we do not know whether these properties can be extended to the other 
phosphorylation sites. 
We have now extended the EAM to consider all 9 tyrosine residues and performed a 
preliminary analysis in silico of how the extended EAM model performs in terms of absolute 
phosphorylation within the first 2 min of EGF stimulation (Fig. 47). The model showed that 
the kinetics of phosphorylation of the single tyrosine residues is very rapid and almost all 
receptors are modified at least in one residue after few seconds of EGFR activation. Overall, 
in a time window of 20-40 seconds, almost all receptors are phosphorylated in five out of nine 
sites. Only ~10% of receptors are predicted to be modified on all the nine tyrosine residues 
after 2 minutes. 
In order to understand whether this behavior reflects what happens in vivo, we are 
currently performing a series of experiments, including the analysis of EGFR phosphorylation 
kinetics at early (< 2 minutes) and late (> 2 minutes) time points after EGFR activation, with 
a particular focus on the kinetics of single phosphosites in the contest of the WT EGFR. For 
this analysis, we will use specific phospho-EGFR antibodies (we have available 8 antibodies 
out of the 9 phosphosites). 
Moreover, we are performing a quantitative analysis of total EGFR phosphorylation and 
ubiquitination, in an attempt to measure the number of receptors that are modified at 2 
minutes and eventually at earlier or later time points. This will be done by comparing the 
amount of EGFR immunoprecipitated with anti-Ub or anti-pY antibodies under stringent lysis 
conditions (i.e., 1% SDS, see Methods Section Protein Buffers), in order to understand the 
absolute number of EGFR molecules that undergo ubiquitination and phosphorylation at the  
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different EGF doses. Experimentally, this estimation will be performed using the same 
approach used for the quantitation of pY-Cbl (see Results Section 3.1). 
We are also interested in studying the behavior of each single tyrosine in an EGFR 
backbone where all the other tyrosines are absent, through the generation of single EGFR 
add-back mutants. In our lab, we previously engineered an EGFR mutant in which all the nine 
phosphorylatable tyrosines in the cytoplasmic tail were mutagenized into phenylalanine (9Y-, 
Fig. 27A), in order to obtain a phosphorylation null receptor. We are now adding back single 
tyrosine residues to the 9Y- tyrosine null backbone to generate 9 single add-back mutants that 
harbor only one out of nine phosphorylatable tyrosines, in order to characterize the 
phosphorylation kinetics of the single phosphosites and to understand the impact of their 
phosphorylation on the remaining sites. 
These experiments will allow us to understand whether, and, if so, how, we have to 
modify the EAM, in order to convert it in absolute quantitative terms. The extension of the 3 
phosphosite-based EAM to a 9 phosphosite-based EAM, while increasing the computational 
efforts in terms of the number of ODE equations, represents a pre-requisite to convert the 
model in absolute quantitative terms. The newly generated model will serve as a starting point 
from which to extend the modeling of EGFR activation, endocytosis and downstream 
signaling. 
2 - EGFR knockout HeLa cells 
Data presented in Results Section 5.1 confirmed that the NIH 3T3 clones represent a useful 
tool to test EGFR-Ub/pY predictions in a homogeneous background, successfully validating 
the EAM. However, we have collected evidence indicating that this cell model system might 
not be suitable for the study of the downstream EGFR response. Indeed, NIH 3T3 cells: 
• are mouse cells engineered to express human EGFR; 
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• express ~5000 endogenous mouse EGFR molecules, which may affect the EGF-
dependent signaling response; 
• are not characterized in terms of EGFR endocytosis. 
We initially attempted to investigate the EGFR entry routes in NIH 3T3 cells by 
performing 125I-EGF internalization kinetic analysis following KD of key players in EGFR 
endocytosis. We optimized the KD conditions for clathrin (specifically blocks CME), 
dynamin 1/2 (should block both CME and NCE), and RTN3 (specifically blocks NCE, 
Caldieri, Barbier et al. 2015) in NIH 3T3 cells. However, the results we obtained from the 
internalization experiments were difficult to interpret because the inhibition of one 
internalization pathway seemed to upregulate the other endocytic routes. We are currently 
performing additional experiments to better clarify the endocytic mechanisms acting in these 
cells. 
However, since the EAM was built on experimental observations generated in HeLa cells, 
we are now generating HeLa knockout (KO) cells to be reconstituted with human EGFR. The 
goal of this alternative approach is to obtain a well-characterized cellular setting in which to 
perform internalization assays aimed at correlating different EGFR expression levels with the 
selection of a particular entry route. 
We managed to generate a HeLa-derived cell line in which endogenous EGFR has been 
knocked out using the CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats)/Cas (CRISP ASsociated protein) technology for genome editing (Ran, Hsu et al. 
2013). The CRISPR/Cas system originated as part of a prokaryotic immune system to confer 
resistance to foreign genetic elements, but in the last two years, the system has been used for 
gene editing. By delivering the Cas9 protein and an appropriate guide RNA (gRNA) into a 
cell, the organism's genome can be cut at any desired location. Cas9 is a nuclease that was 
first discovered as a component of the CRISPR system in Streptococcus pyogenes and has 
been adapted for the use in mammalian cells (Jinek, Chylinski et al. 2012). The WT Cas9 
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endonuclease is guided to the target site by the gRNA, which anneals to the specific target 
sequence on the genome, and is able to introduce double-stranded breaks (DSB) with high 
efficiency. Usually this kind of lesion, in the absence of a DNA template that can be used by 
the homology-directed repair (HDR) machinery, is likely to activate the non-homologous end 
joining (NHEJ) repair system (Sander and Joung 2014) that randomly repairs DNA lesions. If 
overlapping or located in proximity to the ATG of the gene of interest, this lesion can 
determine a functional KO by various mechanisms, including frameshift mutations, disruption 
of the promoter or elimination of the initiation codon.  
To generate the HeLa EGFR KO cell line, we transfected WT HeLa cells with a plasmid 
encoding both the gRNA targeting the first exon of EGFR gene and the Cas9 enzyme (Fig. 
48A), along with GFP for selection. Cas9 is guided to the correct place on the genome by the 
complementarity of the gRNA with its target site, inducing a DSB. In our case, we guided the 
gRNA on the first EGFR exon (Fig. 48B). This event will leave on the genome a lesion, 
usually identified as a small insertion or deletion (Fig. 49A). After enrichment of the 
Figure 48: CRISPR/Cas9 technology. A - pD1301-AD plasmid for mammalian transient transfection. The 
vector carries the Cas9 DNA nuclease and the RNA guide (gRNA), together with a GFP selection element 
that was used to enrich transfected HeLa cells by FACS sorting. B - schematic representation of the 
mapping of gRNA on the human EGFR coding sequence (CDS). Note that the gRNA is centered exactly on 
the ATG of the EGFR CDS. (Image generated with Geneious software) 
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transfected population by FACS sorting (Fig. 49B), HeLa cells were sub-cloned and some 
candidates were tested for EGFR level both by 125I-EGF saturation binding assay (data not 
shown) and WB analysis (Fig. 49C). The technology revealed to be efficient, allowing the 
identification of several clones that have lost EGFR protein expression, concomitant to 
impaired 125I-EGF binding. 
Based on the morphology and the growth rate of the clones tested in Fig. 49C, we chose 
to further characterize clones #9 and #13 (red asterisks in Fig. 49C). To better understand the 
type of lesion that was introduced in each clone, we are now performing DNA sequencing at 
the single allele level, in order to exclude aberrant EGFR truncated products. To this aim, we 
are setting up, together with the Sequencing Facility at our Institute, a Fragment Analysis 
protocol coupled to standard Sanger sequencing (Yang, Steentoft et al. 2015); a procedure 
that will allow the definition - up to the single base level – of the kind of the lesion introduced. 
2.1 - Reconstitution of HeLa EGFR KO cells with WT or mutated 
EGFR 
The HeLa EGFR KO cells will be the starting point for the generation of isogenic cell lines 
expressing different levels of WT EGFR, through the reintroduction of the human EGFR gene 
cloned into a viral vector, as performed in NIH-3T3 clones (see Results Section 8.1). The 
resulting cell lines will be investigated for EGFR-Ub/pY levels and for the selection of the 
internalization route (e.g., CME vs. NCE) upon variation of EGFR/EGF levels. The HeLa cell 
model system represents an ideal starting point for the characterization of the EGFR 
endocytic route in relation to varying EGFR/EGF levels, because the parental cell line has 
been extensively studied by our group in terms of endocytosis (Sigismund, Argenzio et al. 
2008; Sigismund, Algisi et al. 2013).  
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We also intend to exploit HeLa-reconstituted clones to investigate the possible correlation 
between variations in EGFR/EGF levels and EGF-dependent biological readouts. We will 
follow downstream EGFR signaling (e.g. AKT/PI3K, ERK1/2, Ras activation) and biological 
readouts (e.g. migration and/or proliferation) in the selected clones, expressing different 
EGFR surface levels, at different ligand concentrations. 
Figure 49: Generation of HeLa EGFR KO cell lines. A - Schematic representation of the frequency 
of occurrence of insertions/deletions (in/del) at the targeted locus. Note the most frequent mutations that 
usually occour are very small (1-2 bp) in/dels. B - FACS analysis of GFP-positive HeLa cells. Cells 
were either mock treated (CTRL, top panels) or transfected with pD1301-AD-gRNA1 plasmid (HeLa-
EGFR-gRNA1, bottom panels). The threshold for selection of positive cells was set at the threshold 
determined by WT cells. Positive cells were sorted and replated for clone selection. C - Ten clones were 
subjected to WB analysis with the indicated antibodies in comparison to HeLa WT cells. Tubulin (tub) 
was used as loading control. Long exp: long exposure. EGFR protein was undetectable (compared to 
the HeLa WT control, left) in all clones, with the exception of one clone (#17). Asterisks indicates the 
selected clones that are currently under analysis by sequencing to characterize the genetic lesion 
introduced, and that will be used for reconstitution experiments with WT or mutated human EGFR. 
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Finally, we will generate HeLa EGFR KO cells expressing EGFR add-back mutants to 
study the kinetics of the single phosphosites (see Results Section 3). The single add-back 
mutants that have already been generated will be expressed in the newly generated HeLa 
EGFR KO cells and clones expressing levels of mutant EGFR comparable to levels of 
endogenous EGFR will be selected. Analysis of the phosphorylation kinetics and the dose-
response curves of the single phosphosites will be performed. These add-back mutants will be 
also useful to study the role of individual phosphorylation sites in the entry of EGFR into a 
given endocytic pathway or in the coupling with a specific signaling response. 
Together, these experiments we will generate a more complete picture of the EGFR 
system, from the very early activation steps to late events that take place inside the cell after 
receptor stimulation, and possibly their biological implications. Experiments will drive 
mathematical modeling by exploring EGFR endocytosis and EGF-dependent signaling, and 
will provide a way to validate predictions that will eventually be derived from the time-
resolved model.  
3 - Validation of cancer-relevant model predictions using primary cells 
Since the EAM was successful in generating cancer-relevant predictions that were validated 
in cancer cell lines, we plan to extend the validation of these predictions to primary human 
cancer cells, using samples from the primary cell culture facility at the European Institute of 
Oncology (IEO) in Milan. The analysis will include lung and/or breast primary tumor cell 
cultures stratified on the basis of their EGFR status (WT, mutated or overexpressed) 
alongside other standard clinico-pathological parameters. We will determine the basal status 
of EGFR by immune-histochemistry on formalin-fixed, paraffin-embedded (FFPE) specimens.  
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With the obtained primary cell lines, we plan to test the impact of EGFR/EGF levels on: 
• EGFR-Ub and -pY curves by DELFIA; 
• differential CME/NCE entry by the 125I-EGF internalization assay; 
• EGFR degradation/signaling. 
Finally, new experiments will be designed according to new predictions generated by the 
time-resolved model, with the aim to shed light on the link between deregulation of EGFR 
biology and human cancers. 
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Appendix 1 
Reaction type or 
species Symbol 
Optimization 
Range 
(Model) 
Value  
(Model) 
Optimizat
ion Range 
(Typical 
units) 
Value  
(Typical 
units) 
Reference 
Total 
concentration of 
EGFRa 
R T N.O. 0.83 nM N.O. 
250000 
molecules This work 
Concentration of 
Cbl available for 
EGFR interactionb  
Cbl T N.O. 
1.5x10-2 
nM N.O. 
5000 
molecules This work 
Total 
concentration of 
Grb2c 
Grb2T N.O. 3.3 nM N.O. 
1000000 
molecules This work 
Hill coefficient for 
phopshorylation 
curve 
nH  0.5-1.5  1.13  0.5-1.5 1.13 This work 
Half-maximum 
phosphorylation of 
EGFR 
H 0.1-10 nM 4.6 nM 0.58-58.8 ng/ml 27 ng/ml This work 
Maximum 
phosphorylation 
rate constant 
k!"#!"# 0.005-10 s-1 0.0759 s-1 0.005-10 s-1 0.0759 s-1 
> 0.005 s-1 (Olsen, Blagoev et al. 
2006); 0.0733 s-1 (Pryor, Low-
Nam et al. 2013); > 0.075 s-1/ 2 
s-1 [depending on model in 
(Kleiman, Maiwald et al. 2011)]; 
0.2 s-1 (Monast, Furcht et al. 
2012); 1s-1 (Kozer, Barua et al. 
2013) 
Dephosphorylation 
rate constant kptp N.O. 
0.016 
s-1 N.O. 0.016 s
-1 
0.016 s-1 (Kleiman, Maiwald et 
al. 2011); <0.1 s-1 (Olsen, 
Blagoev et al. 2006); 0.01 s-1 
(Kholodenko, Demin et al. 
1999); 0.13 s-1 (Monast, Furcht et 
al. 2012); 1s-1 (Kozer, Barua et 
al. 2013) 
Kd of of 
pY1068/pY1086 
and Grb2 binding 
(and of pY1045 
and Cbl) 
K45 
(K68) 0.2-150 nM 0.2 nM 0.01-7 µM 0.01 µM 
0.4 µM (Lemmon, Ladbury et al. 
1994); 0.7 µM (Chook, Gish et 
al. 1996); 0.1 µM (Cussac, Frech 
et al. 1994); 0.35 µM (Hu and 
Hubbard 2005) 
Kd of Cbl and 
Grb2 binding Kcg 0.006-30 nM 
0.006 
nM 
0.0003-1.5 
µM 0.3 nM 
1.48 nM (Sastry, Lin et al. 
1995); 400 nM (Chook, Gish et 
al. 1996); 1.8 µM (Lemmon, Bu 
et al. 1997); 300–500 µM 
(Houtman, Yamaguchi et al. 
2006); 4 µM and 120 µM [Nter-
SH3 and CterSH3of Grb2 
(Cussac, Frech et al. 1994)] 
Rate constant of 
dissociation of 
pY1068/pY1086 
and Grb2 pY1045 
and Cbl (and of 
pY1045 and Cbl) 
ku45 
(ku68) 
0.001-40 s-1 0.001 s-1 
0.001-40 
s-1 0.01 s
-1 
0.2 s-1 (Chook, Gish et al. 1996); 
0.4-4 s-1 (Cussac, Frech et al. 
1994) 
Rate constant of 
dissociation of Cbl 
and Grb2 
kucg 0.01-100 s-1 0.3 s-1 
0.01-100 
s-1 0.3 s
-1 Not available 
Localization factor fLOC 10-105 nM 
2x104 
nM 
0.5 µM -5 
mM 1 mM This work 
Maximum 
ubiquitination Ubmax 
0.0005-0.05 
nM 
0.0143 
nM 
0.003-0.3 
ng/ml 
0.083 
ng/ml This work 
Maximum 
phosphorylation 
(MPMB) 
pYmax 0-2.5 nM 2.28 nM 0-15 ng/ml 13 ng/ml This work 
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Appendix 1: Model Parameters. Parameters or molecular species were either measured 
(“this work”) or taken from the literature. We distinguish between experimental 
measurements (references in black) and estimates produced by previous modeling studies 
(references in red). Parameters were either fitted in a given interval or not optimized (N.O.).  
EAM parameters      
Maximum 
phosphorylation  pYmax 0-2.5 nM 2.35 nM 0-15 ng/ml 
13.8 
ng/ml This work 
Kd of EGF-EGFR 
binding (high 
affinity) 
K 0.1-20 nM 3.4 nM 0.1-20 nM 3.4 nM 
0.2 nM (Macdonald et al. 
2008), 4.3 nM (French et al. 
1995); 0.67 nM (Waters et al. 
1990); 20 nM (Kholodenko et 
al. 1999); 20 nM (Klein et al. 
2004) 
EGF-EGFR 
association rate 
constant (to a 
preformed EGFR 
dimer) 
kb 0.02-20 nM-1s-1 
5 
nM-1s-1 
0.02-20 (5) 
nM-1s-1 5 nM
-1s-1 
 0.2–0.4 nM-1s-1 (first EGF 
moiety), 2 nM-1s-1 (second 
EGF moiety) (Teramura et al. 
2006) 
Kd of EGF-EGFR 
binding (low 
affinity) 
K1 N.O. 50 nM N.O. 50 nM 
2.9 nM (Macdonald et al. 
2008); 600 nM (Klein et al. 
2004) 
EGF-EGFR 
association rate 
constant (low 
affinity) 
k1b N.O. 3x10
-3 
nM-1s-1 N.O. 
0.003 
nM-1s-1 
0.001 nM-1s-1 (French et al. 
1995); 0.003 nM-1s-1 (Waters 
et al. 1990); 0.004 nM-1s-1 
(Teramura et al. 2006); 0.001 
nM-1s-1 (Monast et al. 2012); 
3x10-3 nM-1s-1 (Kholodenko et 
al. 1999) 
Equilibrium ratio 
of EGFR 
closed/open 
Ke N.O. 30 N.O. 30 20-30 (Klein et al. 2004) 
Rate of closing of 
extracellular 
EGFR domain 
kc N.O. 10 s-1 N.O. 10 s-1 Not available 
As kc when EGFR 
has EGF bound k1c N.O. 10 s
-1 N.O. 10 s-1 Not available 
Dimerization rate 
constant 
kbDIM 
(D) 
1-200 
nM-1s-1 
200 
nM-1 s-1 
0.01-0.2 µm2 
s-1 
0.200 
µm2 s-1 
0.01-0.02 µm2 s-1 (Kusumi et 
al. 1993); 0.05 µm2 s-1  (Low-
Nam et al. 2011); 0.2 µm2 s-1 
(Chung et al. 2010 ) 
Dimer dissociation 
rate constant ku
DIM 0.07–20 s-1 1.1s-1 0.07–20 s-1 1.1s-1 
2 s-1 (Chung et al.2010); 1.24s-
1 (no EGF bound), 0.738s-1 (1 
EGF bound), and 0.271s-1 (2 
EGF bound) (Low-Nam et al. 
2011) 
Phosphorylation 
rate constant kKIN 
0.005-10  
s-1 
0.289 
s-1 0.005-10 s
-1 0.289 s-1 
> 0.005 s-1 (Olsen et al. 2006); 
0.0733 s-1 (Pryor et al. 2013); 
0.2 s-1 (Monast et al. 2012); > 
0.075 s-1/ 2 s-1 [depending on 
model in (Kleiman et al. 
2011)]; 1s-1 Kozer et al. 2013) 
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a. Assuming that HeLa cells contain an average of 2.5-3 x 105 EGFRs (measured by 
saturation binding assay, see Materials and Methods) and that each cell is surrounded by 
 of medium. 
b. We estimated the amount of Cbl available for EGF interaction by measuring the levels of 
Cbl phosphorylated by the EGFR at the maximal EGF concentration (see Result Section 8.1). 
This represents the maximal “active Cbl” fraction, i.e. able to recruit E2 ubiquitin-conjugating 
enzymes and to ubiquitinate the EGFR. Thus, we take this as a proxy for the maximal amount 
of Cbl actually available for binding to the EGFR (measured in Fig. 35). 
c. Grb2 levels as measured in Fig. 35. 
d. In the MPM, we set the active EGFR fraction as an Hill function of EGF and optimized the 
parameters via a best-fit procedure; see Supplementary Information in (Capuani, Conte et al. 
2015). 
0.5 ×10−6ml
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